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Prostate cancer (PCa) is one of the most frequently diagnosed malignancies and second 
leading causes of cancer related death in men worldwide. PCa is remarkably 
heterogeneous, with a range of manifestations from asymptomatic to widespread metastatic 
disease. Active surveillance (AS) is one of the options for men with low grade and low 
volume early PCa. AS involves regular PSA testing, digital examination, and biopsy 
without providing any medical intervention. Although AS decreases unnecessary 
overtreatment for some men, it may cause anxiety over disease progression in others. The 
number of men under AS is increasing as concern about over-treatment has developed in 
recent decades. Hence, in those men undertaking AS, who are otherwise on no specific 
treatment, there is an urgent need to develop an approach to prevent or impede PCa 
progression with no adverse effects that is cost effective for long-term use. 
Traditional Chinese Medicine has been used for centuries in treating and improving the 
symptoms experienced by cancer patients in China. Detoxification recipe (DR) is an anti-
cancer Chinese Medicine formula and consists of two herbs, namely Hedyotis diffusa (HD) 
and Scutellaria barbata (SB). In a recent survey in Taiwan, the combination of HD and SB 
was shown to be the most commonly described herbal medicine in the treatment of cancer. 
However, how HD and SB in combination exerts its anti-cancer action is elusive. The aims 
of this project were to determine the anti-proliferative and its modes of action of DR. 
Specifically, this study aimed to firstly establish the cytostatic action of DR and its impact 
on the cell cycle phase distribution and secondly to determine the underlying molecular 
mechanism contributing to the DR induced cell cycle alteration.  
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Our study revealed that DR has anti-proliferative activity in PCa cells, evidenced by a 
reduction in DNA synthesis by SYBR Green DNA analysis assay and BrdU incorporation. 
This is also supported by the reduction in proliferative cells by Ki-67 immunocytochemical 
staining. The colony formation assay also revealed the long-term inhibitory anti-
proliferative effect of DR. The pH and osmolality test of DR-containing culture medium 
showed that the anti-proliferative activity of DR is intrinsic. Studies in normal mice 
demonstrated that DR did not have any apparent adverse effects at least in the short-term.   
In order to verify the effect of DR on cell cycle progression, flow cytometric cell cycle 
analysis was performed using propidium iodide (PI) staining. PI-stained PCa cells 
indicated that DR accumulates cells in the G2/M phase. Subsequent flow cytometric 
analysis of PI and phospho-Histone H3 co-staining revealed that treatment with DR 
resulted in no increase in M phase cells compared to control cells, suggesting that DR 
arrests the PCa cells at G2 phase.  
To examine the mechanism causing the G2 phase arrest by DR, a DNA damage scenario 
leading to G2 arrest was examined. With irradiated cells as a positive control, we found no 
equivalent foci of phospho-H2AX and 53BP1 in DR-treated cells by immunofluorescence. 
For further verification, immunoblotting of DNA damage response proteins, including total 
and phosphorylated form of ATM, ATR, CHK1 and CHK2, was performed. No activation 
of DNA damage signalling pathways was observed in the presence of DR treatment 
comparing to irradiated cells.  
Cell cycle transition from G2 to M phase is controlled by M phase promoting complex 
Cyclin B1-CDK1 and their positive regulators PLK1 and Aurora A kinases. DR reduced 
all four at both protein and mRNA levels. Since Cyclin B1 and CDK1 confer the G2-M 
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transition, the reduction indicates that DR-induced G2 phase cell cycle arrest is associated 
with the impairment in M phase promoting complex and regulators.  
Lastly, to determine the clinical significance of M phase promoting complex and regulators 
in PCa progression, an online database for genomic analysis and mRNA expression was 
analysed. mRNA expression levels of all four were highly correlated with PCa disease 
progression. We found a deletion of Cyclin B1 and amplification of CDK1, PLK1 and 
Aurora A genes in PCa tissue. 
In summary, the commonly prescribed Chinese herb medicine combination DR has 
significant anti-proliferative activity. DR can diminish the transition from G2 to M phase in 
PCa cells. DR-induced reduction of key proteins essential for mitotic entry is likely 
responsible for the observed impact of DR on the G2-M transition. The potential to use DR 
















1.1 Prevalence of PCa  
Prostate cancer (PCa) is one of the most frequently diagnosed malignancies in men 
worldwide (Ferlay et al. 2010; Siegel et al. 2017), and in Australia, the second most 
common cause of cancer-related deaths after lung cancer. It is reported that one in five 
men will develop PCa during their lifetime and the risk of developing PCa increases with 
age (Klotz et al. 2014). In 2017, it is estimated that 16,665 new cases of PCa will be 
diagnosed and approximately 3,500 men may die of PCa in Australia (Australia Institute of 
Health and Welfare (AIHW), 2017). It is also suggested that this increasing figure is due to 
increase in both PCa incidence and the aging population (Yu et al. 2015).  
PCa is clinically diagnosed by detection of rising serum PSA in combination with digital 
rectal examination. Low sensitivity of rectal examination and lack of symptoms at earlier 
stages of the disease may lead to delayed diagnosis and treatment, which may result in 
advanced stage at presentation (Schröder et al. 2012).  Early detection of PCa through PSA 
screening contributes to decrease in mortality rate; however, there is a concern that PSA 
testing may contribute to overtreatment for low risk PCa (Schröder et al. 2012; Siegel et al. 
2017).  
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1.2 Treatment options 
The choice for treatment of early PCa depends on various factors such as age, PSA level, 
tumour stage, Gleason score and International Society of Urological Pathology (ISUP) 
score. 
1.2.1 Surgery  
One of the most common management of early PCa is surgery. There are several ways of 
performing prostatectomy namely open radical prostatectomy, laparoscopic radical 
prostatectomy and nerve sparing prostatectomy. It is believed that surgery is one of the 
effective treatments for men with localized PCa, with PSA level greater than 10 ng/mL and 
palpable nodules on digital rectal examination (Litwin et al. 2017; Wilt et al. 2012). 
However, regardless of its effectiveness, complications and side effects are common after 
surgery including impotence, urinary incontinence, sexual dysfunction, infertility and risk 
of infection associated with incision (McCullough 2005). 
1.2.2 Radiation therapy 
Radiation therapy is another conventional treatment for early PCa and may also be used 
after surgery for locally advanced and more aggressive cancer. Radiotherapy is delivered 
mainly by two different methods, external beam radiotherapy, which uses external source 
of high X-ray energy to target the cancer cells, and brachytherapy or internal radiotherapy 
where the radiation source is implanted directly within the prostate gland (American 
Cancer Society, 2016). Similar to surgery, radiotherapy may benefit patients with PSA 
level greater than 10 ng/mL (Litwin et al. 2017). Due to advance in technology, high-
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modulated radiotherapy and stereotactic body radiation therapy seem to deliver higher 
doses of radiation to cancer cells resulting in improvement of cancer control. Moreover, 
low dose brachytherapy can be used for men with small tumours and PSA level less than 
10 ng/mL and a low/intermediate Gleason or ISUP score. Ten-year outcomes after surgery 
or radiation therapy showed that, although men who received radiotherapy had better 
urinary and sexual function, they experienced more nocturia and bowel dysfunction 
compared to those who undertook surgery. This study also suggested that surgery and 
radiotherapy were associated with lower incidences of disease progression and metastases 
than men under active monitoring. However, subsequent urinary and bowel side effects 
can be significant after radiotherapy (Hamdy et al. 2016). 
1.2.3 Androgen Deprivation Therapy (ADT) 
ADT is the primary treatment option for metastatic PCa. It is also known as hormonal 
therapy. Two main forms of ADT have been used in management of metastatic PCa.  One 
is through surgical removal of testes where androgen is synthesised. The other is using 
medication to inhibit the production of androgen. As 90% of PCas are dependent on 
androgen (Roy et al. 1998), androgen removal or blockage can prevent the binding of 
androgen to androgen receptors and thereby suppresses cancer growth. (Tan et al. 2015). 
However patients who have received ADT may progress to castration-resistant PCa despite 
initial positive responses (Saad 2012). Besides, ADT treatment may result in sexual 
dysfunction, decrease in bone density, metabolic changes, decreased libido, depression, 
gynecomastia, anemia and fatigue (Nguyen et al. 2015). In addition, increased risks of 
diabetes and cardiovascular events may also occur following ADT (Litwin et al. 2017).  
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1.2.4 Chemotherapy 
Chemotherapy is an effective modality in the treatment of advanced PCa. It is well 
accepted that chemotherapy drugs such as docetaxel and cabazitaxel have contributed to 
the increase in survival rate (Oudard et al. 2017). Both of these chemo drugs were given as 
first line therapy in patients with metastasis castration-resistant PCa (Oudard et al. 2017). It 
is recently reported that combined treatment of docetaxel and ADT is beneficial for men 
with hormone sensitive advanced PCa (García et al. 2017). However, adverse side effects 
of chemotherapy include nausea, vomiting, diarrhoea, hair loss, loss of appetite, changes in 
blood counts, increasing the risk of bleeding or infections, peripheral neuropathy, fatigue 
and allergic reaction.  
1.2.5 Active Surveillance (AS) 
The number of new PCa cases diagnosed by PSA screening has increased since 1980 and 
approximately 50% of cases are classified as low risk (Garisto et al. 2017).  Over-diagnosis 
and over-treatment for low risk PCa has been a common concern (Tosoian et al. 2016). As 
a result AS has become a front line option for men with low risk PCa.  
According to the Johns Hopkins University guidelines, low risk features are as follows:  
PSA level of < 10 ng/mL, PSA density (PSA level divided by prostate volume) < 0.15 
ng/mL/cm3, Gleason score ≤ 6, ≤ 50% involvement of any biopsy core, and ≤ 2 positive 
biopsy cores involved with PCa (Garisto et al. 2017). AS involves digital rectal 
examination annually, PSA test at 3-6 month intervals, a transrectal ultrasound directed 
confirmatory biopsy within 12 month of diagnosis, and serial prostate biopsies at 2-5 year 
intervals (Carter 2016). The purpose of having these regular examinations is to initiate 
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aggressive treatment in those men who have significant disease progression (Litwin et al. 
2017). 
Studies have shown that men with low risk PCa will benefit from AS. A study in men with 
low grade tumours indicated that the mortality rate is the same in men undergoing AS 
compared to those with immediate aggressive interventions (Wilt et al. 2012; Yaxley et al. 
2013). Similarly, a comparison study of the Prostate Testing for Cancer and Treatment 
(ProtecT) trial in UK has shown a 1.5% death from patients on AS compared to 0.9% with 
surgery, and 0.7% with radiation treatment (Hamdy et al. 2016). There was no statistically 
significant difference in the mortality between the mentioned treatment options from this 
study. However, some data suggest that about 24–40% of men need surgical or medical 
treatment after 5 years on surveillance (Carter 2016). During AS, patients and families 
often live with fear and anxiety (Klotz 2013). Also, uncertainty about the future and fear 
over missing the optimal window of opportunity for a cure has made some men seeking 
intervention. In fact, eagerness for active treatment has contributed to overtreatment in 
men with indolent disease (Dall’Era et al. 2012).   
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1.3 Cell Cycle and Key regulators 
The basic cell cycle is divided into two fundamental phases- interphase and mitosis. The 
interphase can be subdivided into G1, S and G2 phase. In G1 (Gap1) phase, the cells decide 
to enter the cell cycle and prepare for DNA synthesis. Synthetic phase (S) is where DNA 
replication takes place. In G2 (Gap2) phase, the cell prepares for the process of division. M 
(Mitosis) phase is the stage in which the replicated chromosomes are segregated into 
separate nuclei and cytokinesis occurs to form two daughter cells. When the cells lack 
specific mitogen signalling after M phase, they exit the cycle and enter into non-dividing, 
quiescent state known as G0 phase. Most adult human tissues consist of cells arrested at G0 
phase. Upon the growth factor or mitogenic stimulation, these G0 cells may enter into cell 
cycle through signalling pathways regulating cyclins and CDKs (Zetterberg et al. 1995).  
1.3.1 The importance of Cyclins and CDKs in cell cycle 
The up and down-regulation of cyclins and CDKs play a crucial role in cell cycle 
progression. A total of 18 cyclins and 13 CDKs have been found in mammalian cells: 
Cyclin A1, A2, B1, B2, C, D1, D2, D3, E1, E2, F, G1, G2, H, I, K, T1, T2 and CDK1-13 
(Malumbres et al. 2001). All cyclins share a region known as the Cyclin box, which can 
bind and activate CDKs (Santo et al. 2015).  
CDKs are serine/threonine kinases and activation of CDKs requires cyclins and activating 
phosphorylation by CDK-activating kinase (CAK). The negative regulation of CDKs is 
accomplished by inhibitory phosphorylation, and binding of CDK inhibitors (CDKIs) such 
as INK4 family and Cip/Kip family (Pajalunga et al. 2008). The structural study of human 
CDK2, as an example, revealed that CDKs have a modified ATP-binding site between the 
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small amino-terminal lobe and the larger carboxy-terminal lobe. When inactive, ATP 
binding site of CDKs is closed by carboxy-terminal lobe. Binding of cyclins to their paired 
CDKs allows CAK to phosphorylate on carboxy terminal of CDKs. The stimulatory 
phosphorylation by CAK opens the ATP binding site and activates kinase activities of 
CDKs (Holt et al. 2009). CDKs level remains relatively constant throughout the cell cycle 
and most regulation is post-translational. As illustrated in Figure 1.1, the sequential 
activation and subsequent inactivation of these cyclin–CDK complexes govern the 
progression of eukaryotic cells through the cell cycle (Santo et al. 2015; Sgambato et al. 
2000).  
Cyclin D1, D2, D3 are known for their association with CDK4/6 and regulate the G1 phase 
of the cell cycle. The level of D type cyclins usually relies on growth factor stimulation 
such as RAS/RAF/MAPK pathway. The primary substrate for Cyclin D-CDK4/6 is the 
retinoblastoma tumour suppressor protein (Rb). The phosphorylation of Rb protein by 
Cyclin D-CDK complexes leads to the activation of E2F protein which in turn induces 
transcription of Cyclin E, Cyclin A and CDKs (Santo et al. 2015). Cyclin E paired with 
CDK2 enhance the phosphorylation of Rb and thus further activate E2F in a positive 
feedback loop (Ohtsubo et al. 1995). Another function of Cyclin E-CDK2 is 
phosphorylating of histone H1 for remodelling chromosome during replication (Johnson et 
al. 1999; Santo et al. 2015).  
During G1-S transition, Cyclin A paired with CDK2 is required for S phase entry. Cyclin A 
may also bind to CDK1 in late S phase to complete S phase and entry into G2/M phase 
(Schulze et al. 1995). Cyclin A, which is found to be colocalised with DNA, is not only 
involved in initiation and completion of DNA synthesis but may also play a role in 
preventing multiple DNA replications within one cycle (Bendris et al. 2011; Girard et al. 
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1991). Cyclins responsible for the G2/M phase are Cyclin A and Cyclin B. The importance 
of Cyclin B1 and CDK1 will be described in more details in the section 1.7.  
Although the function of Cyclin D-CDK4/6, Cyclin A/E-CDK2, Cyclin B1-CDK1 have 
been studied extensively, the exact role of the rest of Cyclins and CDKs remain elusive. 
Some studies indicate that, through phosphorylation of the carboxy-terminal domain of the 
largest subunit of RNA polymerase II, Cyclin C-CDK8, Cyclin T-CDK9 and Cyclin H-
CDK7 (also known as CDK activating kinase, CAK) are also involved in transcription 
machinery (Johnson et al. 1999; Rickert et al. 1999). Cyclin T-CDK9 is also thought to be 
involved in activation and differentiation of normal lymphoid B cells (De Falco et al. 
2008). Cyclin K-CDK13 also bind and phosphorylate RNA polymerase II at Ser5 and Ser2 
at carboxy-terminal domain (Greifenberg et al. 2016).  
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1.3.2 Cell cycle checkpoints 
Cyclin-CDK complex activity is strictly controlled in cell cycle progression. DNA damage 
or other negative regulation of the complexes before the cells reach restriction point may 
result in activation of the cell cycle checkpoints to arrest cells for DNA repair or apoptosis. 
These checkpoints prevent the cell from leaving the phase without completing and entering 
into new phase prematurely (DiPaola 2002; Malumbres et al. 2001). However, overriding 
the cell cycle checkpoints is very common in cancer cells. There are three main 
checkpoints in cell cycle:  G1-S checkpoint, G2 checkpoint, and mitosis spindle assembly 
checkpoint (SAC) as shown in figure 1.1 (Pietenpol et al. 2002). 
 
Figure 1.1 Cyclin-CDKs regulation of the cell cycle and its association with cell cycle 
checkpoints   
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1.3.2.1 G1-S checkpoint 
A series of mechanisms govern the G1-S phase checkpoint. CDK4 and CDK6 are involved 
in early G1. The activity of CDK4 and CDK6 is positively controlled by association with 
D-type Cyclins (D1, D2 and D3), and negatively regulated by binding to CDK inhibitors of 
INK4 and the Cip/Kip family. The family of INK4 inhibitors includes p16INK4A, p15INKB, 
p18INK4C and p19INK4D and the inhibitory activity occur mainly in G1 phase. Cip/ Kip 
inhibitors involve p21Waf1/Cip1, p27Kip1, and p57Kip2, and their activities are not limited to G1 
phase of cell cycle (Malumbres et al. 2001).  
The main function of Cyclin D-CDK4/6 complexes is to activate retinoblastoma (Rb) 
proteins through phosphorylation (Sherr et al. 2004). pRb together with DP1 form a 
complex with E2F and thereby repress the transcription activity of E2F (Eagle et al. 1967). 
As shown in figure 1.2, hyper-phosphorylation of pRb by Cyclin-CDK complexes releases 
the pRb protein from E2F-DP1-pRb complex, thus indirectly activating E2F transcription 
factors, leading to G1-S progression (Dyson 1998).  The list of genes positively regulated 
by E2F includes Cyclin D and E for G1-S transition, Cyclin A and mini-chromosome 
maintenance proteins (MCM) for DNA polymerase, and thymidine-kinase for DNA 
replication of S phase, chromatin structure, chromosome segregation and mitotic spindle 
assembly checkpoint (Malumbres et al. 2009). The elevated Cyclin D-CDK4/6 complexes 
can sequester Cip/Kip inhibitors resulting in the reduction of the inhibitors for Cyclin E-
CDK2 complexes (Agarwal 2000). Hence, defects in the G1 arrest checkpoint may lead to 
enhanced proliferation through inhibiting INK4 and Cip/Kip inhibitors (Engström et al. 
2015), whereas an elevation of INK4 and Cip/Kip inhibitors would trigger the G1/S 




Figure 1.2 Schematic representation of G1-S checkpoint. (1) Cyclin D-CDK4/6 
complexes phosphorylate pRb, causing  (2) partial release of E2F transcription factors, 
which (3) transcribe and stabilize Cyclin E; the latter (4) heterodimerizes with CDK2 and 
(5) the active kinase complex further phosphorylates pRb, and thus further release of more 
E2F. INK4 family proteins prevent CDK4/6 from the association with the D-type Cyclins. 
Cip/Kip family proteins directly add the inhibitory phosphate on the CDKs and thereby 
inhibiting CDKs activity. 
 
1.3.2.2 G2-M checkpoint 
The function of the G2-M checkpoint is to prevent cells entering into M phase to serve the 
purpose of DNA repair and maintaining genomic stability. Similar to G1-S checkpoint, G2-
M checkpoint activation is mediated by activity of Cyclin-CDK complexes, mainly Cyclin 
B1 and CDK1 (also named as cdc2 in yeast). Even though the rise and fall of Cyclin-CDK 
activity govern the checkpoints activity, mechanisms regulating Cyclin B1 and CDK1 are 
important in triggering the checkpoint activation (DiPaola 2002; Visconti et al. 2016). 
During G2-M transition, Cyclin B1-CDK1 complexes are activated by CAK through 
phosphorylation. The activity of this complex is further controlled by inhibitory 
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phosphorylations of CDK1 at Tyr15 by Wee1 (Do et al. 2013; Parker et al. 1992) and at 
Thr14 by Myt1 (Liu et al. 1997). As described in figure 1.3, the removal of this inhibitory 
phosphates is accomplished by phosphatase CDC25C leading to activation of Cyclin B1-
CDK1 complex and increase the activity of CDK1. Once DNA damage is detected, p53 
and two interconnected pathways ataxia-telangectasia mutated (ATM) protein kinase and 
ataxia-telangiectasia-related (ATR) protein kinase are activated in G1, S and G2/M phase 
(Pietenpol et al. 2002; Visconti et al. 2016). This ATM induced signalling in turn activates 
check point kinase 1 (CHK1) (Furnari et al. 1997) and check point kinase 2 (CHK2) 
(Matsuoka et al. 1998). Active CHK1 and CHK2 inhibit the activity of CDC25C through 
phosphorylation at Ser216 upon the activation of ATM. Also this inactive phosphorylation 
by CHK1 and CHK2 creates the favourable binding site for 14-3-3 protein on CDC25C 
(Peng et al. 1997). After binding to 14-3-3 protein, CDC25C is localised in the cytoplasm 
and thus becomes dysfunctional leaving Cyclin B1-CDK1 in inactive stage (Lopez-Girona 
et al. 1999).  
Studies reported that introducing a cytotoxic DNA damaging agent could arrest G2 
checkpoint (Nomura et al. 2007; Zhu et al. 2009). If cancer cells with a defective G1 
checkpoint received DNA damage, these cancer cells are prone to be arrested at G2-M 
phase (DiPaola 2002). The defect in G2-M checkpoint may allow the entry of damaged 
cells to mitosis, which subsequently results in apoptosis or serious consequence if the 
damage is carried to the next cell cycle (Hirose et al. 2001; Jackson et al. 2000; Visconti et 




Figure 1.3 Regulators responsible for G2-M checkpoints. During G2 to M transition, 
Cyclin B1-CDK1 (cdc2) complex needs to be activated.  Negative regulation by Wee1 
involves adding the two phosphates on CDK1 activity site. Dephosphorylation of two 
inhibitory sites by the phosphatase Cdc25C increases the activity of CDK1. DNA damage 
activates CHK1, which inactivates Cdc25C through phosphorylation of cdc25C, resulting 
in the phosphorylation and inactivity of Cyclin B1-CDK1 and G2-M arrest (DiPaola 2002). 
 
1.3.2.3 Mitosis checkpoint or spindle assembly checkpoint (SAC) 
In a normal dividing cell, genomic stability relies on a safeguard mechanism called spindle 
assembly checkpoint (SAC). SAC prevents errors in chromosome segregation by delaying 
the transition of metaphase to anaphase until the correct mitotic spindle assembly is 
completed. This process assures a proper bipolar attachment of all chromosomes to spindle 
microtubule and to align the metaphase plate before entering into anaphase (Diogo et al. 
2017). The sensitivity of SAC to errors in chromosome attachment is accomplished 
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through kinetochore proteins, which are assembled on centromeric region of chromatin. As 
shown in figure 1.4.A, upon the unattached kinetochore, mitotic arrest deficient 2 (Mad 2) 
from mitotic checkpoint complex (MCC) is activated. MCC contains Mad 2, budding 
uninhibited by benzimidazole (Bub) 3, and budding uninhibited by benzimidazole related 1 
(BubR1) (Logarinho et al. 2008). The activated MCC consequently sequesters and inhibits 
cell division cycle 20 (CDC20). CDC20 is the cofactor and activator of anaphase-
promoting complex/ cyclosome (APC/C) and its inhibition by MCC leads to inactivation 
of APC/C. Consequently, the inhibition of APC/C by SAC response prevents the 
degradation of both Cyclin B1 and the anaphase inhibitor securin, leading to mitotic arrest 
and inhibition of sister chromatid separation (Diogo et al. 2017).  
SAC is turned off when the chromosome completes proper bipolar attachment to the 
mitotic spindle and alignment at the mitotic plate. The release of CDC20 activates APC/C, 
allowing APC/C to target and ubiquitinate Cyclin B1 and securin for degradation by the 
26S proteasome. Proteolysis of securin allows protein Separase for cleaving of Cohesin to 
promote sister chromatid separation (Diogo et al. 2017). During mitosis, active Cyclin B1-
CDK1 is required for several mitotic events such as phosphorylation, activation of 
microtubule-associated proteins, nuclear lamins, and centrosomal proteins to initiate 
chromosome condensation, assembly and nuclear envelope breakdown. Cyclin B1 
degradation by APC/C quenches CDK1 activity and results in chromosome separation and 
completion of mitosis and cytokinesis (Figure 1.4 B). Several protein kinases such as 
protein kinases Bub1 (Tang et al. 2004), Polo Like Kinase 1(PLK1) (Lane et al. 1996; 
Strebhardt 2010), monopolar spindle (Mps) 1 (Santaguida et al. 2010) and Aurora B (Hauf 
et al. 2003; Lampson et al. 2011), also play a vital role in SAC. 
Several genes involved in SAC pathway have been reported to be deregulated in different 
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types of cancer including PCa. It has been found that overexpression of SAC member 
proteins, such as Mad2 (Wang et al. 2002), CDC20 (Wu et al. 2013), BubR1 (Fu et al. 
2016), PLK1, Aurora B (Chieffi et al. 2006), Bub1 (Ricke et al. 2011) contributes to 
cancer progression with poor survival in PCa.  
 
Figure 1.4 Molecular view of the spindle assembly checkpoint (SAC) Pathway. (A) 
Immunofluorescence Image of a prometaphase cell, stained for microtubules (green), 
kinetochores (red), and for DNA (blue), showing the presence of unaligned chromosome. 
SAC is on when the chromosomes are not aligned and attached to microtubules correctly, 
leading to activating of inactive Mad2 (o-Mad2) to active (c-Mad2). Active Mad2 recruits 
the MCC complex: Bub3, BubR1, and Cdc20, resulting in inhibition of APC/C. Inactive 
APC/C loose its ability to degrade Cyclin B1 and Cyclin B1 remains associated with 
CDK1 as does securin with serparase, resulting in mitotic arrest. (B) Immunofluorescence 
image of a metaphase cell, stained as in (A), showing all chromosomes aligned at the 
metaphase plate. In this condition, SAC is turned off. MCC is not activated, leading to 
releasing of CDC20 to activate APC/C. This mechanism allows the degradation of Cyclin 
B1 and securin by APC/C, letting the Separase to cleave Cohesins to start the separation of 
sister chromosome, while inactive CDK1 promotes the mitosis exit (Diogo et al. 2017).  
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1.4 Signalling pathways and proteins involved in DNA 
damage response 
DNA damage in human may arise from either physiological processes or environmental 
DNA-damaging agents (Jackson et al. 2009; Valko et al. 2006). Some radioactive 
compounds such as uranium decays contribute to cancer incidence (Jackson et al. 2009). 
DNA damage by these chemicals leads to impairment in base pairing during DNA 
replication and transcription, base loss or DNA single strand breaks (SSBs) and double-
strand breaks (DSBs) (Jackson et al. 2009). In order to repair DNA damage caused by 
either exogenous or endogenous source, cell machinery evolves a mechanism called DNA-
damage response (DDR). DDR detects and signals the DNA lesions, pauses the cell cycle 
transition, and activates the DNA repair system. Hence, DDR entails not only the 
activation of cell cycle checkpoint but also the initiation of apoptosis, transcription and 
DNA repair.  Failure in DNA repair system may lead to genomic instability and 
carcinogenesis (Shaltiel et al. 2015) 
The framework signalling of DDR can be divided into three layers: 1) Sensors, 2) 
Transducers and 3) Effectors as depicted in figure 1.5 (Maréchal et al. 2013). Once DNA is 
damaged, free DSBs ends are recognised by sensors such as MRN complex (Mre11, Rad50 
and NBS1), which is recruited to the DNA damage site. NBS1 directly interacts with DSBs 
and initiates the formation of MRN protein complex. MRN complex subsequently recruits 
and activates transducer kinases including ATM, ATR, DNA-dependent protein kinase 
(DNA-PK) and their downstream kinases such as CHK1 and CHK2 (Maréchal et al. 2013). 
Transducers kinases further activate the effectors proteins such as breast cancer 
susceptibility associated protein 1 (BRCA1), p53, CDC25 phosphatase family etc. 
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Figure 1.5 The framework of the DDR signalling pathway. DDR signalling pathway 
consists of signal sensors, transducers, and effectors. The sensors of DDR are proteins that 
recognize DSBs or SSBs. The transducers are kinases, including ATM, ATR, and their 
downstream kinases. The effectors of this pathway are substrates of transducers kinases 
involved in a broad spectrum of cellular processes that are important for maintenance of 
genomic stability of organisms (Maréchal et al. 2013). 
 
1.4.1 Activation of ATM and ATR 
As the transducer kinase, ATM and ATR are key components of DDR signalling 
pathways. ATM was first discovered in radiation treatment of Ataxia-telangiectasia (AT), a 
neurodegenerative disorder. Hypersensitivity of AT cells to IR leads to identification of 
AT mutated (ATM) gene. The predicted ATM gene share the homology of 
phosphatidylinositol-3 kinase related proteins which play a role in cell cycle control, DNA 
repair, and DNA recombination (Canman et al. 1998; Zakian 1995). ATR was discovered 
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later than ATM, and also belongs to the phosphatidylinositol 3-kinase family (Maréchal et 
al. 2013). In undamaged cells, ATM exists as dimers or oligomers and is altered into 
monomers on activation by DNA damage, whereas ATR forms a complex with ATRIP 
(ATR interacting protein) in the presence or absence of DNA damage (Maréchal et al. 
2013).  
The activation and recruitment of ATM and ATR are different. ATM activation is 
associated with DSBs and ATR is related to SSBs (Jackson et al. 2009). Emerging 
evidence suggests that DSBs not only activate ATM, but also turn on the ATR kinase 
(Shaltiel et al. 2015). The main sensor responsible for ATM activation and recruitment is 
MRN complex (Canman et al. 1998). MDC1 from MRN complex assists ATM to not only 
recognize DSBs but also locates the nucleosomes containing phospho-H2AX thus 
facilitates ATM to recognize the chromatin flanking DSBs and to enhance phospho-H2AX 
foci formation along chromatin (Maréchal et al. 2013). Different from ATM, the 
recruitment of ATR-ATRIP to DNA damage site is facilitated by RPA-coated single 
stranded DNA (ssDNA), which plays an important role in homologous recombination 
(HR) damage repair mechanism (Maréchal et al. 2013). 
A switch in the activating pathway of ATM to ATR has been well documented associated 
with DNA damage repair mechanism (Maréchal et al. 2013; Shiotani et al. 2009). When 
DSBs occur, the cell cycle stage has a major influence on the choice of the repair pathway 
employed. Specifically, DNA damage can trigger either Non-homologous end joining 
(NHEJ) or HR depending on phase of cell cycle. NHEJ is a fast response but error prone to 
re-join DNA ends throughout the cell cycle and ATM activation is involved (Riballo et al. 
2004). In contrast, ATR is associated with HR. HR responds to DSBs occurred during the 
S phase and G2 phase using homologue sequences and errors free. HR initiates repair 
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mechanism using ssDNA ends to search for homologous sequences. A conversion from 
DSBs to ssDNA was carried out by nucleases such as MRN complex and this process is 
called resection (Takeda et al. 2007). This ssDNA can be recognised by ATR and leads to 
ATR activation during S phase (Jackson et al. 2009; Maréchal et al. 2013; Shiotani et al. 
2009). ATM dependent phosphorylation of ATR has also been reported as these two 
kinases share a domain called the putative leucine zipper domain (Canman et al. 1998). 
Activation of ATM and ATR are critical for DSBs induced checkpoint responses as their 
activation lead to activation of DNA damage checkpoints protein to either stop the cell 
cycle progression or apoptosis. 
1.4.2 Activation of CHK2 and CHK1  
There are other transducers of DDR signalling pathway, CHK2 and CHK1. The activation 
of CHK2 and CHK1 by ATM and ATR reduces CDK activity by various mechanisms in 
order to slow down or arrest cell-cycle progression. Although it has long been reported 
dependency of CHK1 on ATR, and CHK2 on ATM, emerging evidence of these kinases 
showed various “crosstalks” among these kinases (Bartek et al. 2003; Do et al. 2013; 
Shaltiel et al. 2015). Following IR induced DNA damage; ATM can phosphorylate both 
CHK2 and CHK1 (Figure 1.5) (Ahn et al. 2004; Liu et al. 2000). Several studies reported 
that DNA damage checkpoint mediators such as p53 binding protein 1 (53BP1), NBS1, 
together with ATM, induce the activation of CHK2 and CHK1 (Bartek et al. 2003). 
In response to DNA damage, ATM phosphorylates CHK2 at Thr68 on N-terminal SQ/TQ-
rich regulatory domain, and it is also suggested that ATR may phosphorylate and activate 
CHK2 in the same manner. Alanine mutation of this phosphorylation site prevents 
activation of CHK2 in vivo (Ahn et al. 2004). Due to its rapid mobility, Thr68 
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phosphorylation by CHK2 is defined as the checkpoint signal spreader (Ahn et al. 2004). 
CHK2 protein is found to be stable as a monomer throughout the cell cycle at its inactive 
stage in the absence of DNA damage (Bartek et al. 2003). Following the DNA damage, 
dimerization of CHK2 monomers followed by multiple inter-molecule phosphorylation 
events at Thr383 and Thr387 within the auto inhibitory loop lead to kinase activation (Ahn et 
al. 2004). Besides, additional auto-phosphorylation at Ser516 on CHK2 induces its full 
kinase activity (Wu et al. 2003). 
In human cells, CHK1 can be phosphorylated at Ser 345 by ATR (Liu et al. 2000). In 
contrast to CHK2 protein, which is stable and expressed throughout the cell cycle, CHK1 
protein is restricted to S and G2 phases. The activation of CHK1 has been found even in 
the normal cell cycle progression and CHK1 is further activated in DNA damage response 
(Bartek et al. 2003). Dimerization and auto-phosphorylation are not necessary in activation 
of CHK1 (Ahn et al. 2004).  
1.4.3 ATM-CHK2, ATR-CHK1 Signal transduction 
The main function of DNA damage checkpoint protein is to delay the cell cycle 
progression and to allow DNA repair before replication or mitosis exit. In response to IR in 
G1 phase, ATM has been found to regulate and phosphorylate p53 at Ser15 in vitro. A study 
also suggests that phosphorylation of p53 resulted from active CHK2 induced by ATM. 
CHK2 phosphorylates p53 at Ser20 after DSBs. As a result, ATM-CHK2 weakens the 
ability of p53 binding to Mouse double minute 2 (MDM2), an E3 ligase. In the absence of 
DNA damage, MDM2 down regulates the stability of p53 facilitating its degradation 
(Canman et al. 1998). So the stable p53 induced by ATM turns on a variety of 
transcriptions such as p21 in order to inhibit the activity of CDKs in G1 phase (Canman et 
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al. 1998; Shaltiel et al. 2015).  
Among the downstream effector substrates of ATM-CHK2, cell division cycle 25 family 
phosphatases, CDC25A (Falck et al. 2001) and CDC25C (Blasina et al. 1999) are well 
known in DNA damage checkpoint signalling. CDC25A and CDC25C function in 
activation of CDK2 and CDK1 by dephosphorylation of inhibitory phosphate from CDKs 
resulting in progression of G2 phase to M phase. The phosphorylation on CDC25A at 
Ser123 by CHK2 leads to degradation of CDC25A via SKP1-cullin-F-box (SCF) proteins in 
G1 phase. Similarly, phosphorylation of CDC25C at Ser216 by CHK2 destabilises this 
phosphatase creating a motif for 14-3-3 proteins for nuclear export (Peng et al. 1997). It is 
followed by degradation of CDC25C and leads to inactivating of Cyclin B1 and CDK1 for 
G2-M transition. CHK2 also phosphorylates and activates Wee1 to inhibit the CDK1 
activity at G2-M transition (Figure 1.6) (Jackson et al. 2009). 
Furthermore, the activation of p38 MAPK family by ATM prevents S phase entry through 
stabilisation of p21 mRNA transiently and promoting the degradation of Cyclin D and the 
CDC25A phosphatase that increases the activity of CDK in G1 phase (Shaltiel et al. 2015). 
It is also reported that active CHK2 phosphorylates E2F1 at Ser364 after DNA damage 
induced by agent etoposide negatively affecting the stability and transcription activity and 
may result in apoptosis (Ahn et al. 2004; Lin et al. 2001).  
Despite the difference in biological role between ATM and ATR, CHK2 and CHK1, these 
two kinases possess overlapping roles in checkpoint signalling. CHK1 is also defined as 
analogue of CHK2 and therefore may have similar effect on p53, CDC25A and CDC25C 
upon DSBs (Liu et al. 2000). CHK1 alone targets Cdc25A even in the absence of DNA 
damage and revealing another function of CHK1 in normal cell cycle transition via 
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Cdc25A (Bartek et al. 2003). CHK1 is also able to phosphorylate on Wee1, which add 
inhibitory phosphates on Cyclin B1-CDK1 complex (Shaltiel et al. 2015). When the DNA 
damage occurs in G2 phase, ATM and CHK2 signalling pathway initiates cell cycle arrest 
at G2 and is later maintained by signal induced by ATR-CHK1. Furthermore, similar to G1 
phase arrest caused by DDR, G2 arrest is likely achieved through inhibition of CDC25 
family phosphatase resulting from p38 activation by ATM and ATR kinases. However, 
ATR induced activation of CHK1 is disabled in G1 phase. Claspin is a positive regulator of 
CHK1 and its degradation by APC/CCDH1 prevents the activation of CHK1 in G0 and G1 
phase (Shaltiel et al. 2015). Therefore, ATM-CHK2 signalling control of G1 checkpoint in 
response to DNA damage (Figure 1.6). 
When the replication forks create ssDNA during S phase, DDR from ssDNA triggers the 
activation of ATR (Jackson et al. 2009; Shaltiel et al. 2015). Both ATM and ATR are 
responsible for signalling events during S phase. In spite of p53 stabilisation induced by 
both ATR and ATM, the effector p21 expression is inhibited during DNA replication by 
the PCNA associated cullin4A RING E3 ubiquitin ligase complex containing Cdt2 (Abbas 
et al. 2008; Shaltiel et al. 2015).  
Unlike the other phases of cell cycle, DDR and DNA repair mechanisms are absent during 
M phase regardless that DSBs (Figure 1.6). PLK1 and CHK2 are co-localised in 
centrosome (Tsvetkov et al. 2003).  In order to support the mitotic exit, PLK1 inhibits the 
CHK1 and CHK2 from being activated by ATR and ATM. First, PLK1 phosphorylates 
CHK2 to prevent dimerization. PLK1 also introduces the degradation of Claspin, which 
bridges between ATR and CHK1 for CHK1 activation, via SCF protein. Second, CDK1 is 
found to phosphorylate RNF8 at Ser198 to prevent the formation of polyubiquitin damage 
site. Third, during mitosis, PLK1, together with unidentified kinase, diminish the 
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recruitment of 53BP1 protein to DNA damage site by adding phosphate at Thr1609 and 
Ser1618 on 53BP1. Phosphorylation of RNF8 and 53BP1 consequently prevent DNA 
damage repair. Together, these mechanisms eliminate most checkpoint signals and DNA 
repair in mitosis (Ahn et al. 2004; Shaltiel et al. 2015). More detail information of the role 




Figure 1.6 DNA damage response signalling in the various stages of the cell cycle. Damaged DNA activates the ATM kinase in all phases 
of the cell cycle. CDK2 forces HR activity in S phase and G2 to activate ATR. CDK2 dependent phosphorylation of ATRIP and Chk1 further 
restrict full activation of ATR and CHK1 to S and G2 phase. Finally, DNA damage signalling is potently inhibited in mitosis due to combined 
action of Cdk1 and Plk1 (Shaltiel et al. 2015). 
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1.4.4 Aberrant regulation of ATM and ATR 
It has been well accepted that a defect in ATM has severe consequences as ATM is 
involved in DNA repair, gene regulation, translation initiation and telomere 
maintenance. Since there is a strong relation between ATM and BRCA1 protein, AT 
patients have increased risk for breast cancer (Friedenson 2007). ATM deficient mice 
are viable with slow growth (Canman et al. 1998). Strong association between 
epigenetic modification (methylation) in ATM and several carcinomas including lung 
cancer and brain tumour has been recorded (Safar et al. 2005). Although ATM and 
ATR share the homology, the mutation in ATR protein is not prone to tumour risk.  
1.4.5 Aberrant regulation of CHK2 and CHK1 
Knock down studies of CHK2 and CHK1 reported that CHK1 is essential for 
embryonic development, and viability (Liu et al. 2000) and is indispensible for 
checkpoints response, while CHK2 may work as a tumour suppressor. A frameshift 
mutation in CHK1 protein has been implicated in colon and endometrial carcinomas 
with microsatellite instability. In small lung carcinomas, a shorter isoform of CHK1 
mRNA, which is thought to encode CHK1 protein lacking catalytic domain has been 
identified (Bartek et al. 2003). Likewise, somatic mutations of CHK2 have been found 
in breast, lung, ovary, colon cancers, osteosarcoma and lymphoma. Down-regulation 
of CHK2 protein level is also common in oncogenesis. Moreover, Thr68 phospho-
CHK2 has been found in primary breast and colon carcinomas with mutant p53 (Ahn 
et al. 2004). 
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1.4.6 γH2AX  
γH2AX or phospho-H2AX is a well-known sensitive biomarker for monitoring DNA 
damage initiation and resolution due to its biological features, or phospho-H2AX foci, 
in response to DNA damage. H2AX belongs to the H2A histone family (H2A, H2B, 
H3 and H4), which forms octamer of core histone protein in the nucleosomes. In 
mammalian cells, the C terminus of H2AX at Ser139 (γH2AX) is phosphorylated by 
DNA damage response kinases such as ATM, ATR and DNAPK (Burma et al. 2001) 
and this C terminal extension region of H2AX is highly conserved among eukaryotes.  
H2AX phosphorylation is a key step in DDR to initiate the DNA repair mechanism. 
Once DSBs occurs, the ability of chromatin modification of H2AX allows increased 
DNA accessibility, recruitment and accumulation of DDR proteins at DNA ends. It 
also helps to re-join the DSBs by anchoring broken ends together through nucleosome 
repositioning, and decreases the density of chromatin (Mah et al. 2010). A study has 
shown that H2AX null mice are sensitive to IR with genomic instability causing 
tumours, and restoration of wild type (WT) H2AX allele causes radiation resistance 
with conserved genome (Celeste et al. 2003).  
ATM is the most potent activator of H2AX and its phosphorylation on H2AX occur on 
DNA adjacent to a DSB as shown in Figure 1.7 (Shaltiel et al. 2015), but others 
indicate that ATR is more important for H2AX phosphorylation in response to DNA 
damage. In order to create a signal amplification loop of phospho-H2AX at the DNA 
damage site, several mediators such as NBS1 (Kobayashi 2004), MDC1 (Lou et al. 
2006) and phospho-H2AX itself (Stucki et al. 2006) facilitate phosphorylation of 
H2AX induced by ATM. The bonds between NBS1 and MDC1 to phospho-H2AX 
 52 
also serve as assembly sites for other DDR proteins including E3 ubiquitin protein 
ligase RNF8, RNF168 (RING finger protein 168), MRN complex, BRCA1 and p53-
binding protein 1 (53BP1), which are essential recognizers and mediators of DDR 
(Palla et al. 2017). This phosphorylation event of H2AX occurs within minutes after 
DNA damage, and rapidly spreads over large chromatin domains (Maréchal et al. 
2013). Distinct nuclear foci formation as a result of H2AX phosphorylation induced by 
ATM and ATR is now widely used as a quantitative marker of individual DSBs (Mah 
et al. 2010). 
Using immunofluorescence microscopy, phospho-H2AX foci can be detected a range 
of quantities from low events just minutes after DSBs until 4hr post radiation with a 
linear relationship between foci formation and dose of IR in human fibroblasts 
(Markova et al. 2007). It has also been suggested that the quantity of phospho-H2AX 
may be used for detection of precancerous lesion as it reflects the genomic instability 
associated with cancer. Additionally, phosphorylated H2AX is applicable for 
observing radiation sensitivity of individual clinical setting in cancer treatment (Mah et 
al. 2010; Olive et al. 2004).   
The presence of phospho-H2AX in normal cells have been reported without being 
affected by external DNA damage revealing multiple function of H2AX in various 
parts of cellular events starting from acetylation, phosphorylation and ubiquitination, 
DNA repair, cell growth etc. In addition, mutations or deletions are very common on 
the chromosome where H2AX is located, leading to variety of human cancers 
(Pouliliou et al. 2014). The expression level of phospho-H2AX is implicated with 
disease progression in different types of cancer. For example, epithelial ovarian cancer 
tissues express significantly higher level of phospho-H2AX than in normal tissue. In 
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breast cancer patients, the increase in phospho-H2AX foci correlates with poor 
prognosis. Similar result has also been found in hepatocellular carcinoma, colon 
carcinomas, fibrosarcoma, osteosarcoma, glioma, and neuroblastoma cells (Palla et al. 
2017). Taken together, phospho-H2AX behaves as a sensitive marker for DSBs, which 
implies genomic instability and may contribute to cancer initiation and progression. 
 
Figure 1.7 Flow chart represent G2 phase arrest on DNA damage response. The 
DNA double strand breaks triggered by IR and other genotoxic events phosphorylate 
H2AX by ATM. γH2AX (phospho-H2AX) is required for phosphorylation of 53BP1 
by ATM and localize 53BP1 into nuclear foci. In turn, ATM together with 53BP1 
phosphorylate of its downstream target p53. 53BP1 is not necessary to couple ATM in 
activation of CHK1 and CHK2. 
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1.4.7 53BP1 
Another important protein that responds to DSBs is 53BP1. 53BP1 was firstly 
described as the binding partner of tumour suppressor protein p53, although the 
significance of the interaction with p53 is still unclear. It has been reported that 53BP1 
functions as a mediator and effector of the DSBs response (Panier et al. 2014). 53BP1 
has been used as clinical prognostic marker because 53BP1 form large foci near DNA 
lesions (Djuzenova et al. 2015) and it also acts as an indicator of where ATM or ATR 
mediated DNA damage signalling is induced (Figure 1.7). 
The mechanism involved in the recruitment of 53BP1 to the site of DNA breaks is 
complicated and still in debate. According to nuclear magnetic resonance and X-ray 
crystallography spectroscopy studies, chromatin binding domain of 53BP1 specifically 
binds to histone H4 dimethylated lysine-20, for its localization to damage sites (Gupta 
et al. 2013; Kim et al. 2006). It has also been reported that phospho-H2AX is necessary 
in recruiting 53BP1 to the DNA damage site and thereby promotes phosphorylation 
events by ATM (Gupta et al. 2013). This recruitment of 53BP1 to the DNA damage 
site by numerous proteins has been reported.  ATM, MDC1, the MRN complex, and 
the RING finger E3 ubiquitin ligases RNF8 and RNF168 are upstream mediators 
found in DNA damage foci (Daley et al. 2014). RNF8 is joined at the DNA damage 
site though MDC1 and its subsequent recruitment of 53BP1 is dependent on the 
interaction between RNF8 and its partner E2 enzyme UBC13. The ubiquitination of 
phospho-H2AX and H2A by RNF 8 is recognised by RNF168. RNF168 together with 
UBC13 further transmit the ubiquitination of histone of phospho-H2AX and lysine 13 
and lysine 15 of histone H2A. This sequential ubiquitination event facilitates the 
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docking site for 53BP1in access to the DNA damage sites (Daley et al. 2014). 
53BP1 is a large protein with no significant enzymatic activity, but it holds interacting 
sites of several proteins related to DSBs response. 53BP1 includes three main sites, 
which can be phosphorylated by ATM upon DNA breaks. Evidence had been found to 
describe the role of 53BP1 on DNA damage site. Firstly, 53BP1 serves as the scaffold 
protein for DSBs repair and signalling proteins such as the chromatin modulator 
EXPAND1 (Huen et al. 2010), RAP1-interacting factor 1, and PAX transactivation 
activation domain interacting protein which subsequently recruits RNF8 and RNF168 
to the damage chromatin site (Daley et al. 2014; Panier et al. 2014). Secondly, 53BP1 
promote DNA damage checkpoint signalling through amplification of ATM activity 
like phospho-H2AX, in response to low levels of DNA damage (DiTullio et al. 2002). 
Thirdly, it is involved as a key player in preserving genome integrity by choosing the 
relevant DNA repair pathways regarding the different cell cycle phases (Gupta et al. 
2013). 53BP1 functions to promote NHEJ and inhibiting HR. Inhibiting of recruitment 
the HR factor BRCA1 by 53BP1 to DSBs has been reported. 
Genomic instability with G2-M check point defect has been reported in both human 
and mouse, in the absent of 53BP1 as a consequence of failure to indicate the damage 
site on chromatin through consequent reduction in phosphorylation of ATM targets 
such as p53, CHK2 and BRCA1 (DiTullio et al. 2002; Panier et al. 2014). 53BP1 is 
under expressed in triple negative breast cancer (Bouwman et al. 2010) 
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1.5 M phase promoting complex and regulators at G2 to 
M phase transition 
Cell cycle progression from G2 to M phase requires the activation of M phase 
promoting complex, which is Cyclin B1-CDK1 and its regulators such as PLK1 and 
Aurora A (Otto et al. 2017).  
1.5.1 Cyclin B1-CDK1 complex  
During cell cycle progression, entry to mitosis is controlled by activation of Maturation 
promoting factor or Mitosis promoting factor (MPF) (Murray et al. 1989).  MPF is 
composed of two different regulatory proteins, CDK1 and its activating partner, Cyclin 
B1 (Murray et al. 1989). Unlike other interphase CDKs, such as CDK2 and CDK4/6, 
CDK1 is the only CDK that is essential for cell cycle progression as the mouse 
embryos failed to develop in the absence of CDK1 (Santamaria et al. 2007). 
Inactivation of CDK1 also prevents tumour formation and dissemination suggesting a 
critical role of CDK1 in cell cycle progression (Diril et al. 2012). The activity of 
CDK1 involved in many cell cycle events such as gene transcriptions, DNA 
replication, chromosome segregation and cell morphogenesis. Emerging evidence 
showed that approximately 75 targets of CDK1 have been identified (Enserink et al. 
2010).  
1.5.1.1 Role of Cyclin B1 and CDK1 at G2/M phase 
Like other CDKs, CDK1 is expressed throughout the cell cycle, although it is activated 
only at G2-M transition (Glotzer et al. 1991). The activity of CDK1 is regulated 
through its phosphorylation mode. The protein level of Cyclin B1 begins to rise at late 
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S phase and reaches its peak level in G2-M transition, followed by its fall in anaphase 
onset (Clute et al. 1999). Once Cyclin B1-CDK1 complex is activated, this complex in 
turn activates numerous proteins from M phase such as microtubule-associated 
proteins, nuclear lamins, histone H1, centrosomal proteins to initiate chromosome 
condensation, assembly and nuclear envelope breakdown (Johnson et al. 1999). In late 
mitosis, Cyclin B1 is degraded by APC/CCDC20 and APC/CCDH1 extinguishing CDK1 
activity and thus consequently allows chromosome segregation and cytokinesis. The 
impairment of Cyclin B1-CDK1 activity at G2-M transition will cause G2 checkpoint 
activation and cell cycle arrest (Otto et al. 2017). 
A correlation has been reported between overexpression of Cyclin B family and human 
cancers including prostate, breast and lung cancers. The high level of Cyclin B1 is also 
associated with tumour grade and poor prognosis. Therefore, the regulation of Cyclin 
B1 and CDK1 at mRNA level, protein level by post translational modification and 
localization are essential in progression of cells from G2 phase to M phase (Porter et al. 
2003; Takizawa et al. 2000).  
1.5.1.2 Regulation of Cyclin B1-CDK1 
There are several mechanisms that are involved in the regulation of Cyclin B1-CDK1 
complex.  
1.5.1.2.1 Regulation by Cyclin B1 
Activity of CDK1 can be regulated fundamentally through synthesis and degradation 
of its binding partner Cyclin B1 as shown in figure 1.8. According to the study in vitro 
and in vivo of xenopus cells, Cyclin B1 level is 20-30 fold higher in late G2 than in G1 
phase as the protein needs to get to peak level for activation of CDK1 (Murray et al. 
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1989). A similar pattern has also been found in mRNA level of Cyclin B1 (Morgan 
1995). The transcription factors that bind to promote region of Cyclin B1 include p53, 
p21, Activator protein 1, c-Myc. Therefore, regulation of the mRNA level of Cyclin 
B1 by these transcription factors may indirectly influence on the CDK1 activity 
(Bretones et al. 2015). Cyclin B1 degradation by APC/C is necessary for driving 
mitotic exit and cytokinesis (Van Zon et al. 2010).  
Interaction between Cyclin B1 and CDK1 through Cyclin motif activates the 
serine/threonine protein kinase activity of the CDK1. Cyclin B1 binding through this 
functional domain allows opening of kinase domain of CDK, which is blocked by T 
loop before interaction. Therefore, mutation on this Cyclin motif may keep CDK1 in 
its inactive stage (Morgan 1995; Porter et al. 2003). 
1.5.1.2.2 Regulation by CAK 
Similar to other CDKs, phosphorylation at the catalytic domain, ie ATP binding site, 
of CDK1 determines the active or inactive form of CDK1. Catalytic cleft of ATP 
binding site needs to be opened by phosphorylation for kinase activation. To achieve 
this activation, CDK1 is phosphorylated on Thr161 by CAK at G2 phase and remains in 
active stage until late M phase (Figure 1.8) (Morgan 1995).  
1.5.1.2.3 Regulation by Myt1 and Wee1 
On the other hand, phosphorylations on Thr14 and/or Tyr15 by Myt1 and Wee1 in the 
nucleus inhibit CDK1 activity by blocking the ATP binding sites respectively (Figure 
1.8) (Do et al. 2013). The increase in activity and protein level of Wee1 during S and 
G2 phases inhibit Cyclin B1-CDK1 activity before G2 phase and upon mitotic entry, 
and its degradation induced by PLK1 enhances the activity of Cyclin B1-CDK1 
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(Matheson et al. 2016). Consistently, following DNA damage, Wee1 is stimulatory 
phosphorylated by CHK1, which inhibits the Cyclin B1-CDK1 activity causing G2 
arrest (Do et al. 2013; Pietenpol et al. 2002; Shaltiel et al. 2015). 
1.5.1.2.4 Regulation by CDC25C 
During G2-M transition, the inhibitory phosphates formed Cyclin B1-CDK1 complex 
is removed by phosphatase CDC25C. CDC25C belongs to CDC25 protein tyrosine 
phosphatases (PTPs) family, which includes three isoforms: CDC25A, CDC25B and 
CDC25C (Figure 1.8). Among them, CDC25A mainly functions in G1 and S phase, 
while CDC25B and CDC25C are involved in G2 phase (Lammer et al. 1998).  
Activity of this phosphatase is regulated by phosphorylation in a cell cycle-dependent 
manner. PLK1 is a well-known positive regulator of CDC25C. The phosphorylation on 
Ser198 at nuclear localization signal of CDC25C by PLK1 locates CDC25C to the 
nucleus and activates its activity (Toyoshima‐Morimoto et al. 2002). Once activated, 
CDC25C removes the inhibitory phosphates from Cyclin B1-CDK1 and enhances cell 
cycle progression.  
CDC25C is phosphorylated at Ser216 by CDC25C associated protein kinase 1 in 
interphase and this phosphorylation site is important for binding to 14-3-3 protein 
(Lopez-Girona et al. 1999; Peng et al. 1998). This interaction enhances cytoplasmic 
localisation of CDC25C and interferes the interaction with Cyclin B1-CDK1 (DiPaola 
2002; Peng et al. 1998). In contrast to Wee1 activity, inhibition of CDC25C by CHK1 
and CHK2 is found after DNA damage.  As aforementioned in G2-M checkpoints, 
CDC25C is inhibited via phosphorylation on Ser216 by both CHK1 and CHK2, and 
thus creates the binding site for 14-3-3 in order to prevent the activation of Cyclin B1-
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CDK1 complex (Pietenpol et al. 2002; Shaltiel et al. 2015). 
Studies have shown that mutations inhibiting the activity of CDC25B and CDC25C 
arrest the cells at G2 phase. Although aberrant expression of CDC25C is not found, 
CDC25A and CDC25B are over expressed in many tumours including: breast, colon, 
gastric, ovarian, thyroid, esophageal, squamous-cell and colorectal carcinomas, 
lymphoma and neuroblastoma and is associated with tumour grade and poor prognosis. 
Structural analysis of CDC25 family suggested that the difference in amino acid 
residues affect the catalysis activity of these three isoforms and thereby affecting 
different substrates (Lavecchia et al. 2010).  
1.5.1.2.5 Regulation by intracellular localization 
Cyclin B1-CDK1 complex is also known to be regulated through its localization. 
Cyclin B1 lacks nuclear localization signal and only presents cytoplasmic retention 
signal (CRS). As a result, it remains in cytoplasm throughout interphase and needs the 
aid of nuclear localization signal from other proteins to be transported into nucleus for 
activation of CDK1 (Porter et al. 2003). The deletion of CRS region allows Cyclin B1 
in the nucleus. It is reported that during the onset of M phase, Cyclin B1 is 
phosphorylated on Ser126 and Ser128 by CDK1 (Borgne et al. 1999) and Ser147 by PLK1 
(Toyoshima-Morimoti et al. 2001). As these phosphorylation sites are on its CRS, 
phosphorylations by PLK1 and CDK1 inhibit CRS leading to localization of Cyclin B1 
in the nucleus (Porter et al. 2003). 
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Figure 1.8 Schematic diagram represents the regulation of Cyclin B1-CDK1 
complex (MPF). Cyclin B1-CDK1 complex is positively regulated by CAK, Cyclin 
B1 synthesis and phosphatase CDC25C and negative regulated by Wee1 and Myt1. 
PLK1 activates CDC25C and inhibits Wee1 in order to activate Cyclin B1-CDK1. 
Activation of Cyclin B1-CDK1 complex leads to cell cycle progression from G2 phase 
to M phase. 
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1.5.2 PLK1 
Polo like kinase 1 (PLK1) belongs to a family of serine/threonine kinases, which 
contains a unique polo-box domain and plays a vital role in cell cycle progression. It is 
commonly accepted that the importance of PLK1 is no less than CDKs as the cells fail 
to complete bipolar spindle attachment in the absence of PLK1 in yeast and animal 
cells (Sumara et al. 2004). The catalytic activity of PLK1 is activated by stimulatory 
phosphorylation at Thr210 by Aurora A and Bora at G2 phase (Macurek et al. 2008; 
Seki et al. 2008) and phosphatase 1 C is thought to dephosphorylate at centrosome. 
PLK1 is targeted for degradation by anaphase-promoting complex/cyclosome, 
APC/CCDH1 through ubiquitination in anaphase and DNA damage (Floyd et al. 2008).  
According to localisation studies of PLK1, the presence of PLK1 in both nucleus and 
cytoplasm indicates its versatile functions and crucial role in cell cycle progression as 
shown in figure 1.9 (Van Vugt et al. 2005). Studies have also uncovered that PLK1 has 
multiple functions in regulating cell cycle such as supporting the entry into mitosis, 
centrosome maturation, spindle assembly, sister chromatid splitting, activation of the 
APC/C and exit from mitosis with the initiation of cytokinesis (Strebhardt 2010).  
Since overexpression of PLK1 in human is strongly correlated with tumour 
progression, inhibitors targeting PLK1 have been identified and developed for clinical 
trial (Strebhardt 2010). Interestingly, although down-regulation of PLK1 causes 
apoptosis in cancer cells, viability of normal cells is not affected by its down-




Figure 1.9 Localisation of PLK1 in G2 phase and M phase of cell cycle by 
immunofluorescence. 
 
1.5.2.1 Role of PLK1 in G2-M transition 
Studies of the protein and mRNA level of PLK1 in both Drosophila melanogaster and 
Saccharomyces cerevisiae showed that the activity of PLK1 is low in G0, G1 and S 
phases, and begins to increase in G2 and reached the peak level during M phase 
(Golsteyn et al. 1994) indicating the importance of PLK1 in G2 and M phase. During 
G2 phase, PLK1 is phosphorylated on Thr210 in the activation loop of the kinase 
domain by Aurora A and Bora (Aurora kinase A activator) causing its activation 
(Macurek et al. 2008; Seki et al. 2008). Active PLK1 controls the G2-M transition via 
regulation of the activity of MPF. There are three significant mechanisms that control 
activity of MPF, Cyclin B1-CDK1, by PLK1. Firstly, PLK1 activates CDC25C 
through phosphorylation at Ser198 and that in turn removes the inhibitory 
phosphorylation on CDK1. Phosphorylation by PLK1 not only activates CDC25C, but 
also translocates CDC25C into the nucleus (Toyoshima‐Morimoto et al. 2002). 
Secondly, PLK1 inhibits Wee1(Watanabe et al. 2004) and Myt1 (Nakajima et al. 
2003), which are the inhibitors of CDK1. Phosphorylated Wee1 is targeted to undergo 
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proteasome-dependent degradation after ubiquitination by the E3 ubiquitin ligase 
SCFβ-TrCP (Watanabe et al. 2004). Thirdly, PLK1 phosphorylates Cyclin B1 on its 
CRS in order to localize Cyclin B1-CDK1 to the nucleus (Figure 1.10) (Toyoshima-
Morimoti et al. 2001). Therefore, the role of PLK1 in G2-M transition is indispensible 
(Strebhardt 2010). 
1.5.2.2 Role of PLK1 in DNA damage response 
Among the many of PLK1 functions, PLK1 is also involved in the G2 checkpoint 
activation after DNA damage. One investigation had shown that the PLK1 is inhibited 
by DNA damage in G2 phase and Mitosis phase in human osteosarcoma cells (Smits et 
al. 2000). This group also reported the association of PLK1 with DDR checkpoint 
protein kinase CHK2 after treating the cells with IR. Furthermore, PLK1 is 
catalytically inactivated and this inactivation is dependent on activity of ATM 
and ATR, which in turn contributes to G2 arrest due to the ability of PLK1 in locating 
Cyclin B1 to the nucleus (Figure 1.10). Consistently, expression of active form of 
PLK1 overrides the DNA damage induced G2 phase arrest (Smits et al. 2000; Van 
Vugt et al. 2005).  
The regulation of PLK1 in checkpoint recovery after DNA damage has been studied in 
yeast, but its function in mammalian cells is very limited. One study had shown that 
although depletion of PLK1 did not have a significant effect on mitotic entry in cells 
with unperturbed cell cycle, PLK1 is essential in damaged cells for mitotic entry after 




Figure 1.10 The role of PLK1 in (a) G2 phase, (b) Mitotic entry and (c) G2-M 
DNA damage checkpoint. 
a) Premature mitotic entry is prevented 
in G2 phase through inhibitory 
phosphorylation on Cdk1 and blocking 
nuclear export of Cyclin B. 
b) During mitotic entry, the activation 
of Plk1 results in multiple processes 
including the activated phosphorylation 
of Cyclin B and Cdc25C, inhibitory 
phosphorylation of Wee1 and Myt1. 
Phosphorylation of Cyclin B and 
Cdc25C, promotes Cyclin B–Cdk1 
activation at the centrosome and a 
feedback loop may involve for signal 
amplification. In contrast inhibitory 
phosphorylation of Wee1 results in its 
degradation.  
c) Upon DNA damage, the G2 DNA 
damage checkpoint prevents mitotic 
entry through activation of checkpoint 
kinases ATM, ATR, Chk1, Chk2 and 
p38 mediate nuclear export of Cdc25B 
and Cdc25C, degradation of Cdc25A, 
activation of Wee1 and inhibition of 
Plk1, resulting in inactivation of Cyclin 
B-Cdk1 with inhibitory 
phosphorylation at Tyr15. 
? indicates unclear mechanism. 
(Van Vugt et al. 2005) 
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1.5.2.3 Role of PLK1 in Mitosis 
The most remarkable feature of PLK1 is its presence in various subcellular structures 
during mitotic progression. The association of PLK1 and centrosomes is found in 
prophase, followed by the accumulation of PLK1 in kinetochore during prometaphase 
and metaphase. During anaphase, it is recruited to spindle attachment and move to 
mid-body in telophase (Petronczki et al. 2008).  
Firstly, PLK1 regulates the maturation of centrosome in prophase. PLK1 recruits the γ-
Tubulin ring complex, which nucleates new microtubules to centrosomes. Another 
component of centrosome regulated by PLK1 is Ninein-like protein whose functions 
are in recruitment of γ-Tubulin ring complex and regulation of microtubule nucleation 
(Petronczki et al. 2008; Strebhardt 2010). During prophase, PLK1 contributes to the 
activation of APC/C, which is an E3 ubiquitin ligase, through multiple events in the 
control of sister-chromatid separation and mitotic exit. Early mitotic inhibitor 1 (EMI1) 
is an inhibitor of APC/C during S and G2 phases. The inhibitory phosphorylation of 
EMI1 by PLK1 leads to SCF dependent degradation of EMI1 activating APC/C for 
chromosome separation. After sudden degradation of EMI1, PLK1 can directly 
phosphorylate the subunits of APC/C and enhances the activity of APC/C beyond the 
prometaphase (Golan et al. 2002). After its full activation, APC/C activates the 
Separase and then active Separase cleves Cohesin allowing the separation of sister 
chromatin (Strebhardt 2010).  
Inactivation of PLK1 induced by siRNA before and after assembly of bipolar spindles 
shows that PLK1 is essential in bipolar spindle attachment and also necessary to 
maintain the proper attachment. In addition, electron microscopy observation of PLK1 
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with abnormal polo box domain shows mislocalisation of PLK1 and consequently 
causes error in microtubule-kinetochore attachment (Sumara et al. 2004). PLK1 is also 
a major player in SAC.  Recruitment of the main components of SAC: Mad1/Mad2 
and Bub3/BubR1 and CENP-E; is increased by the activity of PLK1 through 
phosphorylation and destruction of PLK1 by RNAi or other pharmacological reagents 
arrests the mammalian cells in prometaphase due to failure kinetochore and 
microtubule attachment (Petronczki et al. 2008; Sumara et al. 2004).  
In order to generate two physical distinct daughter cells, the formation of cleavage 
furrow is necessary before cytokinesis. A protein complex called centralspindlin is 
located on spindle midzone between the parallel alignment of two sets of separated 
sister chromosomes. This complex contains Rho GTPase-activating protein HsCYK4 
and the mitosis kinesin like protein 1. PLK1 is localized on the midzone and 
phosphorylates HsCYK4 and thus creates docking site for Rho GTP exchange factor 
ECT2. This event by PLK1 is pre-requisites for assembly of actinomyosin ring 
formation and activation of the small GTPase RhoA, causing cleavage furrow 




1.5.3 Aurora A  
Aurora A kinase, a centrosome-localized protein, belongs to serine threonine kinase 
Aurora kinase family (Marumoto et al. 2002). Like PLK1, overexpression of Aurora A 
kinase is associated with a broad range of human malignancies and has been targeted 
for anti-cancer therapy. A number of Aurora A kinase inhibitors have been 
characterised and clinically assessed (Wang et al. 2014). As an oncogene, Aurora A 
regulates cell cycle progression at multiple levels. It is reported that, among the three 
Aurora kinases: Aurora A, Aurora B and Aurora C, Aurora kinase A and B play crucial 
roles in mitosis of human cells Aurora A has a short amino-acid peptide motif entitled 
the “destruction box” (D-box). This D box is recognised by APC/C for degradation 
through the ubiquitin/proteasome pathway (Yan et al. 2016).  
1.5.3.1 Role of Aurora A in G2-M transition 
One of the most important functions of Aurora in cell cycle regulation is activating 
PLK1 and CDC25C in order to promote cell cycle progression from G2 phase to M 
phase. PLK1 is phosphorylated at Thr210 by Aurora A (Macurek et al. 2008). Aurora A 
together with its partner Bora induce phosphorylation of PLK1 at Thr210 and activate 
PLK1 to initiate entry to M phase (Seki et al. 2008). This study collectively indicated 
PLK1 activation induced by Aurora A on the activation of CDK1 by CDC25C (Seki et 
al. 2008). A positive feedback loop has been found in Aurora A activation mediated by 
Ajuba, one of LIM proteins (Hirota et al. 2003). 
Silencing Aurora A by miRNAs or VX680 reduces the expression of CDC25C in renal 
carcinoma cells (Li et al. 2012). Furthermore, overexpression of Aurora A increases 
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Cyclin B1expression and interrupts the degradation of Cyclin B1 (Qin et al. 2009). It is 
also reported that Aurora A kinase phosphorylates CDC25B at Ser353 leading to its 
activation and may enhance the de phosphorylation of CDK1 inhibitory phosphate and 
localizes the Cyclin B1-CDK1 complex in the nucleus at G2-M transition in Hela cells 
(Dutertre et al. 2004). Consistently, inhibiting Aurora A activity delays M phase entry 
of the cells (Marumoto et al. 2002). 
Emerging evidence shows that Aurora A inhibits tumour suppressor proteins such as 
pRb, p53, p21, p27. Down-regulation of Aurora A in multiple myeloma by Aurora 
kinase inhibitor MLN8237 induces G2/M arrest with the increase of p53, p21 and p27 
protein levels both in vitro and in vivo (Görgün et al. 2010). Similar result has been 
found by using another Aurora A kinase inhibitor MK8745 in HCT cells (Nair et al. 
2012). When Aurora A is transiently down regulated by shRNA osteosarcoma cells, 
the cells viability is inhibited with a significant apoptosis and G2/M arrest (Jiang et al. 
2014).  
1.5.3.2 Role of Aurora A in DNA damage response 
The role of Aurora A in DNA damage response is also documented. The kinase 
activity of Aurora A is inhibited upon DNA damage and arrests the cells at G2 phase 
with dependence on CHK2 and CHK1 kinases (Krystyniak et al. 2006). Up-regulation 
of Aurora A after DNA damage abolishes G2-M arrest. Aurora A also phosphorylates 
p53 at Ser315 disrupting the DNA binding ability of p53 and facilitates the degradation 
of p53 mediated through MDM2. It has been shown that phosphorylation of p53 at 
Ser315 by Aurora A decreases the sensitivity of H1299 cells to Cisplatin and IR (Liu et 
al. 2004; Wang et al. 2014).  
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1.5.3.3 Role of Aurora A in Mitosis   
In mammalian cells, Aurora A level was low in G1 and S phase and accumulated at 
centrosomes during G2 phase. Aurora A kinase activity is highest at G2-M transition in 
human cells. Aurora A undergoes subcellular location throughout the mitosis phase 
indicating its involvement in multiple mitotic events (Wang et al. 2014; Yan et al. 
2016). Firstly, Aurora is involved in centrosome maturation since its accumulation was 
observed in G2 phase. Aurora A depleted cells lack γ-Tubulin recruitment and 
nucleated mitotic microtubules compared to control cells revealing immature 
chromosome (Bai et al. 2014; Hirota et al. 2003). Aurora A depletion at late G2 in 
HeLa cells prevents centriole separation with disrupted spindles after nuclear envelope 
breakdown (NEBD) (Marumoto et al. 2003). 
Aurora A is directly involved in metaphase chromosome alignment through 
centromere protein A (CENP-A). Aurora A phosphorylates CENP-A at Ser7 which is 
prerequisite for Aurora B dependent phosphorylation of CENP-A for proper 
microtubule attachment to kinetochore followed by chromosome alignment and 
segregation (Zeitlin et al. 2001). Besides, Aurora A phosphorylates CENP-E to 
transport protein phosphatase 1 to the outer kinetochore, which weakens the CENP-E's 
affinity for individual microtubules resulting in stable microtubule capture by 
chromosomes (Kim et al. 2010). Deregulation of Aurora A at metaphase by either 
depletion or overexpression leads to impairment in cytokinesis with multi nucleated 
cells. Therefore, sequential timing of activation and inactivation of Aurora A kinase is 
required for cytokinesis. At the end of mitosis, degradation of Aurora A by the 
APC/CCDH1 complex is required for proper cytokinesis and mitotic exit (Yan et al. 
2016). 
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1.6 The use of Traditional Chinese Medicine (TCM) in 
Cancer 
At present, there is a lack of treatment options for men undergoing AS. Since men 
undergoing AS are healthy otherwise, any medical intervention to impede disease 
progression must be efficient, and affordable with minimal side effects. To this end, 
our research team has tuned our attention to TCM.  
TCM has been used for cancer treatment in China for centuries (Liu et al. 2015; Mao et 
al. 2014; McCulloch et al. 2006). Mainly, it is a botanical extract through decoction. 
Unlike a single molecule-based drug, the characteristic of TCM is a mixture of several 
herbs. The philosophy behind this ‘cocktail’ approach is to enhance efficacy and 
minimize adverse effects (Yeh et al. 2014).  
1.7 Detoxification Recipe (DR) 
Described originally as Detoxification Recipe, DR consists of two herbs, namely 
Hedyotis diffusa (HD) and Scutellaria barbata (SB), and remains one of the most 
prescribed herbal medicines for cancer patients today in mainland China and Taiwan 
with minimal reported side effects (Chao et al. 2014; Yeh et al. 2014). Fewer than 5 
English articles have been published in peer-reviewed journals in relation of HD or SB 
to PCa (Marconett et al. 2010; Shoemaker et al. 2005; Wong et al. 2009). None of 
these studies has detailed description about cytostatic action of HD and SB in PCa 
cells. A total of 41 studies on HD and 99 studies on SB in relation to cancer have been 
reported and there has been only one study on the combined effect of HD-SB pair. The 
anti-cancer effect of HD-SB pair was tested in bladder cancer cells, but the mechanism 
of action is still poorly understood (Pan et al. 2016).  
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1.7.1 HD, Hedyotis diffusa (Bai Hua She She Cao) 
Hedyotis diffusa (Bai hua she she cao) is a herb derived from the whole plant of 
Hedyotis diffusa Willd. HD belongs to the family Rubiaceae and also called 
Oldenlandia diffusa Roxb (Stuenæs et al. 2010). In traditional Chinese Medicine, HD 
is commonly used for detoxification, and has long been used as an anti-cancer agent in 
oriental medicine. A number of pharmacological studies have shown that HD has anti-
cancer, anti-inflammatory, anti-oxidative, neuroprotective, hepatoprotective, anti-
mutagenesis and immunomodulating activities (Chen et al. 2016; Niu et al. 2013).  
 
Figure 1.11 Hedyotis diffusa Left: Magnified view of HD flower, leaf, stem and dried 
HD, Right: whole plant of HD with flowers (photo courtesy to Real Natural, Inc.) 
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1.7.1.1 Chemical profiles and properties 
A total of 171 compounds have been discovered in HD including 32 iridoids, 26 
flavonoids, 24 anthraquinones, 26 phenolics and their derivatives, 50 volatile oils and 
13 miscellaneous compounds (Chen et al. 2016). Anthraquinones are well known as 
abundant constituents of the family Rubiaceae and are reputed to have biological 
activities such as antimicrobial, laxative, diuretic, and antineoplastic. The flavonoids 
from HD are mainly glycosides of kaempferol and quercetin and also apparently have 
a wide variety of biological activities including anti-oxidant, anti-inflammatory, anti-
cancer, anti-viral, anti-bacterial, and also cytoprotective effect on coronary and 
vascular systems, the pancreas, and the liver. Terpenoid extracts from HD are mainly 
iridoids and triterpenes. It has been found that iridoids possess anti-inflammatory, anti-
proliferative, neuroprotective, and antioxidant properties. Triterpenes from HD such as 
ursolic acid and oleanolic acid have hepatoprotective, anti-tumour, anti-inflammatory, 
and anti-hyperlipidemic effects (Niu et al. 2013).  
1.7.1.2 Anti-proliferative effect of HD in PCa 
Two studies have reported the anti-proliferative effect of HD extracts in PCa. The first 
study used water extract of HD to test against PCa cell lines (LNCaP and DU145) in 
vitro. The anti-proliferative activity of aqueous extract was shown with growth 
inhibition at 50% (IC50) at 7 mg and 24 mg of raw material/mL after 48 hr treatment in 
LNCaP and DU145 cells, respectively (Gupta et al. 2004). The second study showed 
that cyclotides extracted from the root of HD (1 mg/kg dose) inhibited the 
development of the xenografts PCa cells tumour in weight by 40% and size by 50% 
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(Hu et al. 2015). But the mechanism of how HD inhibits the proliferation of PCa cells 
has not yet been studied.   
1.7.1.3 Anti-proliferative effect of HD in other cancers 
Several studies have tested a variety of HD extracts like methanolic, ethanolic and 
water extract on anti-proliferative effects in different types of cancer such as pancreatic 
cancer (Gupta et al. 2004), lung cancer (Gupta et al. 2004), colorectal cancer (Lin et al. 
2015), leukemia (Niu et al. 2013), cervical cancer (Zhang et al. 2015), ovarian cancer 
(Zhang et al. 2016) and human liver cancer (Li et al. 2016). 
A water extract of HD has anti-proliferative activity in pancreatic cancer cells at 24 
mg/mL and interestingly, the extract has a very limited cytotoxicity with only 10% 
growth inhibition on the normal pancreatic cells even at the concentration of 50 
mg/mL (Gupta et al. 2004). This research group also reported that the oral 
administration of this extract reduced the metastasis of lung up to 70% in vivo study 
(Gupta et al. 2004). 
Lin’s research group demonstrated that an ethanol extract of HD inhibited the growth 
of human colon carcinoma (HT-29) cells in a dose and time dependent manner. This 
research group has also shown that the ethanol extract induces apoptosis with 
activation of caspase-9, caspase-3 and also increased the level of Bax (Lin et al. 2010). 
In addition, the ethanol extract prevented G1 to S transition of HT-29 cells with the 
reduced mRNA expression of Cyclin D1 and CDK4, and increased p21 expression 
(Lin et al. 2012). An animal study using this extract showed that intra-gastric 
administration of HD ethanol extract reduced tumour volume and tumour weight of 
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mouse xenograft model by approximately 50% at the dose of 6 g/kg in colorectal 
cancer (Cai et al. 2012).  
An ethanol extract of HD has anti proliferative activity with the G0/G1 phase arrest and 
also stimulates apoptosis in human leukemia cells (Kuo et al. 2015). Moreover, a 
methanol extract of HD inhibits the growth of human lymphoid leukemia HL-60 cells 
with an induction of p53, down-regulation of p21 and up-regulation of p27 (Niu et al. 
2013).  
A study in cervical cancer found that intra-gastric administration of HD decreased the 
tumour weight by 36% in Hela cell xenograft mice with the reduction in Ki-67 protein 
expression (Zhang et al. 2015). Zhang’s research team has also shown that the crude 
extract of HD inhibits the growth of ovarian cancer cells and induces apoptosis via 
mitochondria associated apoptotic pathway (Zhang et al. 2016).  
Moreover, it has also been reported that a water extract of HD arrests the 
hepatocarcinoma cells at G0/G1 with down-regulation of CDK2, Cyclin E and E2F 
level (Chen et al. 2012). Together, these various extracts of HD appear to have 





1.7.2  SB, Scutellaria barbata (Ban Zhi Lian) 
Scutellaria barbata (Ban Zhi Lian) is a species of flowering plant in the mint family, 
Lamiaceae. In traditional Chinese medicine, SB is used to treat a variety of illnesses 
such as appendicitis, hepatitis, snake bites and various types of cancer such as lung, 
liver, and rectum (Huang 1998). SB has also been used as anti-inflammatory and anti-
tumour agent in traditional Korean medicine. Extracts from SB have growth inhibitory 
effects on a number of human cancers including leukemia, colon cancer, liver cancer 
and skin cancer, in vitro (Goh et al. 2005) .           
 
Figure 1.12 Scutellaria barbata. Left: Magnified view of SB flowers, leaf, stem and 




1.7.2.1 Chemical profiles and properties 
Using an ultrahigh performance liquid chromatography coupled with hybrid 
quadrupole-orbitrap mass spectrometry (UHPLC-quadrupole-orbitrap MS) method, a 
total of 56 compounds, including 20 free flavonoids, 20 flavonoid O-glycosides, 2 
flavonoid C-glycosides, 4 phenylethanoid glycosides, and 10 phenolic compounds 
have been found in an ethanol extract of SB (Ru Li 2015). Among them, flavonoids are 
well known for their anti-proliferative, anti-inflammatory, anti-cancer, anti-viral, and 
anti-bacterial activities. 
1.7.2.2 Anti-proliferative effect of SB in PCa 
The anti-proliferative study of SB on PCa has been reported in the literature. An early 
study of SB in PCa cells showed that aqueous extract of SB inhibited the growth of 
PC-3 cells and LNCaP cells and IC75 values were 1 mg/mL and 1.5 mg/mL, 
respectively (Shoemaker et al. 2005). A study in LNCaP cells treated with SB showed 
anti-proliferative effect and apoptosis effect with the increased expression of Bax, p53, 
Akt, and JNK in vitro. This group also reported that the feeding of SB 32 mg/day 
delayed the tumour development in the respective TRansgenic Adenocarcinoma 
Mouse Prostate (TRAMP) mice compared with sterilized water treated control group 
(Wong et al. 2009). BZL101 is the aqueous phytochemical extract of SB and it is 
shown to arrest the LNCaP cells at G2/M phase and PC-3 cells at S phase. This group 
also reported that G2/M arrest in LNCaP cells was associated with the decreases in 
Cyclin B1, CDK1 and S phase arrest in PC-3 cells was related to the decrease of 
Cyclin A2 and CDK2 (Marconett et al. 2010). 
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1.7.2.3 Anti-proliferative effect of SB in other cancers 
Similar to HD, anti-proliferative effect of SB on different types of cancer such as lung 
cancer (Yin et al. 2004), uterus cancer (Lee et al. 2004), colon cancer (Goh et al. 
2005), colorectal cancer (Yang et al. 2017), leukemia (Kim et al. 2007), liver cancer 
(Dai et al. 2008; Kan et al. 2017) were reported. 
It has been shown that the ethanol extract of SB is effective in inhibiting the growth of 
lung cancer cells by causing apoptosis. According the cDNA microarray analysis, the 
cytotoxic effects of SB resulted from downregulation of several genes which involved 
in DNA damage, cell cycle control, nucleic acid binding and protein phosphorylation 
(Yin et al. 2004). 
Lee’s research group had found that treatment with a water extract from SB inhibits the 
proliferation of uterine smooth muscle cells (Lee et al. 2004). Water extract from SB 
increased uterine smooth muscle cells in G1 phase with increased activity of p27 (Lee 
et al. 2004).  
The proliferation of human colon cancer cells was inhibited after treatment with SB 
extracts in a time-dependent manner. A significant increase in the Sub G1 phase was 
observed after treating with a higher dose of SB extract, suggesting that it induced cell 
death in the human colon cancer and colon rectal cancer cell line (Goh et al. 2005; 
Yang et al. 2017). An ethanol extract of SB has been shown to arrest colon carcinoma 
cells at G1/S phase through p53 and Akt modulated pathway (Wei et al. 2013). The 
chloroform fraction of SB has been shown to have potent inhibitory effect on the 
growth of colon cancer cell lines. The apoptosis induced by chloroform fraction of SB 
with up-regulation of the pro-apoptotic Bax/Bcl-2 ratio was also documented. This 
 79 
study also found a decrease in the expression of Cyclin D1 and CDK4 after SB 
treatment (Zhang et al. 2014).  
A study using a water extract of SB showed anti-proliferative activity of SB inducing 
G1 arrest and a significant apoptosis in the human promyelocytic leukemia HL-60 cell 
line. SB treatment also down-regulate the expression of Cyclin A, D1, D2, D3, and E 
and CDK 2, 4, and 6 with associated up-regulation of p21 (Kim et al. 2007).  
Treatment with SB extract decreased the proliferation of hepatoma cells in a dose 
dependent manner (Kan et al. 2017). A decrease in tumour growth has also found in 
hepatoma H22-bearing mice after treating with SB extract (Kan et al. 2017). 
Previously, Dai’s research group has found that anti-proliferative activity of SB in 
hepatoma cells is associated with apoptosis and the increase of caspase-3 activity in a 
dose-dependent manner (Dai et al. 2008). Taken together, the biological properties of 















2 Hypothesis and Aims 
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Active surveillance (AS) is one of the options for men with early PCa. Recent reports 
highlight that the proportion of men with low-risk PCa on AS are increasing 
worldwide over the decade from 6.7% in 1990-2009 to 40.4% in 2010-2013. In men 
aged ≥75 years, the proportion of men undergoing AS is as high as 76.2% (Cooperberg 
et al. 2015; Tosoian et al. 2016). Considering PCa will remain one of the top cancer 
diagnoses projected for 2030 (Rahib et al. 2014), the absolute number of men on AS 
can be expected to increase further in the coming decades. While novel biomarkers, 
genomic testing, and image-guided biopsy (MRI-targeted biopsy or fusion biopsy) may 
improve disease classification (Carter 2016), the lack of biomarkers that are both 
sensitive and specific enough to predict the progression of PCa  is likely to stay. 
Hence, the need to develop a new treatment option to help men on AS is critically 
important. 
2.1 Targeting cell cycle progression could be a strategy 
to impede PCa progression 
PCa involves an uncontrolled proliferation of prostatic epithelial cells in the prostate 
gland (Lee et al. 2015). In mammalian cells, uncontrolled cell proliferation is a result 
of the disrupted cell cycle regulation. Indeed, many cell cycle regulating genes such as 
phosphatase and tensin homolog (PTEN) (Vignarajan et al. 2014; Vlietstra et al. 1998), 
p53 (Isaacs et al. 1991) and p27 (Chu et al. 2008) are often mutated in PCa. In contrast 
to the normal cell cycle, which is strictly controlled by a series of complex signalling 
pathways responsible for DNA replication and cell division, cell cycle regulatory 
machinery is malfunctioning causing uncontrolled proliferation in cancer cells 
(Malumbres et al. 2001).  
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Ki-67 is a DNA associated nuclear protein expressed during all active phase of cell 
cycle (G1, S, G2 and M phase), but is absent in quiescent cells. Thus, Ki-67 has been 
used as a marker to determine growth fraction of a given cell population (Gerdes et al. 
1984; Khatami et al. 2009). Ki-67 immunostaining has been widely used to determine 
the rate of cancer cell proliferation in various types of cancer including PCa (Berlin et 
al. 2017). The expression level of Ki-67 is low in low-grade and low-volume PCa 
compared with high-grade and high-volume cancers, suggesting an association 
between Ki-67 protein level and disease progression (Khatami et al. 2009; 
Urruticoechea et al. 2005). A recent study has also shown that Ki-67 positivity is 
correlated to increased chance of metastasis, while low Ki-67 positivity is associated 
with better overall and disease specific survival in localised PCa (Berlin et al. 2017). 
Therefore, it is believed that the fraction of Ki-67 positive cancer cells is correlated 
with PCa risk and progression (Berlin et al. 2017; Khatami et al. 2009). We reason that 
a method that is able to impede cell cycle progression and subsequent proliferation is 




2.2 Hypothesis and Aims 
Men undergoing AS need a treatment option in addition to regular check-ups. This 
treatment option should meet the criteria of high efficacy, cost effective and minimal 
toxicity since men undergoing AS are healthy otherwise. The two herbs medicine DR 
is the most commonly prescribed Chinese Medicine to treat cancer in China. The 
overarching goal of this project is to examine the potential of DR to impede PCa 
progression for men under AS.  
2.2.1 Hypotheses  
1) DR has an anti-proliferative activity in PCa cells and can inhibit the cell cycle 
progression. 
 
2) The mode of action of DR involves targeting of key proteins responsible for 
promoting cell cycle progression.  
 
2.2.2 Aims   
The aim of this PhD project was to determine the anti-proliferative action and mode of 
action of DR in PCa cells. Specific aims and experimental approach were outlined as 
follows: 
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2.2.2.1 To determine the anti-proliferative and cytostatic action of DR in 
PCa cells 
To determine the anti-proliferative activity of DR on PCa cells, LNCaP and PC-3 were 
treated with DR and the effect of DR on DNA content was analysed by using SYBR 
Green DNA analysis assay and cytostatic dose of DR was defined. The effect of DR on 
DNA synthesis was verified using BrdU incorporation assay. The proliferative fraction 
of DR treated PCa cells were validated using Ki-67 immunocytochemical staining.  
Colony formation assay was performed on DR treated PCa cells to observe the 
relatively long-term effect of DR. pH and osmolality were tested to exclude any 
external impact independent from any anti-cancer property of DR.  
2.2.2.2 To examine the effect of DR on cell cycle progression of PCa cells 
To examine effect of DR on cell cycle progression, PCa cells treated with DR were 
stained with a DNA dye (PI) and cell cycle analysis was performed using flow 
cytometry. PCa cells treated with DR were additionally co-stained with PI and 
phospho-Histone H3 to further differentiate between G2 and M phases, with 
Nocodazole treated PCa cells as positive control.   
2.2.2.3 To establish the molecular mechanism underlying cytostatic 
action of DR in PCa cells  
To study the molecular mechanism underlying cytostatic action of DR in PCa cells, 
proteins involved in DNA damage response signalling pathways, in particular the 
G2/M checkpoint, were examined. Immunofluorescence and immunoblotting were 
performed to examine the presence of DNA damage in DR treated PCa cells with 
radiation treated PCa cells as positive control. Immunoblotting and RT-PCR were used 
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to determine the expression levels of M phase promoting complex and regulators. The 
Dutch based online tool R2: Genomics Analysis and Visualization Platform was used 
to examine the mRNA expressions of M phase promoting complex and regulators. 
Datasets from cBioportal for Cancer Genomics were analysed to determine the 











3 Materials and Methods 
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3.1 Cell lines and Cell Cultures  
3.1.1 Prostate cancer cell lines 
The lymph node metastasised PCa cell line, LNCaP (Cat. #: CRL- 1740; American 
Type Culture Collection, USA) and the bone metastasised PCa cell line, PC-3 (Cat. #: 
CRL-1435; American Type Culture Collection, USA), were grown in complete RPMI 
medium (Cat. #: A1049101l; Life Technologies, Australia), supplemented with 10% 
(v/v) fetal calf serum (FCS) (Cat #: SFBS-F; Bomogen), penicillin at 100 units/mL and 
streptomycin at 100 μg/mL (Sigma Aldrich, Australia). All the cells were cultured at 
37°C in a humid atmosphere containing 95% air and 5% CO2. The cells were 
maintained at optimal growth by splitting regularly and changing media 2 to 3 times 
per week. 
3.1.2 Cell Passaging  
When cells were 70-80% confluent, cells were subcultured in Corning® T-75 flasks 
(Cat. #: CLS430641, Sigma-Aldrich). Firstly, culture medium was removed and briefly 
rinsed the cell layer with pre-warmed phosphate buffer saline (PBS). PBS was 
aspirated and followed by adding 1 mL of TrypLETM Select (GIBCO®, Life 
Technologies, Australia) solutions. The cells were incubated at 37°C (usually within 3 
to 5 minutes) until the cells were dispersed. Detached cells were collected and 
centrifuged at 1500 rpm for 5 minutes. The supernatant was discarded and cells were 
subsequently re-suspended in 10 mL of respective complete medium by gentle 
pipetting. Appropriate aliquot of the cells at the ratio of 1:6 for LNCaP, cells and 1:10 
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for PC-3 cells was placed into new T75 culture flasks with 15 mL of culture medium. 
The newly passaged cells were then incubated at 37°C. As for cell counting and 
estimating the viable cells over non-viable cells, hemocytometer and trypan blue (Cat 
#: 15250061, Thermo Fisher Scientific, Australia) were used. The passage number of 
cells in this study was 16–34 for LNCaP and 26–42 for PC-3. 
 
3.2 Treatment  
3.2.1 DR Treatment 
DR was provided by Professor Li Zhong from Beijing University of Chinese Medicine. 
DR is comprised of Scutellaria Barbata 30g; Hedyotis Diffusa 30g. The instructions 
for preparing an extract were as follows: The water decoction is extracted twice in 
ethanol and then vacuum dried into powder. This process was conducted in a GMP 
laboratory in Beijing University. Dr Cheang Khoo (National Institute of 
Complementary Medicine) has used his published liquid chromatography-mass 
spectrometry (LC-MS) methods (Lee et al. 2009; Moawad et al. 2010) to profile 
chemicals in DR. Dr Cheang Khoo and his research team has profiled five most 
abundant chemicals from Hedyotis diffusa and three from Scutellaria barbata (Table 
3- 1). These eight compounds have been shown to have anti-cancer property in the 
literature (Gao et al. 2017; Janicke et al. 2011; Kim et al. 2018; Vijayababu et al. 2005; 
Wu et al. 2012; Yan et al. 2017). The four compounds of eight (Oleanolic acid, P-
coumaric acid, Quercetin and Apigenin) were used to standardise DR between three 
different batches.  
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Table 3-1 Chemical profiling in DR measured by LC-MS  
 
DR powder was stored in -20°C. On the day of treatment, DR powder was dissolved in 
the aforementioned complete culture medium at 20 mg/mL by sonication at 35kHz for 
90 minutes using a Sonorex Digitec ultrasonic sonicator (DT 102H, Bandelin). After 
sonication, DR stock solution was checked thoroughly to confirm whether DR powder 
was completely dissolved. Clear coloration of DR stock solution indicates the 
complete dissolving. To make the desired solution, the 20 mg/mL stock solution was 
diluted further to 0.25, 0.5, 0.75 or 1 mg/mL using RPMI culture media. 
3.2.2 Nocodazole treatment  
PCa cells were treated with Nocodazole (Cat. #: M1404, Sigma-Aldrich, Australia) at 
200 - 800 ng/mL for 18 hr. Cells were then harvested and stained for propidium iodide 
(PI) (Cat. #: P4170, Sigma-Aldrich) for flow cytometry DNA analysis and costained 
with PI and antibody (Ab) against phospho-Histone H3 for flow cytometry of DNA 
and mitosis phase analysis.  
Hedyotis diffusa Oleanolic acid 
P-coumaric 
acid Ursolic acid Ferulic acid Quercetin 
Chemical structure 
   
  
Concentration 
(ug/g) 12187 12043 2136 473 439 
Co-efficient 
variation (%) 1.55 0.78 2.20 2.00 1.18 
Scutellaria barbata Apigenin  Scutellarin Scutellarein   
Chemical structure 
   
  
Concentration 
(ug/g) 12492 4541 309   
Co-efficient 
variation (%) 1.24 1.89 0.42   
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3.2.3 Radiation treatment  
The PCa cells were plated in T75 cm2 flasks (Sarsdedt Australia Pty Ltd, Technology 
Park, South Australia) at a density of 1,000,000 cells for PC-3 and 2,000,000 cells for 
LNCaP in 15 mL complete RPMI medium and incubated for 48 hr at 37oC. The cells 
were then irradiated with a 6 MV photon beam produced by a clinical Varian Novalis 
TX linear accelerator at Chris O’Brien lifehouse. The cells were irradiated under full 
scatter conditions as previously described (Mackonis et al. 2012). The cell layer was 
positioned at a depth of 50 mm and irradiated at a gantry angle of 1800, enabling the 
dose to the cell layer to be reliably determined. The cells were irradiated to a uniform 
dose of 0 and 2 Gy. For all experiments, unexposed controls were prepared as same 
exposures. The cells were harvested after 1hr, 2hr and 3hr of radiation treatment for 
immunofluorescence and immunoblotting.  
3.3 SYBR Green Assay  
The PCa cells were trypsinised and seeded in Corning® Costar ® 96-well plates (Cat. #: 
CLS3595, Sigma-Aldrich) at 2500 cells/well for LNCaP and 1200 cells/well for PC-3 
in 200 μL of RPMI medium with supplements. After two days of seeding, the cells in 
one of two 96 wells plate were harvested and stored at -80°C for baseline.  The other 
96 well plates with the same number of seeding were treated with DR at certain 
working concentrations (0 mg/mL, 0.25 mg/mL, 0.5 mg/mL, 0.75 mg/mL or 1 
mg/mL). These 96 wells plates were harvested after 24 hr, 48 hr and 72 hr, thereafter 
kept in -80°C for further DNA synthesis analysis. 
For SYBR Green assay reading, 2 different lysis buffers, Lysis Buffer A (10 mM Tris-
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pH 7.5 and 2 M NaCl) and Lysis Buffer B (100 mM Tris-pH 7.5, 50 mM disodium 
EDTA and 1% Triton X-100) were prepared. The SYBR Green Lysis Buffer was 
prepared with 9 portions of Lysis Buffer A, 1 portion of Lysis Buffer B and SYBR 
Green I (Cat. #: S-7563, Invitrogen) at 1:10,000 dilution. The cells from DR treated 
plates and the baseline plates were thawed at room temperature, and then lysed with 
100ul/well of SYBR Green Lysis Buffer in the dark for 2 hr. After lysing, the cells 
from baseline plates were transferred into the empty wells of treatment plate (see 
Figure 3.1). The intensity of SYBR Green fluorescence was measured using FLUO star 
Optima (BMG Labtech) at wavelength of 485/20 nm for excitation and 528/20 nm for 
emission. The % of growth inhibition was calculated using the following formula.  
(FI of control – FI of Baseline ) – (FI of  treatment – FI of Baseline ) 
                                  
                              (FI of control – Baseline ) 
   ×    100% 
FI = Fluorescence Intensity 
% of Growth Inhibition = 
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Figure 3.1 Example of sample arrangement in 96 well plate for SYBR Green assay 
 
3.4 Colony formation assay 
LNCaP (250,000 cells) and PC-3 (120,000 cells) were seeded in T25 flasks. DR treatment 
was introduced after 48 hr of seeding, at concentration of 0 - 0.75 mg/mL for LNCaP and 
0 - 1 mg/mL for PC-3 with freshly prepared complete RPMI medium. The PCa cells were 
trypsinised after 72 hr of DR treatment and the number of cells in each dose was counted 
using a haemocytometer. Total cell numbers obtained from each of the treated flasks were 
diluted further to achieve optimal numbers of cells to form colonies. 1000 cells for PC-3 
and 5000 cells for LNCaP from each of the samples were counted and seeded into new 
T25 flasks with freshly prepared complete respective medium. These T25 flasks were 
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kept in the incubator for 7-10 days without changing medium to attain the colonies 
growing from a single cell. Medium was removed from T25 flasks and the flasks were 
dried in the 37°C incubator for 3 days and stained with 1% crystal violet in PBS. Each 
T25 flask was then photographed and the colonies consisting of more than 50 cells were 
scored (Figure 3.2).  
 
 
Figure 3.2 Morphology of cancer cell colonies originated from PC-3 cells 
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3.5 Flow cytometric cell cycle analysis 
3.5.1 Propidium Iodide (PI) staining 
The proliferative PCa cells were treated with DR for (24 hr, 48 hr and 72 hr) in T25 cell 
culture flasks. To harvest the cells for flow analysis, the cells were trypsinised and re-
suspended with 300 μL of PBS and subsequently fixed in 700 μL of ice-cold ethanol in 
drop-wise manner while the suspension was vortexed. The cells were fixed in -20°C 
overnight and stored for further analysis. Following fixation, the cells were washed twice 
with pre-cold Flow Washing buffer containing PBS with 5%FCS and 0.02% sodium azide 
to remove the ethanol residual. The cells were then incubated with 20 μg/mL of PI, and 
10 μg/mL RNase A (Cat. #: R6513, Sigma-Aldrich) of for 1 hr at 37°C. After that the 
cells were washed with Flow Washing Buffer and re-suspended in the PBS with 5% (v/v) 
FCS. PI-stained DNA contents were then assessed using FACS Calibur flow cytometer 
(BD Biosciences), acquiring minimum 30,000 events per sample. The percentages of cells 
in each phase of the cell cycle were analysed using Flowjo software 10.0.8 (Tree Star 
Inc., USA). 
3.5.2 Co-staining of PI and phospho-Histone H3 for cell cycle 
analysis 
Phospho-Histone H3 labeling was used to separate the cells in mitosis phase (M phase) 
from G2-M phase. The cells were incubated with Ab against phospho-Histone H3 (1:500, 
Cat #: 9701, Cell Signaling Technology) in PBS at 4°C for overnight and PI staining was 
introduced to samples on the following day. The cells were washed and analysed with 
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FACS Calibur flow cytometer (BD Biosciences), minimum 30,000 events per sample 
were acquired. The percentages of cells in each phase of the cell cycle were analysed 
using Flowjo software 10.0.8. 
3.6 Immunocytochemistry 
3.6.1 Ki-67 Staining 
The expression of Ki-67 in DR treated cells was determined by immunocytochemical 
staining. The cells from T75 cell culture flasks with DR treatment for 72 hr were washed 
with PBS twice and then detached by TripLETM Select. The cells from control group and 
treatment group were collected in 15 mL Falcon tubes by centrifugation at 15,000 rpm for 
5 minutes. The cells were fixed in 10% neutral buffered formalin (Cat. #: 252549, Sigma-
Aldrich) at 4ᵒC for overnight. On following day, formalin was removed from the cell 
pellet by centrifugation. The cell pellets were washed with PBS, and the fixed cells were 
then clotted into 1% agarose, and then dehydrated and embedded in paraffin blocks.  
Each sample were cut into sections of 5 μm thickness using microtone and loaded onto 
Superfrost Plus slides (Menxel-Glaser, Germany). Slides were dried at 45°C overnight 
and baked at 60°C for 1 hr to reduce the possibility of sections falling off the slides prior 
to immunostaining. The sections were deparaffinised in xylene for 40 minutes and 
rehydrated through down-graded ethanol (100%, 95%, and 70%) to distilled water. Then 
slides were subjected to antigen retrieval in Tris–EDTA solution (20.0 mM Tris base, 13.4 
mM EDTA, 12.4 mM tri-sodium citrate, 0.05% Tween 20, pH 8.0) in microwave oven 
for 20 minutes. Afterwards, the sections were cooled down at room temperature, washed 
with distilled water and followed by rinsing with Tris-buffered saline containing Tween 
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(TBST; 200 mM Tris-HCl, 150 mM NaCl, 10 mM Tris-base, 0.5% Tween 20, pH 7.5). 
Sections were blocked with 10% v/v goat serum in TBST for 20 minutes. The blocking 
solution from the sections was rinsed with TBST and incubated with primary Ab to Ki-67 
(1:1000, Cat #: RM-9106-S, Thermo Scientific) in TBST for overnight at 4°C.  
In next day, the sections were rinsed in TBST and each section was sequentially labeled 
with a biotinylated secondary Ab (1:1000, Cat #: BA-1000, Vector Laboratories) for 30 
minutes and Vectastain ABC kit (1:1000, Cat #: PK-4000, Vector Laboratories) for 40 
minutes at room temperature. Between each of these incubations, sections were rinsed 
with distilled water and incubated with TBST for 5 minutes. Thereafter, the 
immunolabelling was visualized with 3, 3'-diaminobenzidine tetra-hydrochloride (DAB, 
Cat #: K3468; Dako), until brown colouration was observed. The immunoreaction of 
DAB was stopped by rinsing the slides with distilled water. The labeled sections were 
then counterstained with haematoxylin and followed by acidic ethanol and Scott’s Blue 
solution. The slides were dehydrated in graded alcohol (70%, 95% and 100%) and 
mounted in Di-n-butyl Phthalate in xylene (DPX; BDH, England) and finally cover-
slipped. The slides were dried for overnight and images were taken for later quantification 
purpose (Xi et al. 2016; Yao et al. 2012).  
3.6.2 BrdU Incorporation  
BrdU (Bromodeoxyuridine, 5-bromo-2'-deoxyuridine) is a synthetic nucleoside, which is 
an analog of thymidine. During DNA replication in S phase of cell cycle, BrdU is 
incorporated into newly synthesised DNA of replication cells, substituting for thymidine. 
Therefore, BrdU incorporation was used as an alternative way to observe DNA synthesis 
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in our DR treated cell culture (Yao et al. 2015). In the last 6 hr of DR treatment, 10 μM 
BrdU (B9285, Sigma-Aldrich) was added into treated LNCaP and PC-3 cultured in T75 
flasks. Cell were harvested and then processed for immunocytochemical staining for 
BrdU incorporation (Cat #: B2531, Sigma-Aldrich). Following antigen retrieval, the 
sections were treated with 2N HCl to denature double-stranded DNA for facilitating the 
access of the Ab to incorporated BrdU. The immunostaining and coloration were 
conducted in a same manner as described in section 3.6.1.  
3.7 Immunofluorescence  
The experimental cells from paraffin blocks were cut into sections of 5 μm thicknesses 
and incubated at 60°C for 1 hr, followed by deparaffinization in xylene, re-hydration in 
graded ethanol and distilled water, and sections were subjected to antigen retrieval in 
Tris–EDTA solution using a microwave oven. The sections were then blocked with 10% 
v/v goat serum and then incubated with primary Ab against to phospho-H2AX (Cat #: 
9718, Cell Signaling Technology) and 53BP1 (Cat #: 4937, Cell Signaling Technology) 
for 20 hr at 4°C. After being rinsed in TBST, each section was subsequently labelled with 
a secondary Ab conjugated with Alaxa594 (Cat #: A-11037, Invitrogen). The labelled 
sections were subsequently counterstained for nuclei with DAPI 4′, 6-Diamidino2-
phenylindole dihydrochloride (Cat #: D8417, Sigma-Aldrich) and cover-slipped. The 
images of both phospho-H2AX and 53BP1 labelling and nuclear staining of each sample 
were obtained from the labelled sections using an Olympus microscope (BX53) equipped 
with CellSens software. The acquired images of phospho-Histone H3 labeling and nuclear 
staining were superimposed and saved as JPEG files from image of each single channel.  
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3.8 Immunoblotting 
3.8.1 Protein extraction and quantification 
The cells that were treated with DR in 6-well plates or T25 flasks were washed twice with 
cold PBS and incubated in lysis buffer (RIPA-buffer, containing 65 mM Tris, 50 mM 
Nacl, 10 M Hcl, 5 mM EDTA, 1% NP-40, 0.5% Sodium deoxycholate, 0.1% SDS and 
10% glycerol at pH7.4, Sigma) supplemented with protease inhibitor cocktail (Cat #: 
11836145001; Roche) and 50 mM sodium fluoride (Cat #: S7920, Sigma Aldrich) in the 
cold room for 45 minutes on the rocker. 1.5 mL Eppendorf tube, pipette tips and rubber 
policeman (Costor, Mexico) were pre-cold in -20°C to preserve protein in cell lysates. 
Cells were then scraped off by rubber policeman on ice and collected into 1.5 mL 
Eppendorf tubes. To avoid protein loss and to eliminate air bubbles, samples were spun 
down at highest speed for 1 minute in the cold room. The cell lysates were then 
homogenized by sonication on ice using a sonicator (XL-2000, Microson Ultrasonic Cell 
Disruptor).  
The protein concentration for each of the sample was measured by using Bio-Rad Dc 
(detergent compatible) protein assay (Bio-Rad laboratories, California). A protein 
standard was prepared using bovine serum albumin (BSA) at 10 mg/mL and it was further 
diluted to the range of 0-4 mg/mL (0 mg/mL, 0.25 mg/mL, 0.5 mg/mL, 1 mg/mL, 2 
mg/mL, 3 mg/mL, and 4 mg/mL) with RIPA buffer (Cat #: R0278, Sigma Aldrich). The 
protein measurement was conducted in Coning 96-well clear flat bottom plates. Each well 
was added with 25 μL of Reagent A of the assay kit (80% v/v surfactant solution and 20% 
v/v alkaline copper tartrate solution), 5 μL of each diluted BSA standard or experimental 
sample, and 200 μL of Reagent B of the assay kit (Folin reagent). Incubation at room 
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temperature for 5 minutes was required for colour development. The intensity of the 
colouration was measured at 595 nm wavelength using a spectrophotometer plate reader 
(Infinite M1000 Pro, Tecan) equipped with Magellan software (version 7.2). The 
absorbance values of all samples was normalised by subtracting them with the absorbance 
value of the control well (0 mg/mL of BSA). The concentration of the protein was 
subsequently calculated using a BSA standard curve. The loading volume required for 50 
μg of protein was calculated based on the protein concentration of each sample. Aliquot 
of samples were stored in -30°C until further analysis.  
3.8.2 SDS-polyacrylamide gel electrophoresis  
The acrylamide-bisacrylamide gels consisting 4% stacking layer and three resolution 
layers, 7%, 10% and 13% gel were prepared 1 day ahead using 40% Acrylamide, 1 M 
Tris HCl pH 6.8 (for stacking gel), 0.5 M Tris HCl pH 8.8 (for resolving gels), 20% SDS, 
dH2O, 10% ammonium persulfate (APS) and TEMED (N, N, N’, N’-
tetramethylethylenediamine). To achieve multiple proteins from the same signalling 
pathway in one membrane, gradient gels were prepared as described in Table 3-1 and 
figure 3.3.  
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Table 3-2 SDS-PAGE gel formulation 
Resolving gel  Stacking gel 
  7% 10% 13%    4% 
Acrylamide 40% 1.75 mL 2.5 mL 3.25 mL  Acrylamide 40% 1 mL 
Tris HCl pH8.8 3.6 mL 3.6 mL 3.6 mL  Tris HCl pH6.8 1.260 mL 
10% SDS 91.2 μL 91.2 μL 91.2 μL  10% SDS 100 μL 
dH2O 4.5 mL 3.8 mL 3 mL  dH2O 7.6 mL 
10% APS 43.2 μL 43.2 μL 43.2 μL  10% APS 50 μL 
TEMED 9 μL 9 μL 9 μL  TEMED 10 μL 
Total  10 mL 10 mL 10 mL  Total 10 mL 
 
 









1         2           3         4           5         6          7          8          9        10 
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3.8.3 Sample preparation for SDS-PAGE 
The required volumes of proteins at 50 μg were mixed with 5x LaemmLi loading dye (1 
M Tris-Cl pH 6.8, 20% SDS, glycerol, B-mercaptoethanol, Bromophenol blue) in a ratio 
of 4:1 and RIPA buffer. The mixtures were centrifuged at 10,000 rpm for 1 minute and 
heated at 95°C on a pre-heat thermomixer (Eppendorf, Germany) for 7 minutes. Total 
volume of 35 μL of protein sample was loaded into respective wells of the gel. To 
determine the migration of the protein with known molecular weight, 5 μL of pre-stained 
protein standard (Cat #: 1610374, Bio-Rad) was also loaded into the two end wells of the 
gel. Proteins were separated on the basic of molecular weight using % SDS-PAGE. 
Electrophoresis was then carried out in Mini-Protean Tetra Cell (Bio-Rad) in the presence 
of running buffer (25 mM Tris, 192 mM Glycine, 0.1% SDS, pH 8.3) at 100V for 
approximately 1 hr until protein reached into 13% of resolving gel and then increased to 
130V for 20 minutes.  
3.8.4 Protein Transfer  
Polyvinylidene fluoride (PVDF) membranes (Cat #: ISEQ00010, Immobilon) were first 
soaked in 100% methanol for 5 minutes and then in pre-cold transfer buffer at 30°C (25 
mM Tris, 192 mM glycine, 10% methanol, pH 8.3) for 10 min prior to electroblotting. 
Pre-soaking of 4 layers of filter papers and sponges in the cold transfer buffer was 
necessary. The transfer cassette sandwich (Mini Trans-Blot Cell, Bio-Rad) was assembled 
in the following order: 1) 1 layer of filter sponge, 2) 4 layers of filter paper, 3) gel, 4) 
PVDF membrane, 5) 4 layers of filter paper, 6) 1 layer of filter sponge. Wet-transfer was 
carried out at 100 V for 2 hr in the cold room for proteins with molecular weight ranging 
from 10 to 75 kDa, and 30 V for 20 hr was used for protein with molecular weight from 
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76 to 350 kDa. To disperse the heat that was being produced during electroblotting, an ice 
pack and a stirring bar were placed in the Trans-Blot cell (Bio-Rad). 
3.8.5 Blocking and Immunodetection  
After transfer, nitrocellulose membranes were washed in 1x TBST (10x TBS solutionand 
0.5 mL (m/v) TWEEN®20, Sigma-Aldrich, pH 7.5) for 5 minutes. To avoid nonspecific 
binding, membranes were blocked in 2% skim milk in TBST for 20 minutes. Membranes 
were then washed with three 5-minutes washes using TBST, followed by incubation with 
primary Ab against the anticipated protein over night or 2 days at 4°C. The optimal 
dilution of each primary Ab, which was determined experimentally, was listed in table 3-
2. These membranes were washed twice in TBST for 10 minutes interval. Membranes 
were then incubated with horse radish peroxidase (HRP) conjugated anti-mouse (Cat 
#:A4416, Sigma-Aldrish) or anti-rabbit (Cat #: A0545, Sigma-Aldrish) secondary 
antibodies (1:10,000) with TBST including 1% skim milk for 2-3 hr in 4 °C.  Membranes 
were again washed in TBST twice. Prior the protein immunodetection, each membrane 
was incubated in 200 μL SuperSignal®West Pico Chemiluminescent Substrate (Cat 
#:34078, Thermo Scientific) or Bio-Rad ClarityTM Western enhanced 
chemiluminescence ECL substrate (Cat #:170-5060, Bio-Rad). Immuno-labelled protein 
bands will be captured by a BioRad ChemiDoc
TM 
MP system (Universal Hood II, Bio-
Rad) equipped with Image Lab (version 5.2.1).  
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3.9 Reverse transcription and quantitative real-time 
polymerase chain reaction 
3.9.1 RNA extraction and quantification 
To harvest for RNA extraction, cell culture medium was aspirated from the T25 flasks of 
PCa cells. The flasks were washed twice with cold PBS before incubation with 300 μL 
lysis buffer, containing guanidine thiocyanate (PureLink RNA Mini Kit, Cat #: 
12183018A, Life Technologies); and 14.3 M (1% v/v) β-mercaptoethanol (Sigma-
Aldrich, Australia) on the slow shaker in the cold room for 10 minutes. Samples were 
kept in -80°C until extraction. On the day of extraction, T25 flasks were thawed and cells 
with the lysis buffer were transferred to RNase free eppendorf tubes using sterile, RNase-
free pipette tips. An equal amount of 70% RNase-free ethanol was added to the samples 
and then voltexed for 30 seconds to disperse any visible precipitate and to prevent 
genomic DNA contamination. The samples were then transferred to spin cartridges up to 
700 μL and centrifuged for 15 seconds at 12,000 x g to allow the precipitated RNA to 
bind to the column matrices (Figure 3.4). The flow through that contains ethanol, DNA 
debris and lysis buffer, was discarded. The spin cartridges were re inserted into the 
collecting tube and followed by washing with 700 μL of washing buffer Ι to remove 
RNA-bound protein. The samples were centrifuged again for 15 seconds at 12,000 x g to 
let protein and ethanol residues through into the collecting tube and then the flow through 
were discarded carefully. The cartridges were inserted into new collecting tubes and 500 
μL of washing buffer ΙΙ was added into the cartridges in order to remove remaining metal 
residue, DNA, wash buffer Ι and/or ethanol. The samples were washed twice with wash 
buffer ΙΙ. The flow through were discarded and then centrifuged again at maximum speed 
for 1-2 min to dry the membrane with the attached RNA. The collecting tubes were 
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discarded and the cartridges were inserted into new recovery RNase-free tubes. RNase-
free water (50 μL) was added into the center of spin cartridge and incubated for 1-2 
minutes to dissolve RNA. The total RNA from the spin cartridges was eluted by 
centrifugation for 2 min at 12,000 x g. The quality and quantity of the extracted RNA 
samples was determined using the NanoDrop ND-1000 Spectrophotometer 
(Thermofisher, Australia). 
 
Figure 3.4 The flow chart illustrating the steps of isolating total RNA using the 
PureLink RNA Mini Kit 
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3.9.2 Reverse transcription (RT) 
To facilitate the PCR analysis of RNA molecules, single stranded RNA was transcribed 
into complementary DNA (cDNA) copy by using reverse transcriptase (RT) enzyme from 
High-Capacity cDNA Reverse Transcription Kit (Cat. #: 4368813, Life Technologies). 
The RT reaction commenced with the addition of master mix I consisting of 50 ng/mL 
Random Hexamer, and 50 μM Oligo (dT). Master mix I was added to 1 μg of RNA 
samples and diethylpyrocarbonate (DEPC)-treated water and the samples were incubated 
with Veriti Thermal Cycler (Applied Biosystems, USA) at 65°C for 5 minutes and 4°C 
for 2 minutes. Following incubation, master mix II was prepared using 10x RT buffer, 25 
mM MgCl2, 10 mM dNTP mix, 100 mM DTT, 20 U/uL of RNase inhibitor and 50 U/uL 
of MultiScribe RT (Life technologies, USA). Non-RT control was prepared as 
aforementioned steps without adding of MultiScribe RT. This non-RT control was 
included to verify the contamination level of cDNA, which may have yielded less than 
optimal results. Formulation of RT reaction was described in Table 3-3.  
Final incubation temperatures varied: 
Annealing:                25 oC for 5 min. 
cDNA synthesis:      42 oC for 30 min  
Terminate reaction:  85 oC for 5 min  
Store cDNA:             hold at 4 oC 
Store samples:         –20 oC until use. 
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Table 3-4 Formulation of reverse transcription reaction  
 




RNA Varied 1000ng 
DEPC-treated H2O 
7.6 – uL of RNA for samples 
8.6 – uL of RNA for –ve control 
Master 
Mix I 
Oligo d(T)16 1 2.5 μM 





10X RT Buffer 2 1X 
25mM MgCl2 1.4 1.75 mM 
10mM dNTP mix 4 0.5 mM 
100mM DTT 1 5.0 mM 
RNase Inhibitor 
1 1 U/μL 
(20 U/ μL) 
MultiScribe RT 
1 2.5 U/μL 
(50 U/ μL) 
Volume Master Mix II/reaction 
10.4 μL for samples 
  9.4 μL for negative control 
FINAL Total Volume:  20.0 μL 
 
3.9.3 Designing the primers 
Two types of primer (forward and reverse) were required for PCR reaction. The sequence 
for the gene of interest was obtained from GeneCards and cDNA sequence was used to 
design primer. Primers were designed using Primer 3 and several parameters were set 
such that the primers length is between 18 to 20 nucleotides, GC% between 45% and 
55%, melting temperature between 55°C and 65°C, annealing temperature between 55°C 
and 80°C, avoid GC clamp and secondary structure, and PCR product size between 100-
200 nucleotides. The outputs, multiple possible forward and reverse primer sequences, 
were additionally screened for their specificity and quality using the following software:  
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1) OligoEvaluator was used to eliminate primers that form medium to very strong 
secondary structures,  
2) In-Silico PCR from UCSC Genome Bioinformatics was used to eliminate primer 
pairs that amplify non-specifically,  
3) NCBI BLAST was used to eliminate primers that amplify genomic DNA and  
4) AmplifX was used to determine overall primer quality.  
The primer sets (forward and reverse) used for PCR amplification were listed in Table 3-4. 
Table 3-5 List of primers 











(F) 5'–CGGGAAGTCACTGGAAACAT–3 '  54 50 
51 126 44% 
CCNB1 
(R) 5'–ATTCTGCATGAACCGATCAA– 3 ' 52 40 
CDC2 
(F) 5'–GGGGTCAGCTCGTTACTCAA– 3 ' 56 55 
51 139 43% 
CDC2 
(R) 5'–AGTGCCCAAAGCTCTGAAAA–3 ' 54 45 
PLK1  
(F) 5'–GCCCCTCACAGTCCTCAATA– 3 ' 55 55 
55 124 58% 
PLK1 
(R) 5'–CTGCAGCATGTCACTGAGGT– 3 ' 56 55 
AURKA 
(F) 5'–TGCACCACTTGGAACAGTTT– 3 ' 54 45 
51 201 39% 
AURKA 
(R) 5'–ACTGACCACCCAAAATCTGC– 3 ' 55 50 
36B4 (F) 5'–TGTTTCATTGTGGGAGCAGA– 3 ' 53 45 
54 170 56% 
36B4 (R) 5'–CGGATATGAGGCAGCAGTTT– 3 ' 54 50 
F = forward, R = Reverse 
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3.9.4 Polymerase chain reaction (PCR) 
Samples for amplification reaction contained (1) SensiMix™ SYBR® No-ROX (Cat. #: 
QT650-05, Bioline), (2) forward and reverse primers of each gene of interest (primers 
were synthesised by Geneworks Australia and Sigma-Aldrich, Australia) and (3) diluted 
cDNA template, and final volume was made up to 20 μL as described in Table (3-5). 18 
μL of the primer with master mix were loaded into each of the sample tubes, 2 μL cDNA 
samples (1/50 dilution) was then added to each pre-loaded sample tubes. Triplicates were 
carried out for each sample. 
Table 3-6 Reagents involved in PCR reaction. 
Reagent Volume  Final Concentration 
SensiMix™ 10 μL 1x 
10μM Primer (F) 0.5 μL 250nM 
10μM Primer (R) 0.5 μL 250nM 
Rnase-free H2O 7 μL   
cDNA 2 μL 1:50 dilution 
Total  20 μL   
 
 
3.9.5 Dilution curve and amplification efficiency 
The PCR efficiency can also affect the quantification of the template, which is dependent 
on the assay, the master mix performance, and sample quality. To determine the 
efficiency of each gene of interest, standard samples were prepared by using one sample 
of cDNA and serial diluting from 1:3 up to 1:81 dilutions, a total of 4 standard points 
(each dilution run in triplicate). A standard curve was constructed by using the 
concentrations against the threshold cycle (CT) value obtained from amplification of each 
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dilution. The equation of linear regression line along with r and R2 were also evaluated to 
examine the linearity of data and amplification efficiency of PCR. A melt-curve analysis 
in each of the genes was also performed to identify the various products of polymerase 
chain reaction. The melt step was set to the following conditions: 1 degree rise in 
temperature from 65°C to 95°C and held for 5 seconds between each rise in temperature. 
Negative controls including non-RT control (reverse transcription control, RNA sample 
with no reverse transcriptase enzyme) and no-template controls (by replacing cDNA with 
MilliQ H2O) were included in each experiment.  
Samples were amplified using a Qiagen Rotor Gene 6000 RT-qPCR machine set to the 
following conditions: 
Table 3-7 Cycling conditions (Rotor-Gene RG-6000 Corbett Research) 
 
Step Cycles Temperature (°C) Time 
Initial Denaturation 1 95 10 mins 
Denaturation 40 95 15 secs 
Annealing 40 60 15 secs 
Extension 40 60 15 secs 
 
3.9.6 Data analysis 
The peak present in the melt curve occurs when there is a rapid increase in the rate of 
fluctuating florescence. Fluorescence decreases as temperature increases. The threshold 
cycle parameter (CT) is the calculated fractional cycle number at which the PCR product 
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crosses a threshold of detection. The greater amount of initial DNA template, the more 
PCR products are accumulated andthe earlier the Ct value for that sample, i.e., lower CT 
values mean higher amounts of your target nucleic acid. The change of the CT Value was 
then normalized with 36B4 and analysed by The Relative Expression Software Tool 
(REST, version 2009). 
3.10  Animal study  
All in vivo experiment were conducted with approval from the Animal Ethics Committee 
at The University of Sydney. Normal mice were randomly divided into DR treatment 
group and vehicle control group (5 mice per group). Subcutaneous injection of vehicle 
(200 μL of PBS) or DR at 1 mg/g begun on day 1 and continued through to day 15. Body 
weights of the mice were measured daily. After 15 days, mice were humanely killed.  
 
3.11 Quantification  
3.11.1 Immunocytochemistry 
At least three images were acquired from each immunostained section using fluorescent 
microscope (BX51, Olympus) and the images were quantified using Image-Pro Plus 
(version 7.0). The number of positive cells  (DAB stained brown cells or negative  
(haematoxylin-stained blue cells) in each acquired image was counted. The positivity of 
each immunolabelling for protein of interest was calculated as following: DAB 
density/(DAB plus haematoxylin density). The positivity was converted into relative 
percentage by using experimental control (vehicle control) as 100%. 
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3.11.2 Immunofluorescence 
The immunofluorescence images captured using fluorescent microscope (BX51, Olympus).   
The phospho-H2AX and 53BP1 foci were quantified using Image J 32 software (1.38x, 
National institutes of health, USA). 
3.11.3 Immunoblotting 
The images captured by ChemiDoc™ XRS+ System (Bio-Rad, Australia) were quantified 
using Image J 32 software (1.38x, National institutes of health, USA). The ratio of band 
intensity between the protein of interest and the housekeeper protein (GAPDH or α-
TUBULIN) was calculated. The net intensity for the band of interest was converted into 
relative percentage by using experimental control as 100%. 
3.12 Statistical Analysis 
Statistical comparison was performed by using NCSS/PASS version 12.0 (NCSS 
Statistical and Power Analysis Software). The processed data were analysed using one-
way ANOVA to determine if a significant change had occurred. Fisher’s least significant 
difference multiple-comparison test (significance: p<0.05) and Kruskal–Wallis multiple-













4 The effect of DR on 




One of the most fundamental traits of cancer cells is the ability to sustain prolonged 
proliferation (Hanahan et al. 2011). Normal cells maintain a homeostasis between cell 
proliferation and apoptosis leading to no net growth of cell population. However, cancer 
cells have the ability to disrupt the balance, resulting in uncontrolled growth. Hence, to 
form clinically relevant tumour, cancer cells require uncontrolled proliferation (Hanahan 
et al. 2011; Malumbres et al. 2001).  Since cancer cell proliferation requires the synthesis 
of DNA, any impact on DNA synthesis will interfere with the proliferative ability of 
cancer cells (Menyhárt et al. 2016). A number of chemo drugs currently available for 
cancer treatment such as cisplatin have achieved anti-proliferative action via their 
disruptive effect on DNA replication (Kelland 2007). Thus, establish new methods using 
natural or synthetic compounds or botanical extract to inhibit cancer cell proliferation is 
expected to interfere cancer DNA synthesis. As aforementioned in Chapter 1, 
proliferation index measured as the percentage of Ki-67 positive cancer cells over total 
cancer cells is correlated with disease progression in PCa, (Halvorsen et al. 2003; 
Khatami et al. 2009). We envisage a method that can impede DNA synthesis, cell cycle 
progression and proliferation and subsequently capable of preventing or slowing PCa 
progression.   
The aim of studies described in this chapter was to determine the effect of DR on 
proliferation of PCa cells.  
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4.2 Materials and Methods 
4.2.1 Prostate cancer cell lines 
The PCa cell line LNCaP and PC-3 were cultured as described in Chapter 3.1.1. 
4.2.2 DR treatment 
DR stock solution and dose range were prepared as described in Chapter 3.2.1.  
4.2.3 SYBR Green assay 
The DNA content of PCa cells was determined using SYBR Green assay as described 
in Chapter 3.3. 
4.2.4 Immunocytochemistry 
The PCa cells block preparation and immunolabelling of BrdU and Ki-67 were 
performed as described in Chapter 3.6.2 and 3.6.1. The quantification was as 
described in Chapter 3.11.1. 
4.2.5 Colony formation assay 
PCa cell colony formation was measured as described in Chapter 3.4. 
4.2.6 Animal study 
The effect of DR on mouse body weights was measured as described in Chapter 3.10.  
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4.2.7 Statistical analysis 
The statistical software NCSS version 12.0 was used for statistical analysis as 
described in Chapter 3.12. 
 
4.3 Results 
4.3.1 DR inhibited the proliferation of PCa cells 
4.3.1.1 Treatment with DR decreased DNA synthesis in PCa cells by SYBR 
Green DNA analysis assay 
We first monitored the change in DNA content in the presence or absence of DR using 
SYBR Green assay. After 48 hr of cell seeding in 96 well plate, LNCaP and PC-3 cells 
were treated with a dose range of DR (0-1 mg/mL) for 24, 48 and 72 hr and analysed by 
SYBR Green DNA assay. In addition to vehicle control, ie zero DR, a second control 
namely a baseline control was also included, which provided the initial DNA content at 
time zero of treatment. By comparing with these two controls, we were able to 
differentiate between the cytostatic and cytotoxic action of DR.  
Vehicle control group represented full growth in which DNA content at 72 hr was 
approximately three times higher than the baseline. At 0.25-0.75 mg/ml the DR action 
was cytostatic. But at 1 mg/mL of DR, the treatment had cytotoxic activity in LNCaP 
cells as the fluorescent intensity was lower than baseline (Figure 4.1). For PC-3 cells, 
0.25-1 mg/mL of DR treatment for 72 hr had cytostatic action (Figure 4.2).  
The cytostatic action or the extent of growth inhibition (GI) induced by DR was estimated 
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by calculating the percentage of GI based on the SYBR Green result. After 72 hr of DR 
treatment, the average GI at 0.25, 0.5, and 0.75 mg/mL were 33%, 61%, and 90% in 
LNCaP cells (Figure 4.1). In PC-3 cells, the average GI at 72 hr were 26%, 58%, 82% 
and 94%, respectively for 0.25, 0.5, 0.75 and 1 mg/mL (Figure 4.2). Apart from dose-
dependence, GI effect appears to be time-dependent over the study period.   
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Figure 4.1 DR inhibited the DNA synthesis of LNCaP cells in a dose-dependent manner. Cells were treated with various doses of DR for 
24 hr, 48 hr and 72 hr. Cells were harvested and analysed with SYBR Green assay. SYBR Green fluorescence intensity reflects the amount of 
DNA content in the experimental samples. Baseline indicates the initial amount of DNA or number of cells at time zero. The percentage of 
growth inhibition was shown in the table. All experiments were performed in triplicates; data were expressed as the mean from three 
independent experiments ± SD. * p<0.01 compared to 0 mg/mL (vehicle control). # p<0.05 compared to 0.25 mg/mL, @ p<0.05 compared to 
0.5 mg/mL. α p<0.05 compared to 0.75 mg/mL. 
  % of Growth inhibition (GI) ± STDEV 
Cells Doses  24hr  48hr 72hr 
LNCaP 
0 mg/mL 0% ± 46% 0% ± 19% 0% ± 23% 
0.25 mg/mL 41% ± 30% 51% ± 38% 33% ± 13%  
0.5 mg/mL 60% ± 28% 66% ± 14%  61% ± 18%  
0.75 mg/mL 120% ± 40%  95% ± 16%  90% ± 7%    














































































Figure 4.2 DR inhibited the DNA synthesis in PC-3 cells in a dose-dependent manner. Cells were treated with various doses of DR for 24 
hr, 48 hr and 72 hr. Cells were harvested and analysed with SYBR Green assay. SYBR Green fluorescence intensity reflects the amount of 
DNA content in the experimental samples. Baseline indicates the initial amount of DNA or number of cells at time zero. The percentage of 
growth inhibition was shown in the table. All experiments were performed in triplicates; data were expressed as the mean from three 
independent experiments ± SD. * p<0.01 compared to 0 mg/mL (vehicle control). # p<0.05 compared to 0.25 mg/mL, @ p<0.05 compared to 































































  % of Growth inhibition (GI) ± STDEV 
Cells Doses  24hr  48hr 72hr 
PC-3  
0 mg/mL 0% ± 31% 0% ± 20% 0% ± 23% 
0.25 mg/mL 9% ± 72% 16% ± 23% 26% ± 25% 
0.5 mg/mL 12% ± 34% 37% ± 16%   58% ± 27%  
0.75 mg/mL 41% ± 47% 67% ± 17%   82% ± 18%  
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In summary, DNA analysis by SYBR Green assay showed that DR significantly reduced 
(p<0.05) the DNA content of PCa cells in a dose and time dependent manner.  We also 
established that 0-0.75 mg/mL of DR should be used in LNCaP cells to study the 
cytostatic action of DR without confounding cytotoxic action. For PC-3 cells, the dose 
range for cytostatic action of DR would be 0-1 mg/mL.   
 
 
4.3.1.2 Treatment with DR decreased BrdU incorporation in PCa cells by 
immunocytochemistry 
To verify the inhibitory action of DR on DNA content by SYBR green assay, the 
immuonocytochemical staining of BrdU was performed. BrdU is thymidine analogue and 
will be incorporated into newly synthesised DNA. PCa cells were treated with DR for 72 
hr and harvested for immunocytochemistry to observe BrdU incorporation. 
There was a significant decrease (p<0.01) in the percentage of BrdU positive LNCaP 
cells. By comparison with the vehicle control, we noted a reduction of 15% at 0.25 
mg/mL, 54% at 0.5 mg/mL and 75% at 0.75 mg/mL in LNCaP cells (Figure 4.3). In PC-3 
cells, the decrease (p<0.01) in BrdU positivity at 0.25, 0.5, 0.75 and 1 mg/mL were 28%, 
49%, 67% and 70%, respectively (Figure 4.4). 
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Figure 4.3 DR decreased the BrdU incorporation in LNCaP cells. LNCaP cells were 
grown in T75 for 48 hr prior to the DR treatment. DR was introduced with different doses 
(0 - 0.75 mg/mL) for 72 hr. Total density of DAB (BrdU positive cells) and haematoxylin 
(total number of cells) in each acquired image was measured and the positivity of BrdU 
was calculated. The values plotted are the mean of 14 sections from each dose taken from 
three independent experiments ± SD. * p<0.01 compared to 0 mg/mL. # p<0.05 compared 
to 0.25 mg/mL, @ p<0.05 compared to 0.5 mg/mL.  



























Figure 4.4 DR decreased the BrdU incorporation in PC-3 cells. PC-3 cells were grown 
in T75 for 48 hr prior to the DR treatment. DR was introduced with different doses (0 - 
0.75 mg/mL) for 72 hr. Total density of DAB (BrdU positive cells) and haematoxylin 
(total number of cells) in each acquired image was measured and the positivity of BrdU 
was calculated. The values plotted are the mean of 9 sections from each dose taken from 
three independent experiments ± SD. * p<0.01 compared to 0 mg/mL. # p<0.05 compared 
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In summary, following the observation that DR decreased DNA content of PCa cells by 
SYBR green assay, immunocytochemical staining of BrdU incorporation demonstrated 
that DR reduced DNA synthesis in a dose-dependent fashion in both LNCaP and PC-3 
cells. 
 
4.3.1.3 Treatment with DR decreased Ki-67 protein level in PCa cells by 
immunocytochemistry 
After confirming an inhibitory effect of DR on DNA synthesis, we next determined DR 
effect on cell proliferation by immunocytochemical analysis of Ki-67. Ki-67 is a nuclear 
protein associated with cycling cells and Ki-67 positivity indicates the fraction of cycling 
cells. PCa cells were treated with DR for 72 hr and harvested for immunochemical 
staining of Ki-67.  
Immunocytochemistry of Ki-67 staining demonstrated that comparing to the control, the 
percentage of Ki-67 positive cells was significantly (p<0.01) reduced by 17%, 49% and 
64% at the dose range of 0.25, 0.5 and 0.75 mg/mL in LNCaP cells, respectively (Figure 
4.5). Similarly, a noticeable reduction (p<0.01) in Ki-67 positivity at the dose range of 
0.25, 0.5, 0.75 and 1 mg/mL was detected with 33%, 48%, 62% and 67% in PC-3 cells, 
respectively (Figure 4.6).  
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Figure 4.5 DR decreased the Ki-67 positivity in LNCaP cells. LNCaP cells were 
grown in T75 for 48 hr prior to the DR treatment. DR was introduced with different doses 
(0 - 0.75mg/mL) for 72 hr. Total density of DAB (Ki-67 positive cells) and haematoxylin 
(total number of cells) in each acquired image was measured and the positivity of Ki-67 
was calculated. The values plotted are the mean of 17 sections from each dose taken from 
three independent experiments ± SD. * p<0.01 compared to 0 mg/mL. # p<0.05 compared 
to 0.25 mg/mL, @ p<0.05 compared to 0.5 mg/mL.  
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Figure 4.6 DR decreased the Ki-67 positivity in PC-3 cells. LNCaP cells were grown in 
T75 for 48 hr prior to the DR treatment. DR was introduced with different doses (0 - 
0.75mg/mL) for 72 hr. Total density of DAB (Ki-67 positive cells) and haematoxylin 
(total number of cells) in each acquired image was measured and the positivity of Ki-67 
was calculated. The values plotted are the mean of 8 sections from each dose taken from 
three independent experiments ± SD. * p<0.01 compared to 0 mg/mL. # p<0.05 compared 
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In summary, Ki-67 immunocytochemical staining demonstrated that DR can reduce the 
proportion of proliferative cancer cells in a dose-dependent manner in PCa cells. 
 
4.3.1.4 Microscopic verification of cytostatic action of DR  
Since cell morphology and confluence in culture are indicative of the healthy status of the 
cells, we evaluated the effect of DR on cells morphology and confluence.  The 
microscopic images of PCa cells at time zero and 72 hr after DR treatment were recorded 
using Olympus fluorescent microscope.  
The control group reached 70%-80% confluence from a baseline at time zero of about 
20% over 72 hr.  The cell confluence was markedly reduced in the presence of DR over 
72 hr. The estimated confluence was about 30% at 0.75 mg/mL (Figure 4.7).  In PC-3 
cells, the control group reached to 80%-90% confluence from 20% at baseline. After 72 
hr treatment with DR, the confluence was noticeably decreased and remained with 50% at 




Figure 4.7 DR decreased the confluence of LNCaP cells. The images of Baseline were 
taken after 48 hr of seeding, before DR was introduced. The rest representative images 
were taken 72 hr after treatment of DR. 40 × magnification of Olympus fluorescent 
microscope was used.  
Baseline 0 mg/mL 





Figure 4.8 DR decreased the confluence of PC-3 cells. The images of Baseline were 
taken after 48 hr of seeding, before DR was introduced. The rest representative images 
were taken 72 hr after treatment of DR. 40 × magnification of Olympus fluorescent 
microscope was used. 
Baseline 0 mg/mL 
0.25 mg/mL 0.5 mg/mL 
0.75 mg/mL 1 mg/mL 
 PC-3 
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In summary, microscopic images of PCa cells supported a cytostatic action of DR in a 
dose dependent manner. 
 
4.3.1.5 Treatment with DR reduced the number of colony formation 
To determine the long-term effect of DR on proliferation of PCa cells, LNCaP and PC-3 
cells were treated with DR at various doses for 72 hr. The cells were then cultured for an 
additional 7 days in the absence of DR at a density appropriate for formation of detectable 
colonies. The number of colonies were quantified and the morphology of colonies were 
recorded using Olympus fluorescence microscope using 40 × magnification.  
A dose dependent decrease was detected in the number of colony formation after DR 
treatment. In LNCaP cells, the number of colony formation was significantly reduced 
(p<0.05) to one third of control at 0.75mg/mL (Figure 4.9). Only 10% of colonies were 




Figure 4.9 DR reduced the colonies formation of LNCaP cells. LNCaP cells were 
treated with DR for 72 hr, and re-seeded for 7 days. Cells were harvested and stained with 
1% crystal violet in PBS. Each sample was photographed and the colonies consisting of 
more than 50 cells were scored by software. The values plotted are the mean from three 
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Figure 4.10 DR reduced the colonies formation of PC-3 cells. PC-3 cells were treated 
with DR for 72 hr, and re-seeded for 7 days. Cells were harvested and stained with 1% 
crystal violet in PBS. Each sample was photographed and the colonies consisting of more 
than 50 cells were scored by software. The values plotted are the mean from three 
independent experiments ± SD. * p<0.01 compared to 0 mg/mL. # p<0.05 compared to 
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In summary, the number of colonies were reduced over 7 days following treatment with 
DR for 72 hr, suggesting a long term inhibitory effect of DR on cell proliferation. 
 
4.3.2 DR did not modulate pH and osmolality of media bathing 
PCa cells 
In order to exclude a possibility that these above findings were associated with 
modulation of pH and osmolality in the presence of DR, these two parameters at various 
dose of DR (0-2 mg/mL) were measured. There was no noticeable change in both 
parameters in culture media (Figure 4.11). 
 
Figure 4.11 DR did not modulate the pH and osmolality of culture media. Complete 
culture media with various dose of DR were tested for (a) pH and (b) osmolality and the 









































4.3.3 Treatment of normal mice with DR did not change animal 
body weight 
To confirm that DR has no significant side effect, two groups of animals (5 
mice/group) were given either PBS (200 ul) or DR (1 mg/g body weight) 
subcutaneously and their body weight was monitored for 15 days. As described in 
figure 4.12, no significant changes in body weight were detected in DR treated groups 
compared to the vehicle control.   
 
Figure 4.12 Treatment of normal mice with DR did not change animal body weight. 
Two groups of normal mice (5 mice/group) were treated with either PBS (200 ul) or DR 


























4.4 Discussion  
One of the hallmarks of cancer is uncontrolled proliferation. Hence, we started by 
investigating the effect of DR on proliferation of PCa cells. We determined whether DR 
could affect DNA synthesis of PCa cells using SYBR Green DNA analysis assay and 
BrdU incorporation as our laboratory previously described (Xi et al. 2016; Yao et al. 
2012). We have found that DR can decrease the DNA content and DNA synthesis. This 
anti proliferative action of DR was supported using Ki-67 immunocytochemical staining 
(Gerdes et al. 1984; Khatami et al. 2009), which indicated the reduction of the 
proliferative or cycling cells. Additionally, the colony formation assay demonstrated that 
a short term exposure of DR may have a long term effect. Importantly, exposure of DR on 
normal mice showed no adverse action over 15 days.  
4.4.1 Selection of SYBR green assay for DNA analysis 
How to choose appropriate methods for in vitro assessment of cell proliferation is 
important. Previous literatures had reported the anti-proliferative activities of HD and SB 
using colorimetric cell viability assay such as MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) (Chen et al. 2012; Gao et al. 2017; Lin et al. 2012; Zhang 
et al. 2017). MTT assay measures the colorimetric intensity resulted from activity of 
NAD(P)H-dependent mitochondria enzyme succinate dehydrogenase. The action of DR 
measured by MTT assay could be misleading if DR affects mitochondria succinate 
dehydrogenase independent from cell proliferation (Bruggisser et al. 2002). A study of 
natural supplement products using MTT assay and DNA dye had shown that MTT assay 
overestimated the anti-proliferative activities of those natural botanical products. This is 
because the mitochondria enzymatic activity is likely to be affected by the chemicals in 
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natural products (Gao et al. 2014; Wang et al. 2010). In our study, DR is herbal derivative 
and using MTT assay may lead to false positive result. As MTT assay rely on the 
enzymatic activity of viable cells, the colorimetric measurement needs to be conducted at 
the end of treatment duration. Baseline, which is the initial cell viability at time-zero, can 
not be measured at the same time with control and treatment group. Consequently, 
without having baseline, a differentiation of cytostatic from cytotoxic action is impossible 
with MTT assay. 
It has been suggested that the assay using DNA dye should provide more consistent result 
since the cell proliferation is directly associated with DNA replication (Menyhárt et al. 
2016; Wang et al. 2010). In our study, we used SYBR Green assay to provide the direct 
evidence of DR action on DNA synthesis.  SYBR Green I can directly bind to minor 
groove of DNA double helix and the fluorescence intensity emitted from DNA represents 
the total DNA content of given sample. The fluorescence intensity in our control cells 
showed three folds increase from baseline at 72 hr, which is consistent with the doubling 
time of LNCaP and PC-3 cells around 34 hr ± 6hr (Cunningham et al. 2015; Horoszewicz 
et al. 1983). 
4.4.2 Cytostatic action of DR  
SYBR Green assay has allowed us to determine a net cytostatic or cytotoxic action by 
comparing two controls: one is at the time zero or baseline, and the other from the vehicle 
control for the same treatment period. If the reduced DNA content compared to vehicle 
control was still above the baseline, it is a cytostatic action. In contrary, a fall below the 
baseline indicates a net of cytotoxic action. Some studies have reported cancer apoptosis 
induced by extracts of HD and SB using very high doses, such as 10 mg/mL in liver 
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cancer cells (Chen et al. 2012) and 3 mg/mL in breast and PCa cells (Marconett et al. 
2010). As our aim is to provide an effective and safe clinical modality to men under AS 
for long term use, we aimed to study the cytostatic action and its underlying mechanism. 
In conclusion, we have provided the direct evidence of the anti-proliferative activity of 















5 The effect of DR on cell 
cycle progression 
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5.1 Introduction  
The key mechanism of cell proliferation is cell cycle progression. In order to divide into 
two daughter cells from a single mother cell, cells must go through the cell cycle phases. 
As aforementioned in Chapter 1, there are 5 distinct phases of the cell cycle (G1, S, G2, M 
and G0 phase). In the G1 phase, cells start preparation to enter into the S phase for DNA 
synthesis. After DNA synthesis in S phase, cells enter the G2 phase. In G2 phase, DNA 
repair mechanism may occur and cells prepare for mitosis phase. During M phase, sister 
chromatid is separated and a single mother cell divides into two new daughter cells. G0 
phase is non-cycling quiescent stage and cells may enter into this stage after mitosis 
depending on availability of mitogen stimulating signal.  
Flow cytometric cell cycle analysis is a fundamental method used to distinguish between 
various phases of the cell cycle based on DNA content. Using the fluorescence intensity 
from DNA dye and light scattering properties of individual cells, flow cytometry allows 
us to measure a population of cells in different phases of cell cycle (Gray et al. 1986).  It 
is noted that cells in G1 phase are diploid, and cells in G2 phase and M phase are 
tetraploid following DNA duplication in S phase. Hence, based on DNA content, flow 
cytometry defines G0/G1 phase and G2/M phase, and S phase is defined as intermediate 
between G0/G1 and G2/M. Two most commonly used DNA dye for cell cycle analysis are 
PI and DAPI (Darzynkiewicz et al. 2001). However, this conventional flow cytometric 
method has limitations.  
Conventional flow cytometry using DNA content analysis fails to distinguish G0 phase 
from G1 phase because both have the same DNA content (diploid). The conventional cell 
cycle analysis is also incapable to separate G2 phase from M phase because both phases 
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have the same DNA content (tetraploid). Among other approaches to distinguish G2 from 
M phase cells, co-staining of DNA with PI and phospho-Histone H3 is one of the most 
specific approaches. Histone H3 is phosphorylated at Ser10 by Aurora B in mitosis phase 
only (Gurley et al. 1978) and therefore can be used as M phase marker. 
In chapter 3, we have demonstrated an unequivocal cytostatic action of DR in PCa cells. 
Since cell cycle progression is the driving force underlying cell proliferation, we aimed to 
further investigate how the cell cycle progression was affected by DR treatment. 
Specifically, we wanted to confirm which cell cycle arrest was associated with cytostatic 
action of DR.  
 
5.2 Materials and Methods 
5.2.1 Prostate cancer cell lines 
The PCa cells lines, LNCaP and PC-3, were cultured as described in Chapter 3.1.1. 
5.2.2 DR treatment 
DR stock solution and various dose range of DR were prepared as described in Chapter 
3.2.1. 
5.2.3 Nocodazole treatment 
Nocodazole treatment to PCa cells was prepared as described in Chapter 3.2.2. 
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5.2.4 Flow cytometric analysis of cell cycle using PI staining 
The cell cycle phase distribution of PCa cells was determined by flow cytometric analysis 
of cells stained with PI as described in Chapter 3.5.1. 
5.2.5 Flow cytometric analysis using co-staining of PI and 
phospho-Histone H3 
The cell cycle phase distribution of PCa cells was determined by flow cytometric analysis 
of cells, stained with both PI and Ab against phospho-Histone H3 as described in 
Chapter 3.5.2. 
5.2.6 Immunoblotting 
The cells were treated in T25 flasks and immunoblotting was performed as described in 
Chapter 3.8. The primary antibodies used are listed in Table 3-2.  
5.2.7 Statistical analysis 
The statistical software NCSS version 12.0 was used for statistical analysis as described 
in Chapter 3.12. 
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5.3 Result  
5.3.1 DR accrued PCa cells at G2/M phase 
5.3.1.1 DR treatment enriched the LNCaP cells at G2/M phase by flow 
cytometric analysis of cell cycle with PI DNA staining. 
Flow cytometric DNA analysis was performed to analyse cell cycle distribution after PCa 
cells were treated with various doses of DR. A time course of treatment for 24, 48 and 72 
hr were chosen to examine if DR had different effects in a course of time. 
Following 24 hr of DR treatment, cell cycle analysis in LNCaP cells showed no 
significant changes in G0/G1 phase at 0.25 and 0.5 mg/mL, but a significant decrease 
(p<0.05) was found at 0.75 mg/mL (Figure 5.1.a). The cells in S phase were significantly 
reduced (p<0.05) at 0.5 and 0.75 mg/mL compared to vehicle control. There was a dose-
dependent increase in cells at G2/M phase after 24 hr of DR treatment at 0.5 mg/mL and 
0.75mg/mL (p<0.01).  
At 48 hr, a trend similar to 24 hr was found at G0/G1 phase of LNCaP cells (Figure 5.1.a). 
Comparing to control, the percentage of cells in S phase with DR was decreased. The 
cells at G2/M phase were increased significantly (p<0.01) at 0.75 mg/mL. 
At 72 hr, 0.25 mg/mL of DR treatment substantially increased the LNCaP cells at G0/G1 
phase and a notable reduction (p<0.05) was observed at 0.75 mg/mL (Figure 5.1.a).  The 
reduction in S phase was significant (p<0.01). The cells at G2/M phase increased with a 
dose-dependent manner and cells were increased to two folds (p<0.01) of control at 0.75 
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mg/mL. Sub G1 was remained unchanged at all time points following the treatment in 
LNCaP cells (Figure 5.1).  
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Figure 5.1 DR increased LNCaP cells at G2/M phase. LNCaP cells were treated with various dose of DR for 24, 48 and 72 hr. Cells 
were harvested and stained with PI for DNA analysis using flow cytometry. (a) The distribution of cell cycle phases in the presence and 
absence of DR at 24, 48 and 72 hr in LNCaP cells. Values presented are indicative of a mean of 3 independent experiments ± SD. *p<0.05 
and **p<0.01 indicate statistical significance in comparison to 0 mg/ml. # p<0.05 compared to 0.25 mg/mL. @ p<0.05 compared to 
0.5mg/mL. (b) Representative histograms of cells at 72 hr of cell cycle analysis were shown. 
   G0/G1 S G2/M Sub G1 
24hr 0 mg/mL 53.8% ± 4.9% 19.5% ± 2.0% 22.8% ± 3.8% 1.2% ± 1.0% 
 0.25 mg/mL 55.1% ± 3.6%   16.8% ± 2.7%  23.9% ± 2.6% 1.1% ± 1.9% 
 0.5 mg/mL 54.2% ± 1.0%   15.1% ± 1.7% * 27.6% ± 1.1%  * 0.4% ± 0.1% 
 0.75 mg/mL 48.2% ± 1.8% * # @ 15.0% ± 3.2% * 33.5% ± 2.5% ** # @ 1.4% ± 1.9% 
          
48hr 0 mg/mL 60.2% ± 5.5% 18.7% ± 2.1% 16.6% ± 4.6% 1.5% ± 0.9% 
 0.25 mg/mL 64.9% ± 4.6% 14.5% ± 0.9% * 18.0% ± 2.7% 0.8% ± 0.8% 
 0.5 mg/mL 58.7% ± 5.5% 15.6% ± 1.0% 23.5% ± 2.4%  0.4% ± 0.3% 
 0.75 mg/mL 45.7% ± 3.2% * # @  13.8% ± 1.9% * 37.7% ± 1.1% ** # @ 0.6% ± 0.2% 
         
72hr 0 mg/mL 61.2% ± 1.45% 19.8% ± 1.4% 16.8% ± 0.4% 0.7% ± 0.2% 
 0.25 mg/mL 70.3% ± 6.7% *  11.5% ± 0.9% ** 15.9% ± 3.5% 0.4% ± 0.3% 
 0.5 mg/mL 64.8% ± 4.3% 14.1% ± 1.2% ** # 18.9% ± 2.9% 0.5% ± 0.1% 
 0.75 mg/mL 49.6% ± 3.1% * # @   14.1% ± 1.4% ** 33.4% ± 2.5% ** # @ 0.7% ± 0.2% 
0mg/mL 0.25mg/mL 0.5mg/mL 0.75mg/mL 
(b) Cell Cycle analysis histograms of LNCaP cells 
(a) LNCaP 
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5.3.1.2 DR treatment enriched the PC-3 cells at G2/M phase by flow 
cytometric analysis of cell cycle with PI DNA staining. 
Flow cytometric analysis in PC-3 cells (Figure 5.2.a) showed that at 24 hr there was no 
significant change in cell cycle phases at 0.25, 0.5 and 0.75 mg/mL of DR treatment 
compared to vehicle control. But high dose (1 mg/mL) of DR significantly accumulate 
(p<0.05) the cells at G2/M phase and consistently decrease the cells at G0/G1 phase.  
After 48 hr of DR treatment, there was a significant decrease in the cells at G0/G1 phase and 
increased G2/M phase cells in dose-dependent manners (p<0.05). There was no apparent 
change in the cells at S phase (Figure 5.2.a).  
At 72 hr, cell cycle distribution of PC-3 was similar to LNCaP cells with a notable increase 
(p<0.05) at G0/G1 phase cells with the low dose (Figure 5.2.a).  But G0/G1 phase cells were 
significantly decreased (p<0.01) when treated with 0.75 and 1 mg/mL. Dose range 0.5-1 
mg/mL of DR increased the PC-3 cells at G2/M phase with a dose-dependent fashion 
(p<0.01) and cells were increased from 26% at vehicle control to 47% at 1 mg/mL. The 
percentage of cells at S phase remained the same between treatment and control group. No 






Figure 5.2 DR increased PC-3 cells at G2/M phase. PC-3 cells were treated with various dose range of DR for 24, 48 and 72 hr. Cells 
were harvested and stained with PI for DNA analysis using flow cytometry. (a) The distribution of cell cycle phases in the presence and 
absence of DR at 24, 48 and 72 hr in PC-3 cells. Values presented are indicative of a mean of 3 independent experiments ± SD. **p<0.01 and 
*p<0.05 indicate statistical significance in comparison to 0 mg/ml. # p<0.05 compared to 0.25 mg/mL. @ p<0.05 compared to 0.5mg/mL. α 
p<0.05 compared to 0.75 mg/mL. (b) Representative histograms of cells at 72 hr of cell cycle analysis were shown. 
  G0/G1 S G2/M Sub G1 
24hr 0 mg/mL 46.0% ± 3.1% 20.9% ± 5.1% 31.6% ± 2.5% 0.4% ± 0.3% 
 0.25 mg/mL 48.6% ± 4.8% 18.0% ± 6.9% 31.9% ± 2.7% 0.4% ± 0.3% 
 0.5 mg/mL 44.0% ± 5.0% 19.0% ± 5.5% 34.8% ± 8.7% 0.9% ± 0.8% 
 0.75 mg/mL 41.4% ± 3.9% 16.9% ± 2.8% 39.2% ± 5.8% 1.1% ± 1.0% 
 1 mg/mL  39.9% ± 0.9%  * # 16.1% ± 4.6% 42.5% ± 5.9%   * # 0.5% ± 0.3% 
                
48hr 0 mg/mL 54.4% ± 1.0% 16.5% ± 0.8% 28.1% ± 0.4% 0.4% ± 0.3% 
 0.25 mg/mL 56.4% ± 2.4% 14.9% ± 2.1% 27.8% ± 1.7% 0.5% ± 0.4% 
 0.5 mg/mL 51.9% ± 1.4% * # 14.4% ± 2.9% 32.5% ± 3.4%  * 0.7% ± 0.6% 
 0.75 mg/mL 42.3% ± 2.0% ** # @ 16.8% ± 2.2% 38.6% ± 1.3%  ** # @ 1.2% ± 1.4% 
 1 mg/mL  35.5% ± 0.1% ** # @ α 18.9% ± 1.8%  42.9% ± 2.3%  ** # @ 1.1% ± 0.7% 
                
72hr 0 mg/mL 57.1% ± 3.2% 15.8% ± 3.4% 26.3% ± 1.0% 0.7% ± 0.5% 
 0.25 mg/mL 63.0% ± 4.0%  * 11.5% ± 3.7% 24.3% ± 1.4%  * 1.0% ± 0.6% 
 0.5 mg/mL 57.2% ± 3.5%  # 11.7% ± 2.6% 29.9% ± 1.7%  ** #  1.0% ± 1.2% 
 0.75 mg/mL 47.2% ± 2.4%  ** # @ 13.2% ± 3.1% 38.5% ± 2.9%  ** # @ 0.9% ± 1.2% 
1 mg/mL 34.6% ± 2.8%  ** # @ α 17.4% ± 2.2% 46.6% ± 3.2%  ** # @ α 0.7% ± 0.4% 
(a) PC-3 
0mg/mL 0.25mg/mL 0.5mg/mL 0.75mg/mL 1mg/mL 
(b) Cell Cycle analysis histograms of PC-3 cells 
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Overall, flow cytometric DNA analysis showed that DR reduced the PCa cells at G0/G1 and 
increased cells at G2-M phase in a dose dependent manner. S phase cells were reduced in 
LNCaP cells, but no change was observed in PC-3 cells. DR had no noticeable effect on Sub 
G1 phase. 
 
5.3.2 DR enriched PCa cells at G2 phase 
5.3.2.1 Establish flow cytometric analysis of PCa cells by co-staining with 
anti phospho-Histone H3 Ab and PI. 
DNA analysis of flow cytometry by PI staining showed that DR accrued the PCa cells at 
G2/M phase. Next, we examined if the accumulated cells were at G2 phase or M phase. 
Considering Histone-H3 is highly phosphorylated at Ser10 in mitosis, we determined the 
effect of DR on Histone-H3 in PCa cells.  
First, we optimised our experimental method. Nocodazole binds to Tubulin with high 
affinity to inhibit microtubule assembly. Here, we used Nocodazole for two purposes. One 
was to maintain or ‘trap’ cells at M phase and the other to have a positive control to validate 
our detection system on cells at M phase. LNCaP cells were treated with various doses of 
Nocodazole (200-800 ng/mL) followed by PI flow analysis. Our data demonstrated that 600 
ng/mL of Nocodazole treatment increased the G2/M phase to 44.8% compared with 15.8% 
in untreated control (p<0.05). No further increase was found at 800 ng/mL (Figure 5.3.a).  
Next, we co-stained LNCaP cells with PI and Ab against phospho-Histone H3 in the 
presence or absence of Nocodazole. By simultaneously determining DNA content and 
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phospho-Histone H3 positivity, phospho-Histone H3 positive tetraploid cells were gated out. 
Method control, which stained with PI only, was included in the analysis to provide 
specificity of the method for phospho-Histone H3. Flow cytometric analysis of co-staining 
revealed a significant escalation in M phase cells in Nocodazole treated LNCaP cells 
compared to control (Figure 5.3.b), indicating the established method should be able to 




Figure 5.3 Nocodazole treatment increased phospho-Histone H3 positive cells. LNCaP cells were treated with a dose range (200-800 
ng/mL) of Nocodazole and harvested for flow cytometric analysis. (a) Table showed the distribution of cell cycle phases in the presence and 
absence of Nocodazole in LNCaP cells. The results were mean value ± SD of two independent experiments. * p<0.05 compared to Control, # 
p<0.05 compared to 200 ng/mL, @ p<0.5 compared to 400 ng/mL. (b) The representative histograms of PI stained control cells and dose 
range (200-800 ng/mL) of Ncodazole treated cells. (c) The representative dot plots, which were co-stained with PI and phosphor-Histone H3 




 Duration   G0/G1 S G2/M Sub G1 
16hr Control 61.9% ± 0.6% 19.3% ± 0.4% 15.8% ± 1.1% 0.8% ± 0.5% 
16hr Nocodazole 200 ng/mL 65.6% ± 0.1%*  16.9% ± 0.5%*  14.8% ± 0.4% 1.0% ± 0.3% 
16hr Nocodazole 400 ng/mL 59.1% ± 0.2%*#  14.2% ± 0.1%*# 24.4% ± 0.5% *#  1.1% ± 0.4% 
16hr Nocodazole 600 ng/mL 41.5% ± 1.5%*#@ 10.8% ± 0.2%*#@ 44.8% ± 0.9% *#@  1.5% ± 0.2% 

















Method Control         
        Control Nocodazole  200 ng/mL 
Nocodazole 
 400 ng/mL 
Nocodazole 
 600 ng/mL 
Nocodazole 
 800 ng/mL 
13.1%    
Nocodazole 
 600 ng/mL 
7.1%    
Nocodazole 
 400 ng/mL 
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5.3.2.2 DR accrued PCa cells at G2 phase by co-staining and 
immunoblotting.  
After establishing the detection method, we determined whether DR arrested the PCa cells at 
M phase, cell cycle analysis with co-stained cells was performed. DR was introduced to the 
PCa cells at the dose of 0-0.75 mg/mL in LNCaP and 0-1 mg/mL in PC-3 cells for 72 hr. 
The Nocodazole at 800 ng/mL was introduced in the last 16 hr prior to harvesting.  
As expected, the treatment with Nocodazole alone maintained a high number of cells at M 
phase compared to the control. Interestingly, treatment with DR significantly reduced cells 
at M phase in a dose-dependent manner (Figure 5.4 and 5.5). Compared to control as 100%, 
0.75 mg/mL of DR decreased (p<0.01) LNCaP cells at M phase by 50% (Figure 5.4.a). 
Similarly, PC-3 cells at M phase were noticeably reduced (p<0.01) by more than 50% even 
at 0.25 mg/mL. The proportion of PC-3 cells in M phase was diminished to only 12% at 1 
mg/mL of DR (Figure 5.5.a).  
 154 
 
Figure 5.4 DR decreased phospho-Histone H3 positive cells by flow cytometric 
analysis in LNCaP cells.  LNCaP cells were treated with various dose of DR for 72 hr. 
Cells were labelled with phospho-Histone H3 to perform the cell cycle analysis. 
Nocodazole (600ng/mL) treated cells were used as positive control. (a) Quantification 
data of three independent experiments mean ± SD were presented. * indicates p<0.01 
compared to 0 mg/ml. (b) The representative dot plots of phospho-Histone H3 positivity 

















  % of phospho-Histone H3 
  LNCaP 
0 mg/mL 0.80% ± 0.17% 
0.25 mg/mL 0.63% ± 0.11%  
0.5 mg/mL 0.53% ± 0.15% * 
0.75 mg/mL 0.39% ± 0.16% *  
Nocodazole 19.0% ± 0.14% 
Method control 0.01% ± 0.00% 
0.75 mg/mL                             Nocodazole                                M ethod control 







Figure 5.5 DR decreased phospho-Histone H3 positive cells by flow cytometry 
analysis in PC-3 cells.  PC-3 cells were treated with various dose range of DR for 72 hr. 
Cells were labelled with phospho-Histone H3 to perform the cell cycle analysis. (a) 
Quantification data of three independent experiments mean ± SD were presented. * 
indicates p<0.01 compared to 0 mg/ml. (b) The representative dot plots of phospho-












  % of phospho-Histone H3 
  PC-3 
0 mg/mL 1.87% ± 0.22% 
0.25 mg/mL 0.56% ± 0.13%  
0.5 mg/mL 0.40% ± 0.12%  
0.75 mg/mL 0.28% ± 0.07% *  
1 mg/mL 0.22% ± 0.06% *  
Method control 0.01% ± 0.02% 
   0 mg/mL                                     0.25 m g/mL                                 0.5 m g/mL  









To confirm the finding from the flow analysis of co-staining, the cancer cells were 
treated in the same fashion and harvested for immunoblotting. Consistently, the protein 
level of phospho-Histone H3 was diminished in both cell lines, while total Histone H3 
level remained unchanged (Figure 5.6), supporting the conclusion that the arrested 
cells are not in the M phase. 
 
Figure 5.6 DR decreased phospho-Histone H3 protein level in PCa cells. PCa cells 
were treated with various dose range of DR for 72 hr and the samples were harvested for 
immunoblotting. (a) The representative images of total and phospho-Histone H3 protein 
level of PCa cells. α-Tubulin served as a loading control. (b) Quantification of 
immunoblotting. Triplicates were normalized by loading control and plotted as the 
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We had confirmed the anti-proliferative activities of DR in chapter 3. This chapter 
described our investigation as how DR impacts the cell cycle distribution. Flow 
cytometry of PI-stained cells showed an accumulation at G2/M phase after treatment with 
DR. Sub G1 population remained unchanged even after 72 hr treatment indicating no 
association with cell death, which was consistent with the cytostatic action of DR at the 
dose used in the study. Subsequent flow cytometric analysis of co-staining with PI and 
phosho-Histone H3 Ab as well immunoblotting showed that DR decreased the phospho-
Histone H3 level, indicating the G2 rather than M phase arrest by DR treatment. 
5.4.1 Differentiation of G2 phase and M phase  
Flow cytometric analysis using PI staining is a conventional method of cell cycle analysis 
based on the quantitation of DNA content. However, cell cycle analysis of PI staining 
alone is not able to separate between G2 and M phase as both phases have similar DNA 
content (tetraploid). To delineate the cells at G2 phase from those at M phase, we used 
phospho-Histone H3, which is a well-characterised M phase marker (Gurley et al. 1978). 
It was reported that phosphorylation at Ser10 of Histone H3 by Aurora B is strictly 
correlated with chromosome condensation during onset of both mitosis and meiosis 
(Chen et al. 2017; Mellone et al. 2003; Sawicka et al. 2012). A mutation in the serine 
residue of Histone H3 caused mitotic defects including chromosome segregation 
(Mellone et al. 2003). Hence, phosphorylation of Histone H3 at Ser10 is indispensable in 
M phase.  
We reasoned that, if DR treated PCa cells were arrested at M phase, we would expect to 
see an increase in phospho-Histone H3 positivity. If a decrease in phospho-Histone H3 
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positivity was observed, it would indicate a blockade of G2-M transition. Our 
experimental results supported the latter. As Nocodazole alone treated PCa cells were 
included as positive control and shown a marked increase in M phase, any increase in 
PCa cells at the M phase following DR treatment would have been detected. 
Immunoblotting with Ab against total and Ser10 phosphorylated form of Histone H3 was 
another clear indication that DR treatment enriched the cells at G2 rather than M phase.  
Since post-translational modification of Histone H3 such as acetylation, phosphorylation, 
methylation can affect the accessibility of chromatin to transcription factors (Sawicka et 
al. 2012), the  reduction of phospho-Histone H3 by DR may prevent the transcriptions of 
those genes essential to promote the mitosis.  
5.4.2 Diversity of cell cycle arrests induced by HD and SB 
A number of studies have reported the cell cycle arrest associated with HD and SB in 
different cancer cells (Chen et al. 2012; Dai et al. 2008; Kim et al. 2007; Kuo et al. 2015; 
Lee et al. 2004; Lin et al. 2012; Marconett et al. 2010; Wei et al. 2013). Most of the cell 
cycle arrest caused by HD was related to G1 phase arrest, including either G0-G1 or G1-S 
arrest (Chen et al. 2012; Kuo et al. 2015; Lin et al. 2012). The cell cycle arrests caused by 
SB were more varied. G1 arrest induced by ethanol extract of SB in colon cancer cells 
(Wei et al. 2013), and water extract in leukaemia cells (Kim et al. 2007) and smooth 
muscle cells (Lee et al. 2004), were also reported. In PCa cells, a study with SB extract 
showed the G2/M arrest in LNCaP and S phase arrest in PC-3 cells (Marconett et al. 
2010). However, no study describing the effect of combination of these two herbal 
medicines on cell cycle has been reported thus far. Therefore, our study has provided 
evidence for the first time of DR on G2 phase cell cycle arrest. Moreover, efforts to 
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dissect G2 phase from M phase has not been made in the study of TCM, even though this 
approach has previously been used in the study with chemical compounds (Zhu et al. 
2009) and drugs (Nomura et al. 2007). 
In conclusion, DR induced accumulation of PCa cells at G2/M by flow cytometric 
analysis of PI-staining is likely due to arrest at G2. Hence, the mechanism of this DR 















6 Molecular Mechanism of 




The mammalian cell cycle is highly regulated through different mechanisms to assure the 
duplication of DNA with high fidelity and successful cell division (Otto et al. 2017). Two 
distinct mechanisms are involved in cell cycle regulation. The first one involves proteins 
such as Cyclins and CDKs, which promote the progression of cell cycle from one phase 
to next in response to growth stimuli. The second regulatory mechanism involves cell 
cycle checkpoint proteins such as INK4, Cip/Kip and checkpoint kinase family proteins. 
They inhibit the activity of Cyclins-CDKs complexes upon genomic instability and anti-
mitogenic stimulation (Malumbres et al. 2001; Otto et al. 2017; Pietenpol et al. 2002). 
Since checkpoint proteins regulate the rate of cell division, the activation of checkpoints 
may cause either cell cycle arrest or cell death.  
Described in chapter 3 and 4, our study revealed that the anti-proliferative activity of DR 
involved enrichment of PCa cells at G2 phase. The mechanisms underlying DR-induced 
G2 phase arrest can be a consequence of DNA damage-triggered activation of G2 
checkpoint. Upon DNA damage, G2 checkpoint kinases CHK1 and CHK2 are activated 
through ATM and ATR signalling pathway. That activation consequently inhibits the 
activity of effector M phase promoting complex, Cyclin B1-CDK1 complex (DiPaola 
2002). CHK1 can activate Wee1 through stimulatory phosphorylation, which in turn 
inhibits the activity of Cyclin B1-CDK1 complex at G2-M transition (Do et al. 2013; 
Pietenpol et al. 2002; Shaltiel et al. 2015). The activity of CDC25C is inhibited by CHK1 
and CHK2 in response to DNA damage, leaving Cyclin B1-CDK1 complex inactive 
(Shaltiel et al. 2015; Toyoshima‐Morimoto et al. 2002). Hence, an activating 
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phosphorylation of DNA damage transducers, CHK1 and CHK2, is a key manifestation 
of DNA damage-induced G2 phase arrest.  
Progression from G2 to M phase requires the M phase promoting complex Cyclin B1-
CDK1, and the positive regulators PLK1 and Aurora A (Otto et al. 2017). During G2 
phase, Aurora A activating phosphorylates PLK1 at Thr210. An active PLK1 is required to 
stimulate Cyclin B1-CDK1 complex and promote G2 to M phase progression, leading to 
centrosome maturation (Macurek et al. 2008). CDC25C is a phosphatase that can remove 
inhibitory phosphates from CDK1 resulting its activation. PLK1 stimulates CDC25C by 
phosphorylation at Ser198 and translocates it into the nucleus to activate the Cyclin B1-
CDK1 complex (Toyoshima‐Morimoto et al. 2002). PLK1 also inactivates Wee1 
(Watanabe et al. 2004), which can add inhibitory phosphate to Cyclin B1-CDK1 at Tyr15 
(Matheson et al. 2016). Studies have reported that PLK1 and Aurora A expressions are 
frequently elevated in cancer including prostate (Mosquera et al. 2013) and down-
regulation of those proteins by respective inhibitors induce cell cycle arrest and apoptosis 
(Görgün et al. 2010; Otto et al. 2017; Rudolph et al. 2009; Strebhardt 2010; Yan et al. 
2016). Hence, the protein levels of Aurora A, PLK1 and Cyclin B1-CDK1 complex 
reflect the cellular readiness to progress to M phase.  
The aim of the studies described in this chapter was to examine the mechanism by which 
DR caused arrest of PCa cells at G2 phase leading to blockage of G2-M transition. 
Specially, we determined firstly if DR caused DNA damage, and secondly if DR inhibited 
M phase promoting complex and regulators. Lastly, we examined the clinical significance 
of M phase promoting complex and its regulators in PCa by analyzing the various 
datasets including R2 Genomic Analysis and Visualization Platform and cBiooportal for 
Cancer Genomic.  
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6.2 Materials and Methods 
 
6.2.1 Prostate cancer cell lines 
The PCa cell lines LNCa and PC-3 cells were cultured as described in Chapter 3.1.1. 
 
6.2.2 DR treatment 
DR stock solution and various dose range of DR were prepared as described in 
Chapter 3.2.1. 
6.2.3 Radiation treatment  
Radiation treated PCa cells were prepared as described in Chapter 3.2.3. 
6.2.4 Immunofluorescence 
Immunolabelling of phospho-H2AX and 53BP1 in PCa cells were prepared as 
described in Chapter 3.7. 
6.2.5 Immunoblotting   
The cells were treated in T25 flasks and immunoblotting was performed as described 
in Chapter 3.8. The primary antibodies used are listed in Table 3-2. 
 165 
6.2.6 RT-PCR 
RT-PCR was performed as described in Chapter 3.9. All the primer sequences used 
for RT-PCR in this study are listed in Table 3-4.  
6.2.7 Database analysis  
The statistical difference in mRNA levels of Cyclin B1, CDK1, PLK1 or Aurora A 
between benign prostatic hyperplasia (BPH) and PCa, or between primary and 
metastatic PCa were analysed using the Dutch based online tool R2: Genomics 
Analysis and Visualization Platform. The prostate data set used for analysis was 
Sawyers–370. All data were log-transformed provided by dataset.  
The genomic alterations of four genes associated with PCa were determined using 
datasets from cBioportal for Cancer Genomics. The data of genomic alterations in 
Cyclin B1, CDK1, PLK1 and Aurora A genes were analysed across 13 studies, over 
2700 specimens of PCa.  
6.2.8 Statistical analysis  
The statistical software NCSS version 12.0 was used for statistical analysis as 
described in Chapter 3.12. Comparison between BPH and cancer, or primary and 
metastasis from R2: Sawyers-370 dataset were performed using one-way ANOVA. 
The correlations between each mRNA levels of gene of interest and Ki-67 were 





6.3.1 DR solicited no DNA damage in PCa cells  
 
6.3.1.1 DR did not initiate phospho-H2AX and 53BP1 foci by 
immunofluorescence 
As a delay in G2-M transition is often associated with DNA damage, we questioned 
whether DR could cause DNA damage in the treated cells. The PCa cells treated with DR 
were analysed for DNA damage based on phospho-H2AX and p53-binding protein 1 
(53BP1) foci. In parallel, the cancer cells treated with IR (2 Gy) were included as positive 
control.   
Immunofluorescence imaging showed that phospho-H2AX and 53BP1 foci were induced 
in PCa cells treated with IR at 2 Gy. But DR did not initiate phospho-H2AX and 53BP1 
foci in comparison with irradiated cells (Figure 6.1, 6.2, 6.3, 6.4 and 6.5).  
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Figure 6.1 DR did not increase the phospho-H2AX in LNCaP cells by 
immunofluorescence. LNCaP cells were treated with IR (2Gy) for positive control and 
harvested 3 hr after treatment. DR was introduced to LNCaP cells for 72 hr, and 
harvested to fix with 10% formalin in PBS. Samples were embedded in paraffin block 
and 5 μm thickness slices were cut to perform immunostaining, using the Ab against 
phospho-H2AX. DAPI was used for nuclear stain. Representative images of LNCaP cells 
were shown. Columns (left to right), nucleus (blue), phospho-H2AX (green), and merge. 
Arrows indicated phospho-H2AX foci. 









Figure 6.2 DR did not increase the phospho-H2AX in PC-3 cells by 
immunofluorescence. PC-3 cells were treated with IR (2Gy) for positive control and 
harvested 3 hr after treatment. DR was introduced to PC-3 cells for 72 hr, and harvested 
to fix with 10% formalin in PBS. Samples were embedded in paraffin block and 5 μm 
thickness slices were cut to perform immunostaining, using the Ab against phospho-
H2AX. DAPI was used for nuclear stain. Representative images of PC-3 cells were 
shown. Columns (left to right), nucleus (blue), phospho-H2AX (green), and merge. 
Arrows indicated phospho-H2AX foci. 










Figure 6.3 DR did not increase the 53BP1 in LNCaP cells by immunofluorescence. 
LNCaP cells were treated with IR (2Gy) for positive control and harvested 3 hr after 
treatment. DR was introduced to LNCaP cells for 72 hr, and harvested to fix with 10% 
formalin in PBS. Samples were embedded in paraffin block and 5 μm thickness slices 
were cut to perform immunostaining, using the Ab against 53BP1. DAPI was used for 
nuclear stain. Columns (left to right), nucleus (blue), 53BP1 (red), and merge. 
Representative images were shown. Arrows indicated 53BP1 foci. 
 
 









Figure 6.4 DR did not increase the 53BP1 in PC-3 cells by immunofluorescence. PC-
3 cells were treated with IR (2Gy) for positive control and harvested 3 hr after treatment. 
DR was introduced to PC-3 cells for 72 hr, and harvested to fix with 10% formalin in 
PBS. Samples were embedded in paraffin block and 5 μm thickness slices were cut to 
perform immunostaining, using the Ab against 53BP1. DAPI was used for nuclear stain. 
Representative images were also shown. Columns (left to right), nucleus (blue), 53BP1 
(red), and merge. Arrows indicated 53BP1 foci. 










Figure 6.5 Quantification of phospho-H2AX and 53BP1 immunofluorescence 
staining in PCa cells. Immunofluorescence results from triplicates were quantified and 
plotted as the average number of number of foci per nucleus ± SD. * represents 
statistically significant compared to 0 p<0.05. 
 
Hence, no distinct foci of phospho-H2AX and 53BP1 were found in DR treated PCa cells 
in comparison to radiation treated cells (Figure 6.1 - 6.5). 
 
6.3.1.2 DR had no effect on DNA damage response transducer proteins by 
immunoblotting. 
To confirm that DR did not initiate DNA damage response in the treated cells, the major 
components or transducers of DNA damage response including total and phosphorylated 
ATR, ATM, CHK1 and CHK2 were examined by immunoblotting. PCa cells were treated 
with DR for 72 hr, and at the same time the same batch of PCa cells were treated with IR 
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Consistent with the findings of phospho-H2AX and 53BP1, DR treatment did not result in 
detectable changes in either phosphorylated or total protein kinase level in LNCaP cells 
(Figure 6.6 and 6.7). In contrast, irradiation led to increased levels of phosphorylated 
ATM, ATR and CHK2 without an obvious change in total protein levels (Figure 6.6 and 
6.7). The radiation did not elicit an obvious alteration in total and phosphorylated CHK1.  
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Figure 6.6 DR did not increase DNA damage response proteins in LNCaP cells by 
immunoblotting. DR was introduced to LNCaP cells for 72 hr, and harvested for 
immunoblotting. The same batch of LNCaP cells were also treated with IR (2Gy) and 
harvested 1 hr, 2 hr and 3 hr after treatment. IR treated cells were used as positive control 
for activation of DNA of damage response. The immunoblot images were representative 
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Figure 6.7 Quantification of immunoblotting in DNA damage response proteins in 
LNCaP cells. Immunoblotting results from triplicates were normalized by respective 
loading control. Histograms were plotted from the average density from three 




In PC-3 cells, consistent with aforementioned results of phospho-H2AX and 53BP1, 
there were no significant changes in the DNA damage response transducer kinases 
after DR treatment (Figure 6.8 and 6.9). Irradiation increased both total and 
phosphorylated form of ATM, ATR and CHK2 in PC-3 cells, (Figure 6.8 and 6.9), 
while no significant change was observed in both total and phospho-CHK1. 
 
Figure 6.8 DR did not increase DNA damage response proteins in PC-3 cells by 
immunoblotting. DR was introduced to PC-3 cells for 72 hr, and harvested for 
immunoblotting. The same batch of PC-3 cells were also treated with IR (2Gy) and 
harvested 1 hr, 2 hr and 3 hr after treatment. IR treated cells were used as positive control 
for activation of DNA of damage response. The immunoblot images were representative 
of three independent experiments. GAPDH served as a loading control. 
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Figure 6.9 Quantification of immunoblotting in DNA damage response proteins in 
PC-3 cells. Immunoblotting resulted from triplicates were normalized by respective 
loading control. Histograms were plotted from the average density from three 
independent experiments ± SD. * represents statistically significant compared to 0 and No 
IR p<0.05. 
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Comparing to vehicle control and radiation-treated PCa cells, immunoblotting showed no 




6.3.2 DR impaired the expression of mitosis promoting complex 
and regulators in PCa cells 
 
6.3.2.1 DR reduced the protein levels of M phase promoting complex and 
regulators governing G2-M transition 
Following exclusion of the possibility that DR-impeding G2-M transition was due to 
DNA damage-triggered G2 arrest, we examined the effect of DR on protein levels of 
Cyclin B1, CDK1, PLK-1 and Aurora A kinase, as these proteins are required for 
promoting G2-M transition. After treatment of PCa cell lines with DR for 72 hr, these 
proteins were measured by immunoblotting.  
Immunoblotting showed that DR reduced protein levels of all four proteins in PCa cells 
(p<0.05).  High dose of DR (at 0.75 mg/mL) decreased the protein levels of Cyclin B1, 
CDK1 and PLK1 by approximately 60% and Aurora A by 75% in LNCaP cells (Figure 
6.10.a - 6.11.a). A 60% reduction was found in inactive phosphorylated form of CDK1 
(CDK1-Tyr15), following the DR treatment at high dose, although it was not statistically 
significant.  
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In PC-3 cells, high dose (1 mg/mL) of DR reduced the protein levels of Cyclin B1 and 
CDK1 by 50%, Aurora A by 60% and PLK1 by 75%, respectively (Figure 6.10.b- 
6.11.b).  There was no significant change in the level of phospho-CDK1 in PC-3 cells 
after DR treatment.  
 
 
Figure 6.10 DR decreased the protein level of M phase promoting complex and 
regulators. PCa cells were cultured for 48 hr and treated with DR for 72 hr. Images 
presented were the representative of three independent experiments in (a) LNCaP and (b) 
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Figure 6.11 Quantification of immunoblotting in M phase promoting complex and 
regulators in PCa cells. Immunoblotting resulted from triplicates were normalized by 
respective loading control. Histograms were plotted from the average density from four 
independent experiments ± SD. * p<0.05 compared to 0 mg/mL. # p<0.05 compared to 
0.25 mg/mL, @ p< 0.05 compared to 0.5 mg/mL, α p<0.05 compared to 0.75 mg/mL.  
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Following the confirmation of DR did not cause DNA damage, immunoblotting of M 
phase promoting complex and regulators showed that DR reduced all four proteins in PCa 
cells.  
 
6.3.2.2 Establish RT-PCR analysis of M phase promoting complex and 
regulators 
To determine the mRNA level of M phase promoting complex and regulators in DR 
treated PCa cells, we firstly established RT-PCR analysis. A serial dilution of cDNA 
reversed transcribed from total RNA extracted from PCa cells was employed to check the 
amplification efficiency of housekeeper gene, 36B4 and genes of interest, Cyclin B1, 
CDK1, PLK1 and Aurora A by RT-PCR. We also analysed the melting curves of all five 
genes to determine the specificity of the amplified PCR products. Here, we presented the 
data from housekeeper 36B4 and CDK1 as the representative gene of interest.  
In control LNCaP cells, the threshold cycle (CT) values reflected by 36B4 amplicon at 
1/3, 1/9, 1/27 and 1/81 dilutions of cDNA were 14.2, 15.9, 17.5 and 19.3, respectively. 
The average difference of CT values between every three-fold dilution was 1.7 (Figure 
6.12.a and b). In DR (0.5 mg/mL) treated LNCaP cells, the CT values of 36B4 at 1/3, 1/9, 
1/27 and 1/81 dilutions were 12.4, 14.2, 15.7 and 17.4, respectively and the average 
difference of CT values between every three fold dilution was 1.6 (Figure 6.12.a and b). 
The amplification efficiencies calculated in control and DR treated cells were 96% and 
100%, respectively (Figure 6.12.b). Both control and DR treated LNCaP cells showed a 
single peak of 36B4 at 86°C in the melting curve analysis (Figure 6.12.c). 
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The CT values of CDK1 gene in control at 1/3, 1/9, 1/27 and 1/81 dilutions of cDNA were 
18.9, 20.4, 22.3 and 24.3, respectively and the average difference was 1.8 (Figure 6.13.a 
and b). The CT values of CDK1 cDNA dilutions in DR treated cells were 19, 20.3, 22 and 
23.6, respectively, and the average difference was 1.6 (Figure 6.13.a and b). The 
amplification efficiencies of CDK1 gene calculated in both control and DR treated 
LNCaP cells were 83% and 100% respectively (Figure 6.13.b). A single peak at 81°C was 




Figure 6.12 DR had no effect on the amplification efficiency of 36B4 by RT-PCR in 
LNCaP cells. Cells were treated with either vehicle control or 0.5 mg/mL of DR for 72 
hr. A serial dilution of a cDNA template extracted from LNCaP cells was run using 
primers of 36B4 and results were generated as a dilution curve. (a) The amplification 
plots of 36B4. (b) The dilution curves were plotted using the log of dilution factor against 
the threshold cycle (CT) value obtained from amplification of each dilution. The equation 
of linear regression line along with r and R2 were also evaluated to examine the linearity 
of data and amplification efficiency of RT-PCR. (c) A melt-curve analysis in each of the 
genes was also performed to identify the various products of polymerase chain reaction.  
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Figure 6.13 DR had no effect on the amplification efficiency of CDK1 by RT-PCR in 
LNCaP cells.  Cells were treated with either vehicle control or 0.5 mg/mL of DR for 72 
hr. A serial dilution of a cDNA template extracted from LNCaP cells was run using 
primers of CDK1 and results were generated as a dilution curve. (a) The amplification 
plots of CDK1. (b) The dilution curves were plotted using the log of dilution factor 
against the threshold cycle (CT) value obtained from amplification of each dilution. The 
equation of linear regression line along with r and R2 were also evaluated to examine the 
linearity of data and amplification efficiency of RT-PCR. (c) A melt-curve analysis in 




In PC-3 cells, CT values of 36B4 in control at 1/3, 1/9, 1/27 and 1/81 dilutions were 11.2, 
12.7, 14.1 and 15.8, respectively. The average difference of CT values between every 
three fold dilution was 1.6 (Figure 6.14.a and b). The CT values of 36B4 in DR treated 
PC-3 cells at 1/3, 1/9, 1/27 and 1/81 dilutions were 12.3, 14.5, 16.4 and 17.7, respectively 
and the average difference of CT values from serial dilution was 1.8 (Figure 6.14.a and b). 
There was a moderate difference in amplification efficiencies between control and DR 
treated cells with 100% and 88%, respectively (Figure 6.14.b). A single peak at 86°C was 
observed in both control and DR treated PC-3 cells in the melting curve analysis (Figure 
6.14.c). 
The CT values of CDK1 gene in control at 1/3, 1/9, 1/27 and 1/81 dilutions of cDNA were 
15.5, 17, 18.5 and 20.29, respectively and the average difference was 1.6 (Figure 6.15.a 
and b). The CT values of CDK1 cDNA dilutions in DR treated cells were 16, 17.5, 19.1 
and 20.8, respectively, and the average difference was 1.6 (Figure 6.15.a and b). The 
calculated amplification efficiency of CDK1 gene in both control and DR treated PC-3 
cells was 100% (Figure 6.15.b). Both control and DR treated cells illustrated a single 
peak at 80°C in the melting curve analysis (Figure 6.15.c). 
 185 
 
Figure 6.14 DR had no effect on the amplification efficiency of 36B4 by RT-PCR in 
PC-3 cells. Cells were treated with either vehicle control or 0.5 mg/mL of DR for 72 hr. 
A serial dilution of a cDNA template extracted from PC-3 cells was run using primers of 
36B4 and results were generated as a dilution curve. (a) The amplification plots of 36B4. 
(b) The dilution curves were plotted using the log of dilution factor against the threshold 
cycle (CT) value obtained from amplification of each dilution. The equation of linear 
regression line along with r and R2 were also evaluated to examine the linearity of data 
and amplification efficiency of RT-PCR. (c) A melt-curve analysis in each of the genes 




Figure 6.15 DR had no effect on the amplification efficiency of CDK1 by RT-PCR in 
PC-3 cells. Cells were treated with either vehicle control or 0.5 mg/mL of DR for 72 hr. 
A serial dilution of a cDNA template extracted from PC-3 cells was run using primers of 
CDK1 and results were generated as a dilution curve. (a) The amplification plots of 
CDK1. (b) The dilution curves were plotted using the log of dilution factor against the 
threshold cycle (CT) value obtained from amplification of each dilution. The equation of 
linear regression line along with r and R2 were also evaluated to examine the linearity of 
data and amplification efficiency of RT-PCR. (c) A melt-curve analysis in each of the 




Together, amplification plot and dilution curve of 36B4 and CDK1 showed that treatment 
with DR did not affect the amplification efficiency of cDNA associated with those genes 
by RT-PCR. Melting curve analysis also revealed that primers of those genes were 
specific.   
6.3.2.3 DR reduced the mRNA level of M phase promoting complex and 
regulators  
 
After validating the RT-PCR, we performed RT-PCR to examine the mRNA level of 
Cyclin B1, CDK1, PLK1 and Aurora A in DR treated PCa cells. At 0.5 and 0.75 mg/mL, 
DR significantly reduced (p<0.05) the mRNA levels of all four genes in LNCaP cells 
(Figure 6.16.a). Considering the vehicle control as 100%, the mRNA levels of Cyclin B1, 
CDK1, PLK1 and Aurora A at 0.5 mg/mL were reduced by 50%, 67%, 65% and 67%, 
respectively. Further reduction was found in mRNA level of four genes at 0.75 mg/mL by 
60%, 72%, 77% and 73%, respectively.  
In PC-3 cells, DR dose range (0.5-1 mg/mL) significantly decreased (p<0.05) mRNA 
levels of all four genes of interest (Figure 6.16.b).  The reductions in mRNA levels of 
four genes at 0.5 mg/mL were 83%, 76%, 89% and 81%, respectively. At 0.75 mg/mL, 
the mRNA levels of four genes were reduced by 83%, 82%, 90% and 78%, respectively. 
1 mg/mL of DR further decreased the mRNA levels of all four genes by 89%, 86%, 93% 
and 85%, respectively.  
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Figure 6.16 DR decreased the mRNA levels of Cyclin B1, CDK1, PLK1 and Aurora A. 
PCa cells were cultured for 48 hr and treated with DR for 72 hr. Cells were washed with 
pre cold PBS and lysate buffer was added into the samples. Total RNA content were 
extracted and samples was analysed by RT-PCR. HK, housekeeping protein 36B4 was 
used as loading control. The results are representative of three experiments. * p<0.05 
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Taken together, RT-PCR of PCa cells showed that DR decreased the mRNA levels of 
all four proteins. 
 
6.3.3 mRNA levels of Cyclin B1, CDK1, PLK1 and Aurora A were 
increased in human PCa tissue and correlated with disease 
progression.  
 
6.3.3.1 mRNA levels of Cyclin B1, CDK1, PLK1 and Aurora A were 
increased in PCa  
 
To determine whether M phase promoting complex and regulators are associated with 
PCa, mRNA levels of each gene were analysed using R2 microarray analysis and 
visualization platform. Analysis of Sawyers–370 dataset showed that mRNA levels of 
Cyclin B1, CDK1, PLK1 and Aurora A in PCa (N=300) were significantly higher 
(p<0.05) than that in BPH (N=58) (Figure 6.17).  
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Figure 6.17 mRNA levels of M phase promoting complex and regulators in BPH and 
cancer tissue of prostate. mRNA levels of M phase promoting complex and regulators 
were plotted for BPH (n=58) and PCa (n=300) tissues from prostate dataset of Sawyers–
370, using R2 microarray analysis and visualization platform. p values of statistical 
difference between BPH and PCa were described.    
 
6.3.3.2 mRNA levels of Cyclin B1, CDK1, PLK1 and Aurora A were 
increased in metastatic PCa tissues 
Next, to examine the correlation between four proteins of interest and cancer progression, 
the mRNA levels of each gene were investigated in Sawyers-370 dataset from R2 
database. Analysis on Sawyers-370 dataset revealed that the each mRNA levels were 
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significantly higher (p<0.01) in metastasis (n=38) than in primary PCa tumour (262) 




Figure 6.18 mRNA levels of M phase promoting complex and regulators in 
metastasis and primary tumour. mRNA levels of M phase promoting complex and 
regulators were plotted for Metastasis (38) and Primary tumour (262) from prostate 
dataset of Sawyers–370 of R2 microarray analysis and visualization platform. p values of 
statistically difference between metastasis and primary tumour were described. 
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6.3.3.3 mRNA levels of Cyclin B1, CDK1, PLK1 and Aurora A were 
correlated with Ki-67 expression level 
To determine whether Cyclin B1, CDK1, PLK1 and Aurora A expressions are associated 
with proliferative marker Ki-67, the correlation between the mRNA levels of four genes 
of interest and Ki-67 was analysed using Sawyers–370 dataset (n=370) of R2 microarray 
analysis and visualization platform. The mRNA levels of all four genes were positively 
correlated (p<0.01) with Ki-67 (Figure 6.19). 
 
Figure 6.19 M phase promoting complex and regulators were correlated with 
proliferative marker Ki-67 in PCa tissues. mRNA levels of M phase promoting 
complex and regulators and Ki-67 were plotted from prostate dataset of Sawyers–370 of 
R2 microarray analysis and visualization platform (n=370). r values and p values are 
described. 
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6.3.3.4 Genomic alterations of Cyclin B1, CDK1, PLK1 and Aurora A in 
PCa tissues 
To investigate the association between genomic alterations in PCa, 13 different datasets 
from over 27,00 patients on cBioportal database were analysed to visualise the 
multidimensional cancer genomics data. The summary data of gene alterations such as 
mutation, deletion, amplification and multiple alterations in Cyclin B1, CDK1, PLK1 and 
Aurora A genes were presented in figure 6.19 and the quantitative analysis of gene 
alterations from each of the study were shown in Table 6-1 to 6-4 (Cerami et al. 2012; 
Gao et al. 2013).  
The most common genomic alteration of Cyclin B1 in PCa was deletion and it was found 
in 6 of 13 datasets with the highest of 13% and lowest of 0.9% (Table 6-1 and Figure 
6.20). Amplification was found in 5 of 13 datasets with the highest of 7.5% and the 
lowest of 0.2%. Only one dataset showed the mutation of Cyclin B1 gene in PCa with 
0.7%.  
Table 6-1 Alteration summary for Cyclin B1 gene in 13 PCa datasets. 
 
 
Source No of cases % of Mutation % of Deletion % of Amplification 
% of Multiple 
Alterations 
1 Prostate MSKCC 2010  216 - - - - 
2 Prostate Organoids 12 - - - - 
3 Prostate MSKCC 2014  104 - - - - 
4 Prad_mskcc_2017  504 - - - - 
5 Prostate (Broad/Cornell 2012)  112 - - - - 
6 PRAD Hallmarks (CPCG-GENE, 2017) 477 - - - - 
7 Prostate (SU2C)  150 0.7% - 0.7% - 
8 Prostate (Broad/Cornell 2013)  56 - 3.6% - - 
9 Prostate (TCGA) 492 - 5.9% 0.2% - 
10 Prostate (TCGA 2015) 333 - 6.0% 0.3% - 
11 NEPC (Trento/Cornell/Broad 2016)  107 - 0.9% 7.5% - 
12 Prostate (FHCRC, 2016)  136 - 8.8% 0.7% - 
13 Prostate (MICH)  61 - 13.1% - - 
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Amplification was the most common gene alteration of CDK1 and it was found in 8 of 13 
datasets with the highest of 15% and lowest of 0.4% (Table 6-2 and Figure 6.20). 
Deletion and mutation of CDK1 gene were observed in 2 and 3 datasets of PCa and the 
highest percentage was 0.9% and the lowest were 0.8% and 0.2%, respectively.  
Table 6-2 Alteration summary for CDK1 gene in 13 PCa datasets. 
 
The most common alteration in PLK1 gene was amplification and it was found in 5 of 13 
datasets with the highest of 14% and the lowest of 0.6% (Table 6-3 and Figure 6.20). 
Deletion and mutation of PLK1 gene were found in 3 of 13 datasets with the highest of 
2% and 1.5%, respectively and the lowest of 0.2%.  
Table 6-3 Alteration summary for PLK1 gene in 13 PCa datasets. 
 
 
Source No of cases % of Mutation % of Deletion % of Amplification 
% of Multiple 
Alterations 
1 Prostate MSKCC 2010  103 - - 1.0% - 
2 Prostate Organoids 12 - - - - 
3 Prostate MSKCC 2014  104 - - - - 
4 Prad_mskcc_2017  504 - - - - 
5 Prostate (Broad/Cornell 2012)  112 - - - - 
6 PRAD Hallmarks (CPCG-GENE, 2017) 477 - - - - 
7 Prostate (SU2C)  150 0.7% - 10.0% - 
8 Prostate (Broad/Cornell 2013)  56 - - 1.8% - 
9 Prostate (TCGA) 492 0.2% 0.8% 0.4% - 
10 Prostate (TCGA 2015) 333 - 0.9% 0.6% - 
11 NEPC (Trento/Cornell/Broad 2016)  107 0.9% - 15.0% - 
12 Prostate (FHCRC, 2016)  136 - - 3.7% - 
13 Prostate (MICH)  61 - - 4.9% - 
Source No of cases % of Mutation % of Deletion % of Amplification 
% of Multiple 
Alterations 
1 Prostate MSKCC 2010  216 - - - - 
2 Prostate Organoids 12 - - - - 
3 Prostate MSKCC 2014  104 - - - - 
4 Prad_mskcc_2017  504 - - - - 
5 Prostate (Broad/Cornell 2012)  112 - - - - 
6 PRAD Hallmarks (CPCG-GENE, 2017) 477 - - - - 
7 Prostate (SU2C)  150 2.0% - - - 
8 Prostate (Broad/Cornell 2013)  56 - - - - 
9 Prostate (TCGA) 492 0.2% 0.2% 0.6% - 
10 Prostate (TCGA 2015) 333 0.3% 0.3% 0.9% - 
11 NEPC (Trento/Cornell/Broad 2016)  107 - - 14.0% - 
12 Prostate (FHCRC, 2016)  136 - 1.5% 2.9% - 
13 Prostate (MICH)  61 - - 1.6% - 
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Amplification was most common alteration of Aurora A gene and 7 of 13 studies reported 
in PCa with the highest of 25% and the lowest of 0.4% (Table 6-4 and Figure 6.20). 
Mutation of Aurora A was found in 5 of 13 datasets with the highest of 2% and the lowest 
of 0.2%. Deletion of Aurora A gene was shown in 1 of 13 datasets with 0.6%.  
Table 6-4 Alteration summary for Aurora A gene in 13 PCa datasets. 
 
In summary, searching cBioPortal across 13 PCa datasets, we found a deletion in Cyclin 
B1 gene and amplification of CDK1, PLK1 and Aurora A genes in PCa suggesting their 
association with PCa.  
Source No of cases % of Mutation % of Deletion % of Amplification 
% of Multiple 
Alterations 
1 Prostate MSKCC 2010  216 - - - - 
2 Prostate Organoids 12 - - - - 
3 Prostate MSKCC 2014  104 - - - - 
4 Prad_mskcc_2017  501 0.2% - 0.4% - 
5 Prostate (Broad/Cornell 2012)  109 0.9% - - - 
6 PRAD Hallmarks (CPCG-GENE, 2017) 449 0.2% - - - 
7 Prostate (SU2C)  150 2.0% - 3.3% - 
8 Prostate (Broad/Cornell 2013)  56 - - - - 
9 Prostate (TCGA) 492 - - 0.6% - 
10 Prostate (TCGA 2015) 333 - 0.6% 1.2% - 
11 NEPC (Trento/Cornell/Broad 2016)  107 1.9% - 25.2% - 
12 Prostate (FHCRC, 2016)  136 - - 0.7% - 
13 Prostate (MICH)  61 - - 1.6% - 
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Figure 6.20 Gene alterations of Cyclin B1, CDK1, PLK1 and Aurora A associated 
with PCa. Using cBioportal genomic database, gene alterations of were analysed across 
13 datasets. CAN is defined as copy number alteration. 
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6.4 Discussion 
After confirming the G2 arrest caused by DR, we questioned what is the mechanism 
causing G2 arrest in DR treated PCa cells. The G2 checkpoint can be activated due to 
DNA damage, thereby inhibits the activity of effector proteins Cyclin B1-CDK1 complex 
through DNA damage signalling transducer kinases such as ATM, ATR, CHK1 and 
CHK2 (DiPaola 2002).  Indeed, the DNA damaging agent could arrest G2 checkpoint by 
activating the damage signalling pathway (Hirose et al. 2001; Jackson et al. 2000). 
However, using immunofluorescence, we found neither significant increase in phospho-
H2AX and 53BP1 foci nor activation of DNA damage transducer kinases in DR treated 
PCa cells. But, interestingly, the downstream effector protein Cyclin B1-CDK1 complex, 
which is responsible for the transition of G2 to M phase and activators PLK1 and Aurora 
A were clearly reduced at protein level following DR treatment in both PCa cell lines. 
Our well-optimised RT-PCR also showed that DR reduced mRNA levels of all four 
genes.  
When we searched for the clinical relevance of M phase promoting complex and the two 
regulators using R2 genomic analysis and visualizing platform, we found that the mRNA 
levels of all four were higher in PCa compared to BPH. Also, the mRNA levels of M 
phase promoting complex and regulators were higher in metastasis than primary tumour. 
Moreover, increased mRNA levels were highly correlated with increased Ki-67 
expression level. Using cBioportal genomic database, we found a deletion of Cyclin B1 
and amplifications of CDK1, PLK1 and Aurora A genes across 13 datasets.  
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6.4.1 Cytostatic dose of DR caused no DNA damage 
DNA damage repair can be activated by double strand breaks induced by irradiation 
(Jackson et al. 2009). Therefore, by including the radiation-treated cells as positive 
control, we could verify that our system is able to detect DNA damage if it is present. 
Immunofluorescence based assays are sensitive and reliable in visualization of distinct 
nuclear foci formed by H2AX phosphorylation and 53BP1 upon DNA damage (Mah et al. 
2010; Panier et al. 2014). The conventional methods based on DNA fragmentation by 
constant field gel electrophoresis or pulsed field gel and comet assay can only detect 
larger doses of IR. But, immunofluorescence of phospho-H2AX and 53BP1 can detect a 
range from low to high dose of radiation consistent with clinical use (Taneja et al. 2004). 
In addition, immunofluorescence detection of phospho-H2AX and 53BP1 foci can locate 
the DNA damage site with intact cell morphology and does not need lysing the cells in 
contrast to DNA fragmentation based assays (Yu et al. 2006). 
Phospho-H2AX is an important initiator for DNA repair and its deficiency would lead to 
chromosomal instability and apoptosis due to a lack of activation of G2/M checkpoint and 
G2/M arrest (Mah et al. 2010). 53BP1, which is the binding partner of p53, is the mediator 
and effector of DNA double strand break response and play multiple roles in DNA 
damage signalling (Panier et al. 2014). In our study, radiation-treated PCa cells clearly 
exhibited phsopho-H2AX and 53BP1 foci formation. Yet, there was no clear increase of 
both foci in DR treated cells compared with vehicle control. 
In eukaryotes, ATM induced stimulatory phosphorylation of H2AX at Ser134 (γ-H2AX) 
and formation of phospho-H2AX foci along the DNA damage site initiate DNA repair 
mechanism (Mah et al. 2010; Markova et al. 2007). The recruitment of 53BP1 protein to 
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DNA damage site and rapid formation of 53BP1 foci is also induced by ATM or ATR 
mediated DNA damage response (Daley et al. 2014). Hence, as aforementioned in chapter 
1, ATM, ATR, CHK1 and CHK2 are main transducers of DNA damage signalling 
pathway. Consistently, immunoblotting of ATM and ATR in radiation treated PCa cells 
showed an increase in the phosphorylated form of both ATM and ATR, which 
represented their activation induced by radiation. Moreover, CHK2, a DNA damage 
transducer and checkpoint protein, was notably phosphorylated in PCa cells by radiation. 
By comparison with activated DNA damage repair mediators and transducer proteins in 
radiation-treated PCa cells, it is clear that there was no sign of DNA damage transducers 
activation in the DR treated PCa cells, although more replicates could have used for the 
immunblotting of DNA damage checkpoint proteins as the error bars in quantification 
were relatively high.  
Very limited information was available on DNA damage induced by HD and SB. Kho’s 
group reported that ethanol extract of HD alone induced DNA damage and cell death 
using comet assay in human leukemia cells (Kuo et al. 2015). Our study showed no 
association between the cytostatic action of DR and DNA damage in PCa cells. 
6.4.2 Enrichment of PCa cells at G2 phase is associated with 
impairment in M phase promoting complex and regulators 
The biological pathways involved in G2 checkpoint are the signalling cascades that inhibit 
the activation of CDK1. Several G2 checkpoint proteins such as CHK1 and CHK2 are 
upstream negative regulators of CDK1 and main transducers of DNA damage response. 
The activation of CHK1 and CHK2 could increase Tyr15 phosphorylated form of CDK1 
through enhancing the activity of Wee1 and inhibiting the activity of CDC25C (Ahn et al. 
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2004; Shaltiel et al. 2015). In our study, we have found a reduction of the effectors Cyclin 
B1 and CDK1 by DR without activation of DNA damage response transducers proteins, 
CHK1 and CHK2. Immunoblotting revealed that DR reduced both total and 
phosphorylated form of CDK1 in LNCaP cells. While a decrease in total CDK1 was 
noted in PC-3, the change in phospho-CDK1 was not obvious. This observation suggests 
that a reduction of CDK1 caused by DR is independent from transducer proteins of DNA 
damaging signalling pathway.  
PLK1 and Aurora A are positive regulators of Cyclin B1-CDK1 complex (DiPaola 2002; 
Otto et al. 2017). The phosphorylation on Cyclin B1 by PLK1 leads to nuclear 
localisation of Cyclin B1-CDK1 complex to promote G2-M transition (Strebhardt 2010; 
Toyoshima-Morimoti et al. 2001). PLK1 not only activates but also localizes the 
CDC25C, whose function in de-phosphorylation of inhibitory phosphate on Try15 of 
CDK1 resulting in CDK1 activation thus promoting cells progressing from G2 phase to M 
phase (Toyoshima‐Morimoto et al. 2002). Aurora A can phosphorylate and activate the 
PLK1. Our study showed a substantial reduction of Cyclin B1, CDK1, PLK1 and Aurora 
A by DR, suggesting the impairment of these four proteins is most likely responsible for 
activating the G2 checkpoint and blocking the G2 to M transition. This is an interesting 
finding as it indicates that impairment of M phase promoting complex and two regulators 
can trigger G2 arrest in PCa cells without involving upstream DNA damage transducer 
proteins.  
This observation is consistent with the previous finding where BZL101, a phytochemical 
extract from SB was found to arrest LNCaP cells in the G2/M phase by ablating the 
expression of Cyclin B1 and CDK1 (Marconett et al. 2010). Early studies on flavoprotein 
inhibitor in liver cancer and breast cancer cells showed G2 arrest with impairment in 
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Cyclin B1 (Scaife 2004). Studies have also reported that down regulation of Cyclin B1 
and CDK1 by anti-cancer drugs induce G2/M arrest (Lohberger et al. 2015; Shi et al. 
2017). Interestingly, one study on the effect of Menthol in PC-3 cells reported G2/M 
phase arrest associated with reduction of PLK1 and CDC25C, together with defect in 
nuclear localisation of both proteins (Kim et al. 2012). Similarly, the association between 
the loss of Aurora A and G2/M phase arrest has been documented in human small cell 
lung cancer cells (Lu et al. 2014). Together, these information suggested that G2 phase 
cell cycle arrest induced by DR was mainly due to down regulation of Cyclin B1, CDK1, 
PLK1 and Aurora A. 
6.4.3 Clinical relevance of M phase promoting complex and 
regulators 
Following the observation that the impairment in transition of PCa cells from G2 phase to 
M phase by DR was likely due to reduction in M phase promoting complex and 
regulators, we wanted to establish the clinical relevance of those proteins. When we 
searched for the mRNA expression of four proteins using R2 database, we found that the 
mRNA levels of all four were strongly correlated with disease status and tumour types 
suggesting the importance of those proteins for disease progression. In addition, mRNA 
levels of M phase promoting complex and regulators were correlated significantly with 
Ki-67 mRNA levels. As we discussed in chapter 1, Ki-67 expression level is associated 
with tumour grade and therefore our analysis also supported the notion that Cyclin B1, 
CDK1, PLK1 and Aurora A are associated with disease status and progression.  
Reduction of those proteins by DR treatment may have a high inhibitory effect on PCa 
progression. Emerging evidence also supported that PLK1 and Aurora A can be 
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prognostic markers for various types of cancer and therefore, natural or synthetic 
inhibitors targeting those proteins could be clinically significant (Otto et al. 2017; 
Strebhardt et al. 2006; Yan et al. 2016).  
By studying the genomic alterations of M phase promoting complex and regulators on 
cBioportal across 13 different datasets, we also found amplifications in CDK1, PLK1 and 
Aurora A genes in PCa. It may also be suggested that amplification of those three genes 
could be the reason for the increase in mRNA expressions of CDK1, PLK1 and Aurora A 
in PCa. Mutation and deletion of those three genes were also found in PCa. But the 
deletion mainly occurred in Cyclin B1 gene in PCa. Considering Cyclin B1 protein 
together with CDK1 promotes cell cycle progression, the deletion of this gene in PCa is 
unexpected. The mechanism of how deletion of Cyclin B1 gene related to PCa is also 
unclear.  
The genetic alterations of M phase promoting complex and regulators were varied across 
the 13 studies reflecting the clinical heterogeneity of PCa. Apart from heterogeneity, 
another possible reason might be the difference in sample number and type. The 
percentages of amplification were varied across the datasets. Based on CDK1, the high 
frequency of gene amplification occurs in the study with low sample numbers. For 
example, although TCGA dataset (The Cancer Genome Atlas Research 2015) and 
Broad/Cornell dataset (Baca et al. 2013) used similar tumour type, the difference in 
sample numbers (333 and 56, respectively) may cause variation in percentage of 
amplification. Therefore, it is possible that the real frequencies of amplifications may not 
be as it appears to be. For sample type, NEPC and Prostate SUTC studies obtained the 
specimens from metastatic tumour (Beltran et al. 2016; Robinson et al. 2015) and the 
specimens of TCGA (Cell 2015) study were derived from primary tumour (The Cancer 
 203 
Genome Atlas Research 2015) suggesting the percentages of genetic alteration may be 
associated with tumour types. 
In summary, mRNA levels of M phase promoting complex and regulators were correlated 
with prostate disease status, i.e. BPH and cancer, and tumour types, i.e. primary and 
metastatic cancer. These data suggest that, by reducing the mRNA and protein levels of 
these PCa progression-associated key players, DR may impede PCa progression in men 
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7.1 Discussion  
PCa is one of the leading causes of cancer related death in men worldwide (Aggarwal et 
al. 2017). Men with low grade and low volume PCa often opt for AS.   While this option 
decreases unnecessary overtreatment for some men (Klotz et al. 2014), it does cause 
anxiety about the possibility of undetected disease progression in many men (Klotz 
2013). Indeed, 24–40% of men under AS can experience disease progression, ultimately 
requiring medical intervention (ie. prostatectomy or radiation).  As discussed in the 
introduction, there is no treatment modality available at present for men under AS, apart 
from regular PSA testing, digital examination, and biopsy. Hence, there is an excellent 
prospect for a cost effective and non-toxic therapy that could help preventing or impeding 
disease progression. If this alternate therapy was failed, the choice for definitive treatment 
(prostatectomy or radiation) at a later stage would still be present. 
TCM has been used for over centuries in treating and improving the symptoms 
experienced by cancer patients (Liu et al. 2015). TCM has attracted our attention as it 
may meet the three needs for men under AS. DR recipe contains HD and SB, both have 
been reported as the most common herbal medicines used in the treatment of breast (Yeh 
et al. 2014) and colon cancer (Chao et al. 2014) in China. However, a detailed 
understanding of the mechanism of HD and SB in combination in PCa is lacking.   
 207 
7.1.1 Major findings 
Firstly, we found that DR has anti-proliferative activity in PCa cells through inhibiting the 
DNA synthesis as assessed by SYBR Green assay and BrdU incorporation. 
Immunocytochemical staining of Ki-67 showed a clear reduction in proliferative cells 
after 72 hr of DR treatment. Long-term inhibitory effect of DR on cancer cell 
proliferation was noted by the colony formation assay. The pH and osmolality test of DR 
containing culture medium indicated that the anti-proliferative activity of DR is intrinsic. 
An animal study demonstrated that DR may not have apparent adverse action at least in a 
short-term.   
Secondly, flow cytometric cell cycle analysis of PI-stained PCa cells indicated that DR 
induces cell accumulation at the G2/M phase and subsequent flow cytometry using co-
staining of PI and phospho-Histone H3 showed the reduction in M phase cells, suggesting 
that DR arrests the PCa cells at the G2 phase. G2 phase cell cycle arrest is often associated 
with DNA damage and therefore, we performed immunofluorescence of DNA damage 
markers phospho-H2AX and 53BP1. Using radiation treated PCa cells as positive control 
for DNA damage, we confirmed that DR did not induce the DNA damage foci. Consistent 
with this finding, immunoblotting of DNA damage checkpoint proteins (CHK1 and 
CHK2) also showed no activation in comparison to radiation-treated PCa cells.  
Thirdly, M phase promoting complex and its regulators are important for transition of G2 
phase to M phase. Immunoblotting and RT-PCR showed that both protein and mRNA 
levels of all four were reduced by DR. The activity of Cyclin B1-CDK1 complex and its 
positive regulators PLK1 and Aurora A kinase confer the G2-M transition, and a reduction 
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of their mRNA and proteins by DR revealed a mechanism by which DR impairs the 
transition of G2 phase to M phase.  
Lastly, using a Dutch based online tool (R2: Genomics Analysis and Visualization 
Platform), we showed that mRNA expression levels of M phase promoting complex and 
its regulators in PCa tissues were strongly correlated with disease status and tumour 
types. The mRNA levels of those four were positively correlated with that of Ki-67 
supporting their association with disease progression. Studying the genomic alterations of 
those four genes across 13 datasets from cBioportal, we found that amplifications in 
CDK1, PLK1 and Aurora A genes and a deletion in Cyclin B1 in PCa.  
7.1.2 Validity and significance of the major finding 
Two PCa cell lines, LNCaP and PC-3, were used in the study. LNCaP cells express 
androgen receptors (AR) and secrete prostate specific antigen (PSA) (Horoszewicz et al. 
1983). Being dependent on androgens, LNCaP is a model of hormone sensitive PCa. 
Originally from human bone metastases PCa cells, PC-3 lacks AR and PSA expression 
(Kaighn et al. 1979). Tumour suppressor p53 is mutated in PC-3 (Isaacs et al. 1991), 
while WT p53 is found in LNCaP cells (Cunningham et al. 2015). Furthermore, abnormal 
regulations of the PTEN gene, are frequently found in primary (Cairns et al. 1997) and 
metastatic PCa (Cunningham et al. 2015; Suzuki et al. 1998). Both LNCaP and PC-3 cells 
lack a functional PTEN gene, specifically a frame-shift mutation in LNCaP cells 
(Vlietstra et al. 1998) and a deletion in PC-3 cells (Li et al. 1997). Our study showed that 
DR has similar effect on both cell lines suggesting the cytostatic action of DR is not 
associated with AR or p53 function. Since both PCa cell lines contain dysfunctional 
PTEN, the anti-proliferative effect of DR may not require the presence of WT PTEN.    
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The anti-proliferative activity of DR was determined by carefully chosen assays. MTT 
and MTS are popular cell viability assays based on mitochondria enzyme activities, but 
their limitations are undeniable in the study using botanical products because of their 
likely effect on mitochondria (Menyhárt et al. 2016; Wang et al. 2010). Since 
proliferation must be reflected on DNA synthesis, we chose SYBR Green DNA analysis 
to investigate the replicative capacity of PCa in the presence of DR. By further including 
two controls, vehicle and baseline DNA content, we were able to further distinguish 
cytostatic from cytotoxic doses of DR by SYBR green assay.  
Not many methods are available to separate out activity on G2 from M phases. Using 
Nocodazole treated PCa cells as a positive control for cells arrested at mitosis, co-staining 
of PCa cells with PI and phospho-Histone H3 Ab followed by flow cytometry analysis 
revealed that DR induces the accumulation of PCa cells at G2 phase. After exclusion of 
DR induced DNA damage causing G2 arrest, we established that DR reduced at both 
mRNA and protein levels Cyclin B1, CDK1, PLK1 and Aurora A. We propose that DR 
impairs the transition of G2 to M phase of PCa cells through these proteins. 
Finally, the approach used in this study from establishing DR effect on proliferation, cell 
cycle distribution and then mechanism for arresting at particular cell cycle phase will be 
useful not only for understanding the action and mode of action of DR, but also providing 
a practical platform to assess the biological activity of TCM in future.   
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7.2 Limitations and Future Directions 
Previous studies have shown the anti-tumour activity of SB in PCa using TRAMP 
transgenic models (Wong et al. 2009). However, no specific mechanism of DR action was 
examined. Based on our study, it will be informative if the immunostaining or 
immunoblotting can be used to verify DR effect on phospho-H3 and Cyclin B1, CDK1, 
PLK1 and Aurora A in tumours in mice. For DR action, it would also be meaningful if we 
could establish the effect of DR on both prevention and progression of tumours.  For 
prevention, DR can be given prior to implantation of PCa cells for impeding progression, 
DR will be given after tumour has been established.   
Due to time limitations of this project, we were not able to perform the aforementioned 
preventive or treatment study in animals, apart from a short-term toxicity study with a 
dose calculated based on human intake of DR. We have prepared PCa cells transduced 
with Green fluorescence plasmid (Yao et al. 2015). By measuring the fluorescence 
intensity of the tumour in vivo, we would be able to monitor the tumour growth 
quantitatively and accurately.  
Further studies are also needed to determine the effect of DR on stability of mRNAs of 
Cyclin B1, CDK1, PLK1 and Aurora A. The reduction of the steady-state mRNA levels of 
these four proteins in the presence of DR is expected due to a decrease in either gene 
transcription or mRNA stability. To determine mRNA stability, actinomycin D can be 
used to inhibit transcription. The decay of the pre-transcribed mRNA over time measured 
by RT-PCR in the presence or absence of DR will reflect its impact on mRNA stability. 
Previous studies have demonstrated that the stability of mRNA is reflected on the length 
of poly A tail. To prevent the degradation of mRNA in the cytomplasm, poly A tail is 
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added at 3’ end of mRNA. Therefore, if a study with actinomycin D indicates a reduction 
in mRNA stability in the presence of DR, we will verify that by a RT-PCR based method 
to measure individual mRNA poly (A) length followed by sequencing of PCR product to 
get an accurate quantification of the number of adenosine (Kusov et al. 2001). If mRNA 
stability is not affected, we would then examine whether transcriptional activity or 
accumulation of RNA polymerase II at the promoter regions of those four genes are 
compromised by DR in vitro by chromatin immunoprecipitation.  
Build on the foundation laid through this project, further study on the action of DR in vivo 
and the mode of action at deep levels are expected to provide more insight into the 
fascinating capacity of TCM in cancer prevention and treatment.   
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